

Eur päisches Patentamt
Eur pean Patent Offic
Office européen des brevets



(1) Publication number:

0 612 846 A1

EUROPEAN PATENT APPLICATION

- 2) Application number: 94101207.2
- ② Date of filing: 27.01.94
- Declaration under Rule 28(4) EPC (expert solution)
- (9) Int. Cl.<sup>5</sup>; C12N 15/27, C07K 3/00, C12P 21/02, C07K 13/00, G06F 15/60

- Priority: 28.01.93 US 10099
- (3) Date of publication of application: 31.08.94 Bulletin 94/35
- Designated Contracting States: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
- Applicant: AMGEN INC.
   Amgen Center,
   1840 Dehavilland Drive
   Thousand Oaks, CA 91320-1789 (US)
- inventor: Osslund, Timothy 475 Vista Montana Camarillo, California 93010 (US)
- Representative: Vosslus, Volker, Dr. et al Dr. Volker Vosslus
   Patentanwaltskanziel - Rechtsanwaltskanziel Holbeinstrasse 5
   D-81679 München (DE)
- G-CSF analog compositions and methods.
- ② Provided herein are granulocyte colony stimulating factor ("G-CSF") analogs, compositions containing such analogs, and related compositions. In another aspect, provided herein are nucleic acids encoding the present analogs or related nucleic acids, related host cells and vectors. In yet another aspect, provided herein are computer programs and apparatuses for expressing the three dimensional structure of G-CSF and analogs thereof. In another aspect, provided herein are methods for rationally designing G-CSF analogs and related compositions. In yet another aspect, provided herein are methods for treatment using the present G-CSF analogs.

### Field of the Invention

This invention relates to granulocyte colony stimulating factor ("G-CSF") analogs, compositions containing such analogs, and related compositions. In another aspect, the present invention relates to nucleic acids encoding the present analogs or related nucleic acids, related host cells and vectors. In another aspect, the invention relates to computer programs and apparatuses for expressing the three dimensional structure of G-CSF analogs thereof. In another aspect, the invention relates to methods for retainally designing G-CSF analogs and related compositions. In yet another aspect, the present invention relates to methods for treatment using the present G-CSF analogs.

### Background

Hematopoiesis is controlled by two systems: the cells within the bone marrow microenvironment and growth factors. Also called colony stimulating factors, stimulate committed progenitor or cells to proliferate and to form colonies of differentiating blood cells. One of these factors is granulocyte colony stimulating factor, nerein called G-CSF, which preferentially stimulates the growth and development of neutrophis, indicating a potential use in neutropenic states. Welle et al., PNAS-USA &2; 152e-1530 (1985). Souza et al., Science 232: 61-65 (1986) and Gabrilove, J. Seminars in Hematology 26: (2) 1-14 (1989).

In humans, endogenous G-GSF is detectable in blood plasma, Jones et al., Bailliere's Clinical Hematology 2 (1): 83-111 (1989), G-GSF is produced by fibroblasts, macrophages, T cells trophoblasts, endothelial cells and epithelial cells and is the expression product of a single copy gene comprised of four exons and five introns located on chromosomes eventeen. Transcription of this locus produces a mRNA species which is differentially processed, resulting in two forms of G-GSF mRNA, one version coding for a protein of 174 amino acids, Nagata et al., EMBO J 5: 575-581 (1989), and the form comprised of 174 amino acids has been found to have the greatest specific in who blotogical activity. G-GSF is species cross-reactive, such that when human G-GSF is administered to another mammal such as a mouse, canine or monkey, sustained neutrophil leukocytosis is elicited. Mocre et al., PNAS-USA 84: 7134-7136 (1987).

Human G-CSF can be obtained and purified from a number of sources. Natural human G-CSF (nith-CSF) can be isolated from the supernatants of cultured human tumor cell lines. The development of recombinant DNA technology, see, for instance, U.S. Patent 4,810,843 (Souza) incorporated herein by reference, has enabled the production of commercial scale quantities of G-CSF in glycosylated form as a product of eukaryotic host cell expression, and of G-CSF in non-glycosylated form as a product of protaryotic host cell expression.

G-CSF has been found to be useful in the treatment of indications where an increase in neutrophils will provide benefits. For example, for cancer patients, G-CSF is beneficial as a means of selectively stimulating neutrophil production in compensate for hematopoietic deficits resulting from chemotherapy or radiation therapy. Other indications include treatment of various infectious diseases and related conditions, such as sepsis, which is tylically cused by a metabolie of bacteria. G-CSF is also useful alone, or in combination with other compounds, such as other cytokines, for growth or expansion of cells in culture, for example, for bone marrow transplants.

Signal transduction, the way in which G-CSF effects cellular metabolism, is not currently thoroughly understood. G-CSF binds to a cell-surface receptor which apparently initiates the changes within particular progenitor cells, leading to cell differentiation.

Various altered G-CSP's have been reported. Generally, for design of drugs, certain changes are known to have certain structural effects. For example, deleting one cysteine could result in the unfolding of a molecule which is, in its unaltered state, is normally tolded via a disulfide bridge. There are other known methods for adding, deleting or substituting armine acids in order to chance the function of a protein.

Recombinant human G-CSF mutants have been prepared, but the method of preparation does not include overall structure-function relationship information. For example, the mutation and biochemical modification of Cys 18 has been reported. Kuga et al., Biochem. Biophy. Res. Comm 159: 103-111 (1989); Lu et al., Arch, Biochem. Biophys. 288: 81-92 (1989).

In U.S. Patient No. 4, 810, 643, entitled, "Production of Pluripotent Granulocyte Colony-Stimulating Factor" (as cited above), polypeptide analogs and peptide fragments of G-CSF are disclosed generally. Specific G-CSF analogs disclosed include those with the cysteins at positions 17, 36, 42, 64, and 74 (of the 174 amino acid species or of those having 175 amino acids, the additional amino acid being an N-terminal methorine) substituted with another amino acid, (such as serine), and G-CSF with an alanine in the first (N-

terminal) position.

EP 0 335 423 entitled "Modified human G-CSF" reportedly discloses the modification of at least one amino group in a polypeptide having hG-CSF activity.

EP 0 272 703 entitled "Novel Polypeptide" reportedly discloses G-CSF derivatives having an amino acid substituted or deleted at or "in the neighborhood" of the N terminus.

EP 0 459 830, entitled "Polypeptides" reportedly discloses derivatives of naturally occurring G-CSF having at least one of the biological properties of naturally occurring G-CSF and a solution stability of at least 35% at 5 mg/ml in which the derivative has at least Cys<sup>27</sup> of the native sequence replaced by a Ser<sup>27</sup> residue and Asp<sup>27</sup> of the native sequence replaced by a Ser<sup>27</sup> residue.

EP 0 256 843 entitled "Expression of G-CSF and Muteins Thereof and Their Uses" reportedly discloses a modified DNA sequence encoding G-CSF wherein the N-terminus is modified for enhanced expression of protein in recombinant host cells, without changing the amino add sequence of the protein.

EP 0 243 153 entitled "Human G-CSF Protein Expression" reportedly discloses G-CSF to be modified by inactivating at least one yeast KEX2 protease processing site for increased yield in recombinant production using yeast.

Shaw, U.S. Patent No. 4,904,584, entitled "Site-Specific Homogeneous Modification of Polypeptides," reportedly discloses lysine altered proteins.

WO/9012874 reportedly discloses cysteine altered variants of proteins.

Australian patent application Document No. AU-A-1094892, entitled, "Improved Activation of Recombinant Proteins" reportedly discloses the addition of amino acids to either terminus of a G-CSF molecule for the purpose of aiding in the folding of the molecule after prokaryotic expression.

Australian patient application Document No. AUA-7583091, entitled, "Muteins of the Granulocyte Colony Stimulating Factor (C-GSP)" reportedly discloses muteins of the granulocyte stimulating factor G-CSF in the sequence Leu-Gly-His-Ser-Leu-Gly-He at position 50-56 of G-CSF with 174 amino acids, and position 51 to 59 of the G-CSF with 174 mino acids, and at least one of the four histadine residues at positions 43, 79, 158 and 170 of the mature G-CSF with 174 amino acids or at positions 48, 82, 159, or 173 of the mature G-CSF with 177 amino acids.

GB 2 213 821, entitled "Synthetic Human Granulocyte Cotory, Stimulating Factor Gene" reportedly discloses a synthetic G-CSF-encoding nucleic acid sequence incorporating restriction sites to facilitate the so cassette mutagenesis of selected regions, and flanking restriction sites to facilitate the incorporation of the gene into a desired expression system.

G-GSF has reportedly been crystallized to some extent, e.g., EP 344 786, and the overall structure of G-GSF has been sumised, but only on a gross level. Bazan, firmunology Today 11: 350-354 (1989); Parry et al., J. Molecular Recognition 8: 107-110 (1988). To date, there have been no reports of the overall structure of G-GSF, and no systematic studies of the relationship of the overall structure and function of the molecule, studies which are essential to the systematic design of G-GSF analogs. Accordingly, there exists a need for a method of this systematic design of G-GSF analogs, and the resultant compositions.

### Summary of the Invention

The three dimensional structure of G-CSF has now been determined to the atomic level. From this three-dimensional structure, one can now forecast with substantial certainty how changes in the composition of a G-CSF molecule may result in structural changes. These structural characteristics may be correlated with biological activity to design and produce G-CSF analogs.

48 Allhough others had speculated reparding the three dimensional structure of G-CSF, Bazan, Immunol-opy Today II; 350-354 (1990): Parry et al., J. Molecular Recognition 8: 107-110 (1988), these speculations were of no help to those wishing to prepare G-CSF analogs either because the surmised structure own incorrect (Perry et al., suppr.) and/or because the surmised structure provided no detail correlating the constituent moieties with structure. The present determination of the three-dimensional structure to the atomic level is by far the most complete analysis to data, and provides important information to those wishing to design and prepare G-CSF analogs. For example, from the present three dimensional structural analysis, precise areas of hydrophobicity and hydrophibicity had be been determined.

Relative hydrophobicity is important because it directly relates to the stability of the molecule. Generally, blotogical molecules, found in aqueous environments, are externally hydrophicia dinternally 56 hydrophobic; in accordance with the second law of thermodynamics provides, this is the lowest energy state and provides for stability. Although one could have speculated that G-CSPs internal core would be hydrophobic, and the outer areas would be hydrophilic, one would have had no way of knowing specific hydrophobic or hydrophilic areas. With the presentive provided knowledge of areas of hydrophobic-

ity/philicity, one may forecast with substantial certainty which changes to the G-CSF molecule will affect the overall structure of the molecule.

As a general rule, one may use knowledge of the geography of the hydrophobic and hydrophilic regions to design analogs in which the overall G-CSF structure is not changed out of thange does after biological activity "biological activity" being used here in its broadest sense to denote function.) One may correlate biological activity to structure. If the structure is not changed, and the mutation has no effect on biological activity, then the mutation has no the control is activity. Then the mutation has no the control is expected activity, then the residue for atom) is essential to at least one biological function. Some of the present working examples were designed to provide no change in overall structure, or yet have a change in biological function.

Based on the correlation of structure to biological activity, one aspect of the present invention relates to G-CSF analogs. These analogs are molecules which have more, fewer, different or modified amino acid residues from the G-CSF amino acid sequence. The modifications may be by addition, substitution, or deletion of one or more amino acid residues. The modification may include the addition or substitution of 15 analogs of the amino acids themselves, such as peptidomimetics or amino acids with altered mojeties such as altered side groups. The G-CSF used as a basis for comparison may be of human, animal or recombinant nucleic acid-technology origin (although the working examples disclosed herein are based on the recombinant production of the 174 amino acid species of human G-CSF, having an extra N-terminus methionyl residue). The analogs may possess functions different from natural human G-CSF molecule, or 20 may exhibit the same functions, or varying degrees of the same functions. For example, the analogs may be designed to have a higher or lower biological activity, have a longer shelf-life or a decrease in stability, be easier to formulate, or more difficult to combine with other ingredients. The analogs may have no hematopoietic activity, and may therefore be useful as an antagonist against G-CSF effect (as, for example, in the overproduction of G-CSF). From time to time herein the present analogs are referred to as proteins or 25 peptides for convenience, but contemplated herein are other types of molecules, such as peptidomimetics or chemically modified peptides.

In another aspect, the present invention relates to related compositions containing a G-CSF analog as an active ingredient. The term, "related composition," as used herein, is meant to denote a composition which may be obtained once the identity of the G-CSF analog is secretained (such as a G-CSF analog as labeled with a detectable label, related receptor or pharmaceucidal composition). Also considered a related composition are chemically modified versions of the G-CSF analog, such as those having attached at least one polyethylene glycol molecule.

For example, one may prepare a G-CSF analog to which a detectable label is attached, such as a fluorescent, chemiluminescent or radioactive molecule.

35 - Another example is a pharmaceutical composition which may be formulated by known techniques using known materials, see, e.g., Reminglori's Pharmaceutical Sciences, 18th Ed. (1980, Mack Publishing Co., Easton, Pennsylvania 18042) pages 1435-1712, which are herein incorporated by reference. Generally, the formulation will depend on a variety of factors such as administration, stability, production concerns and other factors. The G-CSF analog may be administered by injection or by pulmonary administration via oir halaston. Enteric dosage forms may also be available for the present G-CSF analog compositions, and therefore or all administration may be effective. G-CSF analogs may be inserted into liposomes or other microcarriers for delivery, and may be formulated in gels or other composition storage and the composition will be put, generally, for G-CSF analogs having at least one of the biological activities of natural G-CSF, preferred pharmaceutical compositions are those prepared for subcultaneous injection or for pulmonary administration via inhalation, although the particular formulations for each type of administration will depend on the characteristics of the analos.

Another example of related composition is a receptor for the present analog. As used herein, the term "receptor" indicates a moiety which selectively binds to the present analog molecule. For example, so antibodies, or fragments thereot, or "recombinant antibodies" (see Huse et al., Science 246:1275 (1989)) may be used as receptors. Selective binding does not mean only specific binding (atthough binding-special receptors are encompassed herein), but rather that the binding is not a random event. Receptors may be on the cell surface or inter-or extra-cellular, and may act to effectuate, inhibit or localize the biological activity of the present analogs. Receptor binding may also be a triggering mechanism for a cascade of activity si indirectly related to the analog itself. Also contemplated herein are nucleic acids, vectors containing such nucleic acids which encode such receptors.

Another example of a related composition is a G-CSF analog with a chemical moiety attached. Generally, chemical modification may alter biological activity or antigenicity of a protein, or may alter other

characteristics, and those factors will be taken into account by a skilled practitioner. As noted above, one example of such chemical motely is polyethylene glycol. Modification may include the addition of one or more hydrophilic or hydrophobic polymer molecules, fatty acid molecules, or polysaccharide molecules. Examples of chemical modifiers include polyethylene glycol, alkpolyethylene glycols, Dipolytamina acids, polyvintybyrrolidorie, polyvinyl alcohol, pyran copolymer, acetic acid-gylation, propionic acid, planitic acid, stearic acid, dextran, carboxymethyl cellulose, pullulan, or agarose. See, Francis, Focus on Growth Factors 3: 4-10 (May 1982) (published by Mediscripti, Mountview Courf, Friem Barnet Lane, London N20 OLD, UIÇ). Also, chemical modification may include an additional protein or portion thereof, use of a cytotoxic agent, or an antibody. The chemical modification may also include lexity.

In another aspect, the present invention relates to nucleic acids encoding such analogs. The nucleic acids may be DNAs or RNAs or derivatives thereof, and will typically be cloned and expressed on a vector, such as a phage or plasmid containing appropriate regulatory sequences. The nucleic acids may be labeled (such as using a radioactive, chemiluminescent, or fluorescent label) for diagnostic or prognostic purposes, for example. The nucleic acid sequence may be optimized for expression, such as including codons preferred for bacterial expression. The nucleic acid and its complementary strand, and modifications thereof which do not prevent encoposition of the desired analog are here contemplated.

In another aspect, the present invention relates to host cells containing the above nucleic acids encoding the present analosi. Host cells may be eukaryotic or prokaryotic, and expression systems may include extra sleps relating to the attachment (or prevention) of sugar groups (glycosylation), proper fading 20 of the molecule, the addition or deletion of leader sequences or other factors incident to recombinant expression.

In another aspect the present invention relates to antisense nucleic acids which act to prevent or modify the type or amount of expression of such nucleic acid sequences. These may be prepared by known called a sequences.

In another aspect of the present invention, the nucleic acids encoding a present analog may be used for gene therapy purposes, for example, by placing a vector containing the analog-encoding sequence into a necipient so the nucleic acid itself is expressed inside the recipient who is in need of the analog composition. The vector may first be placed in a carrier, such as a cell, and then the carrier placed into the recipient. Such expression may be localized or systemic. Other carriers include non-naturally occurring carriers, such as liposomes or other microcarriers or particles, which may act to mediate gene transfer into a recipient.

The present invention also provides for computer programs for the expression (such as visual display) of the G-CSF or analog three dimensional structure, and further, a computer program which expresses the identity of each constituent of a G-CSF molecule and the precise location within the overall structure of that 35 constituent, down to the atomic level. Set forth below is one example of such program. There are many currently available computer programs for the expression of the three dimensional structure of a molecule, Generally, these programs provide for inputting of the coordinates for the three dimensional structure of a molecule (i.e., for example, a numerical assignment for each atom of a G-CSF molecule along an x, y, and z axis), means to express (such as visually display) such coordinates, means to alter such coordinates and 40 means to express an image of a molecule having such altered coordinates. One may program crystallographic information, i.e., the coordinates of the location of the atoms of a G-CSF molecule in three dimension space, wherein such coordinates have been obtained from crystallographic analysis of said G-CSF molecule, into such programs to generate a computer program for the expression (such as visual display) of the G-CSF three dimensional structure. Also provided, therefore, is a computer program for the expression 45 of G-CSF analog three dimensional structure. Preferred is the computer program Insight II, version 4. available from Biosym, San Diego, California, with the coordinates as set forth in FIGURE 5 input. Preferred expression means is on a Silicon Graphics 320 VGX computer, with Crystal Eyes glasses (also available from Silicon Graphics), which allows one to view the G-CSF molecule or its analog stereoscopically. Alternatively, the present G-CSF crystallographic coordinates and diffraction data are also deposited in the 50 Protein Data Bank, Chemistry Department, Brookhaven National Laboratory, Upton, New York 119723, USA. One may use these data in preparing a different computer program for expression of the three dimensional structure of a G-CSF molecule or analog thereof. Therefore, another aspect of the present invention is a computer program for the expression of the three dimensional structure of a G-CSF molecule. Also provided is said computer program for visual display of the three dimensional structure of a G-CSF ss molecule; and further, said program having means for altering such visual display. Apparatus useful for expression of such computer program, particularly for the visual display of the computer image of said three dimensional structure of a G-CSF molecule or analog thereof is also therefore here provided, as well as means for preparing said computer program and apparatus.

The computer program is useful for preparation of G-CSF analogs because one may select specific sites on the G-CSF molecule for attention and readily ascertain the effect the alteration will have on the overall structure of the G-CSF molecule. Selection of said site for attention will depend on the desired biological characteristic of the G-CSF analogule. If now ever to randomly change said G-CSF molecule (-met-s hu-G-CSF) there would be 175°° possible substitutions, and even more analogs having multiple changes, additions or deletions. By viewing the three dimensional structure wherein said structure is correlated with the composition of the molecule, the selection for sites of alteration is no longer a random event, but sites for alteration may be determined rationally.

As set forth above, identity of the three dimensional structure of G-CSF, including the placement of each constituent down to the atomic level has now yielded information regarding which moleties are necessary to maintain the overall structure of the G-CSF molecule. One may therefore select whether to maintain the overall structure of the G-CSF molecule when preparing a G-CSF analog of the present invention, or whether (and how) to change the overall structure of the G-CSF molecule when preparing a G-CSF analog of the present invention. Optionally, once one has prepared such analog, one may test such sanalog for a desired characteristic.

One may, for example, seek to maintain the overall structure possessed by a non-altered natural or recombinant G-CSF molecule. The overall structure is presented in Figures 2, 3, and 4, and is described in more detail below. Maintenance of the overall structure may ensure receptor binding, a necessary characteristic for an analog possessing the hematopoletic capabilities of natural G-CSF (if no receptor binding, signal transduction does not result from the presence of the analog). It is contemplated that one class of G-CSF analogs will possess the three dimensional core structure of a natural or recombinant (non-altered) G-CSF molecule, yet possess different characteristics, such as an increased ability to selectively stimulate neutrophils. Another class of G-CSF analog are those with a different overall structure which diminishes the ability of a G-CSF analog molecule to bind to a G-CSF receptor, and possesses a diminished ability to selectively stimulate neutrophils as compared to non-altered natural or recombinant G-

CSF.

For example, it is now known which moieties within the internal regions of the G-CSF molecule are hydrophobic, and, correspondingly, which moieties on the external portion of the G-CSF molecule are hydrophobic. Without knowledge of the overall three dimensional structure, preferably to the atomic level as 20 provided herein, one could not forecast which alterations within this hydrophobic internal area would result in a change in the overall structural configerous could result in a change in the overall structural configerous could result in a functional change, such as lack of receptor binding, for example, and therefore, diminishment of biological activity as found in non-altered aC-SF. Another class of G-CSF analogs is therefore G-CSF analogs which possess the same hydrophobicity as (non-altered) natural or recombinant G-CSF. More than the control of the

Another example relates to external loops which are structures which connect the internal one (Pelices) of the G-CSF molecule. From the three dimensional structure — including information regarding the spatial tocation of the amino acid residues — one may forecast that certain changes in certain loops with not result in overall conformational changes. Therefore, another class of G-CSF analogs provided herein is that having an attered external loop but possessing the same overall structure as (non-titiened) natural or recombinant G-CSF. More particularly, another class of G-CSF analogs provided herein are those having an attered external loop, said loop beings selected from the loop present between helicias A and B; between helicias C and C; between helicias C and B, between helicias D and A, as those loops and helicias are identified herein. More particularly, said loops, perfearby the AB loop andor the CD loop are altered to increase the half life of the molecule by stabilizing said loops. Such stabilization may be by connecting all or a portion of said loops) to a portion of an alpha helical bundle found in the core of a G-CSF or analog) molecule. Such connection may be via beta sheet, sait bridge, disulfide bonds, hydrophobic interaction or other connecting means available to those sittled in the act, wherein such connecting means available to those sittled in the act, wherein such connecting means available to those sittled in the act, wherein such connecting means available to those sittled in the act, wherein such connecting means available to those sittled in the act, wherein such connecting means available to those sittled in the act, wherein such connecting means available to those sittled in the act, wherein such connecting means availate to the said external loop or loops. For example, one may stabilize the AB or CD loops by connecting the AB loop to one of the helices within the internal region of the molecule.

The N-terminus also may be altered without change in the overall structure of a G-CSF molecule, because the N-terminus does not effect structural stability of the internal helices, and, although the external loops are or

Additionally, such external loops may be the site(s) for chemical modification because in (non-altered) natural or recombinant G-CSF such loops are relatively flexible and tend not to interfere with receptor binding. Thus, there would be additional room for a chemical moiety to be directly attached (or indirectly

attached via another chemical moiety which serves as a chemical connecting means). The chemical moiety may be selected from a variety of moieties available for modification of one or more function of a G-CSF molecule. For example, an external loop may provide sites for the addition of one or more polymer which serves to increase serum half-life, such as a polyethylene glycol of molecules. Such may be added wherein said loop is attered to include additional lysines which have reactive side groups to which polyethylene glycol moieties are capable of attaching. Other classes of chemical moieties may also be attached to one or more external loops, including but not limited to other biologically active molecules, such as receptors, other therapeutic proteins (such as other hematopoietic factors which would engender a hybrid molecule), or cytotics agents (such as diphtheria toxin). This list is of course not complete; one skilled in the art possessed of the desired chemical moiety will have the means to effect attachment of said desired moiety to the desired external loop. Therefore, another class of the present G-CSF analogs includes those with at least one alteration in an external loop wherein said atteration provides for the addition of a chemical moiety to with a tleast one elevation in an external loop wherein said atteration provides for the addition of a chemical moiety to the desired chemical molecule.

Deletions, such as deletions of sites recognized by proteins for degradation of the molecule, may also be effectual in the external loops. This provides alternative means for increasing hat-life of a molecule otherwise having the G-CSF receptor binding and signal transduction capabilities (i.e., the ability to selectively stimulate the maturation of neutrophils). Therefore, another class of the present G-CSF analogis includes these with at least one alteration in an external loop wherein said alteration decreases the turnover of said analog by proteases. Preferred loops for such alterations are the AB loop and the CD loop. One may prepare an abbreviated G-CSF molecule by deleting a portion of the amino acid residues found in the external loops (identified in more detail below), said abbreviated G-CSF molecule may have additional advantages in preparation or in biological function.

Another example relates to the relative charges between amino acid residues which are in proximity to each other. As noted above, the G-CSF molecule contains a relatively fightly packed four helical bundle. Some of the faces on the helices face other helices. At the point (such as a residue) where a helix faces another helix, the two animo acid moleties which face sech other may have the same charge, and thus tend to repel each other, which lends instability to the overall molecule. This may be eliminated by changing the charge (to an opposite charge) of one or both of the animo acid moleties so that there is no repelling. Therefore, another class of G-CSF analogs includes those G-CSF analogs having been altered so modify instability due to surface interactions such as electrocheare location.

In another aspect, the present invention relates to methods for designing G-CSF analogs and related compositions and the products of those methods. The end products of the methods may be the G-CSF analogs as defined above or related compositions. For instance, the examples disclosed herein demonstrate (a) the effects of changes in the constituents (i.e., chemical motients of the G-CSF molecule on the G-CSF solicule on the G-CSF solicule on the G-CSF solicule on the G-CSF aspect of the disclosule of the disclosu

(a) viewing information conveying the three dimensional structure of a G-CSF molecule wherein the chemical moleities, such as each amino acid residue or each atom of each amino acid residue, of the G-CSF molecule are correlated with said structure;

(b) selecting from said information a site on a G-CSF molecule for alteration;

(c) preparing a G-CSF analog molecule having such alteration; and

(d) optionally, testing such G-CSF analog molecule for a desired characteristic.

One may use the here provided computer programs for a computer-based method for preparing a G-CSF analog. Another aspect of the present invention is therefore a computer based method for preparing a 45 G-CSF analog comprising the steps of:

(a) providing computer expression of the three dimensional structure of a G-CSF molecule wherein the chemical moleties, such as each amino acid residue or each atom of each amino acid residue, of the G-CSF molecule are correlated with said structure;

(b) selecting from said computer expression a site on a G-CSF molecule for alteration;

(c) preparing a G-CSF molecule having such alteration; and

(d) optionally, testing such G-CSF molecule for a desired characteristic-

More specifically, the present invention provides a method for preparing a G-CSF analog comprising

(a) viewing the three dimensional structure of a G-CSF molecule via a computer, said computer programmed (i) to express the coordinates of a G-CSF molecule in three dimensional space, and (ii) to allow for entry of information for alteration of said G-CSF expression and viewing thereof:

(b) selecting a site on said visual image of said G-CSF molecule for alteration;

(c) entering information for said alteration on said computer;

(d) viewing a three dimensional structure of said altered G-CSF molecule via said computer;

(e) optionally repeating steps (a)-(e);

(f) preparing a G-CSF analog with said alteration; and

(g) optionally testing said G-CSF analog for a desired characteristic.

In another aspect, the present invention relates to methods of using the present G-CSF analogs and related compositions and methods for the treatment or protection of mammals, either alone or in combination with other hematopoietic factors or drugs in the treatment of hematopoietic disorders. It is contemplated that one spect of designing G-CSF analogs will be the goal of enhancing or modifying the characteristics non-modified G-SF is known to have.

For example, the present analogs may possess enhanced or modified activities, so, where G-CSF is useful in the treatment of (for example) neutropenia, the present compositions and methods may also be of such use.

Another example is the modification of G-CSF for the purpose of interacting more effectively when used in combination with other factors particularly in the treatment of hematopolietic disorders. One example of such combination use is to use an early-acting hematopolietic factor (i.e., a factor which acts earlier in the hematopolietis cascade on relatively undifferentiated cells) and either simultaneously or in seriatinu set of a later-acting hematopolietic factor, such as G-CSF or analog hereof (as G-CSF acts on the CFU-GM lineage in the selective stimulation of neutrophils). The present methods and compositions may be useful in therapy involving such combinations or "Occlusia" of hematopolietic factors.

The present compositions and methods may also be useful in the treatment of leukopenia, mylogenous leukemia, severe chronic neutropenia, aplastic anemia, glycogen storage disease, mucosistitis, and other bone marrow failure states. The present compositions and methods may also be useful in the treatment of hematopoletic deficits arising from chemotherapy or from radiation therapy. The success of bone marrow transplantation, or the use of peripheral blood progenitor cells for transplantation, for example, may be 25 enhanced by application of the present compositions (proteins or nucleic acids for gene therapy) and methods. The present compositions and methods may also be useful in the treatment of infectious diseases, such in the context of wound healing, burn treatment, bacteremia, septicemia, fungal infections, endocarditis, osteopyelitis, infection related to abdominal trauma, infections not responding to antibiotics, pneumonia and the treatment of bacterial inflammation may also benefit from the application of the present ac compositions and methods. In addition, the present compositions and methods may be useful in the treatment of leukemia based upon a reported ability to differentiate leukemic cells. Welte et al., PNAS-USA 82: 1526-1530 (1985). Other applications include the treatment of individuals with tumors, using the present compositions and methods, optionally in the presence of receptors (such as antibodies) which bind to the tumor cells. For review articles on therapeutic applications, see Lieshhke and Burgess, N.Engl.J.Med. 327: 28-34 and 99-106 (1992) both of which are herein incorporated by reference.

The present compositions and methods may also be useful to act as intermediaries in the production of other moleties; for example, C-CSF has been reported to intlunence the production of other hematopoletic factors and this function (if ascertained) may be enhanced or modified via the present compositions and/or methods.

The compositions related to the present G-CSF analogs, such as receptors, may be useful to act as an antagonist which prevents the activity of G-CSF or an analog. One may obtain a composition with some or all of the activity of non-altered G-CSF or a G-CSF analog, and add one or more chemical moletles to after one or more properties of such G-CSF or analog. With knowledge of the three dimensional conformation, one may forecast the best geographic location for such chemical modification to achieve the desired effect.

General objectives in chemical modification may include improved half-life (such as reduced renal, immunological or cellular clearance), altered bioactivity (such as altered enzymatic properties, dissociated bioactivities or activity in organic solvents), reduced toxicity (such as concealing toxic epitopes, compartentaziation, and selective biodistribution), altered immunoreactivity (reduced minungenicity, reduced antigenicity or adjuvant action), or altered physical properties (such as increased solubility, improved mechanical stabilization). See Francis, Focus on Growth Factors 3: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London N20 OLD, UK).

The examples below are illustrative of the present invention and are not intended as a limitation. It is understood that variations and modifications will occur to those skilled in the art, and it is intended that the sa appended claims cover all such equivalent variations which come within the scope of the invention as claimed.

### Detailed Description of the Drawings

FIGURE 1 is an illustration of the amino acid sequence of the 174 amino acid species of G-CSF with an additional N-terminal methionine (Seq. ID No.: 1) (Seq. ID No.: 2).

FIGURE 2 is an topology diagram of the crystalline structure of G-CSF, as well as hGH, GH-CSF, INF-B, IL-2, and IL-4. These illustrations are based on inspection of cited references. The length of secondary structural elements are drawn in proportion to the number of residues. A. B. C. and D helices are labeled according to the scheme used herein for G-CSF. For INF-B, the original labeling of helices is indicated in perentheses.

FIGURE 3 is an "ribbom diagram" of the three dimensional structure of G-CSF. Helix A is amino acid residues 11-39 (numbered according to Figure 1, above), helix B is amino acid residues 72-91, helix C is amino acid residues 100-123, and helix D is amino acid residues 143-173. The relatively short 31<sup>th</sup> helix is at amino acid residues 48-53. Residues 93-95 form almost one turn of a left handerd helix.

FIGURE 4 is a "barrel diagram" of the three dimensional structure of G-CSF. Shown in various shades of gray are the overall cylinders and their orientations for the three dimensional structure of G-CSF. The numbers indicate amino acid residue position according to FIGURE 1 above.

FIGURE 5 is a list of the coordinates used to generate a computer-aided visual image of the threedimensional structure of G-CSF. The coordinates are set forth below. The columns correspond to separate

(i) Field 1 (from the left hand side) is the atom,

(ii) Field 2 is the assigned atom number,

(iii) Field 3 is the atom name (according to the periodic table standard nomenclature, with CB being carbon atom Beta. CG is Carbon atom Gamma, etc.):

 (iv) Field 4 is the residue type (according to three letter nomenclature for amino acids as found in, e.g., Stryer, Biochemistry, 3d Ed., W.H. Freeman and Company, N.Y. 1988, inside back cover);

(v) Fields 5-7 are the x-axis, y-axis and z-axis positions of the atom;

(vi) Field 8 (often a "1.00") designates occupancy at that position;

(vii) Field 9 designates the B-factor;

(viii) Field 10 designates the molecule designation. Three molecules (designated a, b, and c) of G-CSF visualized together as a unit. The designation a, b, or c indicates which coordinates are from which molecule. The number after the letter (1, 2, or 3) indicates the assigned amino acid residue position, with molecule A having assigned positions 10-175, molecule B having assigned positions 210-375, and molecule C having assigned positions 410-575. These positions were so designated so that there would be no overlap among the three molecules which crystallized together. (The "W" designation indicates water).

FIGURE 6 is a schematic representation of the strategy involved in refining the crystallization matrix for parameters involved in crystallization. The crystallization matrix corresponds to the final concentration of the components (salts, buffers and precipitants) of the crystallization solutions in the wells of a 24 well tissue culture plate. These concentrations are produced by pipetting the appropriate volume of stock solutions into the wells of the microtiter plate. To design the matrix, the crystallographer decides on an upper and lower concentration of the component. These upper and lower concentrations can be pipetted along either the rows (e.g., A1-A6, B1-B6, C1-C6 or D1-D6) or along the entire tray (A1-D6). The former method is useful for checking reproducibility of crystal growth of a single component along a limited number of wells, whereas 45 the later method is more useful in initial screening. The results of several stages of refinement of the crystallization matrix are illustrated by a representation of three plates. The increase in shading in the wells indicates a positive crystallization result which, in the final stages, would be X-ray quality crystals but in the initial stages could be oil droplets, granular precipitates or small crystals approximately less than 0.05 mm in size. Part A represents an initial screen of one parameter in which the range of concentration between the 50 first well (A1) and last well (D6) is large and the concentration increase between wells is calculated as (-(concentration A1)-(concentration D6))/23). Part B represents that in later stages of the crystallization matrix refinement of the concentration spread between A1 and D6 would be reduced which would result in more crystals formed per plate. Part C indicates a final stage of matrix refinement in which quality crystals are found in most wells of the plate.

...

### Detailed Description of the Invention

The present invention grows out of the discovery of the three dimensional structure of G-CSF. This three dimensional structure has been expressed via computer program for stereocopic viewing. By viewing this stereoscopically, structure-function relationships identified and G-CSF analogs have been designed and made.

### The Overall Three Dimensional Structure of G-CSF

The G-CSF used to ascertain the structure was a non-glycosylated 174 amino acid species having an Art Netrominal methionine residue incident to bacterial expression. The DNA and amino acid sequence of this G-CSF and illustrated in EIGIRF 1.

Overall, the three dimensional structure of G-CSF is predominantly helical, with 103 of the 175 residues corning a 4-shiph-helical bundle. The only other secondary structure is found in the top between the first 15 two long helicas where a 4 residue 3°0 helix is immediately followed by a 6 residue alpha helix. As shown in FIGURE 2, the overall structure has been compared with the structure reported for other proteins; growth hormone (Abdel-Meguid et al., PNAS-USA 84, 6134 (1967) and Vos et al., Science 255: 305-312 (1992), granulocyte macrophage colony stimulating factor (Didercines et al., Science 254: 1779-1782 (1991), interferon-6 (Senda et al., EMBO J. 11; 3193-3201 (1992)), interleukin-2 (McKay Science 257: 1673-1677 (1992)) and interleukin-4 (Powers et al., Science 258: 1673-1677 (1992)), and Smith et al., J. Mb Biol. 224: 899-904 (1992)). Structural similarity among these growth factors occurs despite the absence of similarity in their amino acid sequences.

Presently, the structural information was correlation of G-CSF biochemistry, and this can be summarized as follows (with sequence position t being at the N-terminus):

Sequence Position	Description of Structure	Analysis
1-10	Extended chain	Deletion causes no loss of biological activity
Cys t8	Partially buried	Reactive with DTNB and
	, , , , , , , , , , , , , , , , , , ,	Thimersososl but not with
		iodo-acetate
34	Alternative splice site	Insertion reduces biological activity
20-47 (inclusive)	Helix A, first disulfide and portion of AB helix	Predicted receptor binding region
		based on neutralizing antibody data
20, 23, 24	Helix A	Single alanine mutation of residue(s)
i		reduces biological activity. Predicted
1		receptor binding (Site B).
t 65-t 75 (inclusive)	Carboxy terminus	Deletion reduces biological activity

This biochemical information, having been gleaned from antibody binding studies, see Layton et al., Biochemistry 268: 23815-23823 (1991), was superimposed on the three-dimensional structure in order to design G-CSF analogs. The design, preparation, and testing of these G-CSF analogs is described in Example 1 below.

### EXAMPLE 1

2

This Example describes the preparation of crystalline G-CSF, the visualization of the three dimensional structure of recombinant human G-CSF via computer-generated image, the preparation of analogs, using site-directed mutagenesis or nucleic acid amplification methods, the biological assays and HPLC analysis used to analyze the G-CSF analogs, and the resulting determination of overall structure/function relationships. All cided publications are herein incorporated by reference.

### A. Use of Automated Crystallization

The need for a three-dimensional structure of recombinant human granulocyte colony stimulating factor (r-hu-G-CSF), and the availability of large quantities of the purified protein, led to methods of crystal growth by incomplete factorial sampling and seeding. Starting with the implementation of incomplete factorial

crystallization described by Jancarik and Kim J. Appl. Crystallogr. 22, 409 (1991) solution conditions that yielded oil droplets and birefringence aggregates were ascertained. Also, software and hardware of an automated pipetting system were modified to produce some 400 different crystallization conditions per day. Weber, J. Appl. Crystallogr. 20: 368-373 (1987). This procedure led to a crystallization solution which produced r-bur-G-CSF crystallogr.

The size, reproducibility and quality of the crystals was improved by a seeding method in which the number of "nucleation initiating units" was estimated by serial distinction of a seeding solution. These methods yielded reproducible growth of 20 mm r-hu-G-CSF crystals. The space group of these crystals is P2;2,2, with cell dimensions of a = 90 Å, b = 110 Å and c = 49 Å, and they diffract to a resolution of 20 Å.

### 1. Overall Methodology

10 .

25

To search for the crystallizing conditions of a new protein, Carter and Carter, J. Biol. Chem. 25t. 122191-12220 (1979) proposed the incomplete factorial method. They suggested that a sampling of a large 15 number of randomly selected, but generally probable, crystallizing conditions may lead to a successful combination of reagents that produce protein crystallization. This idea was implemented by Janacarik and Kim, J. Appl. Crystallogr. 24 409(1991), who described 32 solutions for the initial crystallization trials which cover a range of plt, salls and precipitants. Here we describe an extension of their implementation to an expanded set of 70 solutions. To minimize the human effort and error of solution preparation, the method 28 has been programmed for an automatic injection machine.

Following Weber's method of successive automated grid searching (SAGS), L'Cryst. Growth 90: 318-324(1988), the robotic system was used to generate a series of solutions which continually refined the crystalization conditions of temperature, pH, salts and precipitant. Once a solution that could reproducibly gover crystals was determined, a seeding technique which greatly improved the quality of the crystals was developed. When these methods were combined, hundreds of diffraction quality crystals (crystals diffracting to at least about 2.5 Angstroms, preferably having at least portions diffracting to below 2 Angstroms, and more preferably, approximately 1 Angstrom were produced in a few days.

Generally, the method for crystallization, which may be used with any protein one desires to crystallize, comprises the steps of:

(a) combining aqueous aliquots of the desired protein with either (i) aliquots of a salt solution, each aliquot having a different concentration of salt; or (ii) aliquot of a precipitant solution, each aliquot having a different concentration of precipitant, optionally wherein each combined aliquot is combined in the presence of a range of pH;

(b) observing said combined aliquots for precrystalline formations, and selecting said sail or precipitant combination and said pH within its efficacious in producing precytalline forms, or, if no precrystalline forms are so produced, increasing the protein starting concentration of said aqueous aliquots of protein; (c) after said sail or said precipitant concentration is selected, repeating step (a) with said previously unselected solution in the presence of said selected concentration; and

(d) repeating step (b) and step (a) until a crystal of desired quality is obtained.

The above method may optionally be automated, which provides vast savings in time and labor.

Preferred protein starting concentrations are between 10mg/ml and 20mg/ml, however this starting concentration will vary with the protein (the GCSP below was analyzed using 33mg/ml). A preferred range of salt solution to begin analysis with is (NaCl) of 0-25M. A preferred precipitant is polyethylene glycol 8000, however, other precipitants include organic solvents (such as ethanol), polyethylene glycol 8000, however, other precipitants include organic solvents (such as ethanol), polyethylene glycol molecules at having a molecular weight in the range of 500-20,000, and other precipitants known to those skilled in the art. The preferred pH range is pH 4.5. 5.0, 5.5, 6.0, 8.5, 7.0, 7.5, 8.0, 8.5, m.0. Precrystallization forms include oits, birefringement precipitants, small crystals (x approximately 0.56 mm), medium crystals (approximately 0.5 to 5 mm) and large crystals 2 papoximately 0.5 mm). The preferred dim for waiting to sea crystalline structure is 48 hours, although weekly observation is also preferred, and generally, after so about one month, a different protein concentration is situacing (generally the protein concentration is increased). Automation is preferred, using the Accullex system as modified. The preferred automation parameters are described below.

Generally, protein with a concentration between 10 mg/ml and 20 mg/ml was combined with a range of NaCl solutions from 0-2.5 M, and each such combination was performed (separately) in the presence of the sa bove range of concentrations. Once a precrystalization structure is observed, that salt concentration and Hr ange are optimized in a separate experiment, until the desired crystal quality is achieved. Next, the precipitant concentration, in the presence of varying levels of pH is also optimized. When both are optimized, the optimal conditions are performed at once to achieve the desired result (this is diagrammed in

### FIGURE 6).

### a. Implementation of an automated pipetting system

Drops and reservoir solutions were prepared by an Accullex pipetining system (IGN Pharmaceuticals, Costa Mesa, CA) which is controlled by a personal computer that sends ASCII codes through a standard serial interface. The pipetier samples six different solutions by means of a rotating valve and pipeties these solutions onto a plate whose translation in a xy coordinate system can be controlled. The vertical component of the system manuplates a sviringe that is capable both of dispensing and refrieving liquid.

The software provided with the Accullex was based on the SAGS method as proposed by Cox and Weber JADP, Crystallog 2.0 366-373 (1987). This method involves the systematic variation of two major crystallization parameters. pH and precipitant concentration, with provision to vary two others. While building on those concepts, the software used here provided greater fleability in the design and implementation of the crystallization solutions used in the automated grid searching strategy. As a result of 15 this flexibility the present software also created a larger number of different solutions. This is essential for the implementation of the incomplete factorial method as described in that section below.

To improve the speed and design of the automated grid searching strategy, the Accultex pipetting system required software and hatdware modifications. The hardware changes allowed the use of two different micro-litter trays, one used for handing drop and one used for sitting drop experiments, and a 2P Pleaglass tray which held 24 additional buffer, salt and precipitant solutions. These additional solutions expanded the grid of crystallizing conditions that could be surveyed.

To utilize the hardware modifications, the pipetting software was written in two subroutiness tone subroutine allows the crystallographer to design a matrix of crystallization solutions based on the concentrations of their components and the second subroutine to translate these concentrations into the computer solutions to the proper violence of the solutions into the crystallization trays. The concentration matrices can be generated by either of two programs. The first program (MRF, available form Amgen, Inc., Thousand Oaks, CA) refers to a list of stock solution concentrations supplied by the crystalligrapher and calculates the required volume to be pipette to achieve the designated concentration. The second method, which is preferred, incorporates a spread sheet program (Lotus ) which can be used to make more solphisticated gradients of precipitants or pH. The concentration matrix created by either program is interpreted by the control program (SUX, a modification of the program found in the Accultex pipetter originally and available from Amgen, Inc.; Thousand Oaks, CA) and the wells are filled accordingly.

### b. Implementation of the Incomplete Factorial Method

The convenience of the modified pipetting system for preparing diverse solutions improved the implementation of an expanded incomplete factorial method. The development of a new set of crystallization solutions having "random" components was generated using the program INFAC Carter et al., J.Cryst. Growth 90: 80-73(1988) which produced a list containing 96 random combinations of catcir from three ariables. Combinations of calcium and phosphate which immediately precipitated were eliminated, leaving 70 distinct combinations of precipitants, salts and butters. These combinations are prepared using the automated pipeter and incubated for 1 week. The mixtures were inspected and solutions which formed precipitants were prepared again with lower concentrations of their components. This was repeated until all wells were clear of precipitant.

### c. Crystallization of r-hu-G-CSF

35

Several different crystallization strategies were used to find a solution which produced x-ray quality crystals. These strategies included the use of the incomplete factorial method, refinement of the crystallizaso tion conditions using successive automated grid searches (SAGS), implementation of a seeding technique and development of a crystal production procedure which yielded hundreds of quality crystals overnight. Unless otherwise noted the screening and production of r-hu-C-SF crystals utilized the hanging drop vapor diffusion method. Alinsen et al., Physical principles of protein crystallization. In: Eisenberg (ed.), Advances in Protein Chemistry 41: 133 (1991).

The initial screening for crystallization conditions of r-hu-G-CSF used the Jancarik and Kim, JappiCrystallogr, 24: 409(1991) incompleie factorial method which resulted in several solutions that produced "precrystalization" results. These results included biretiniquent precipitants, oils and very small crystals (< 0.05 mm). These precrystallizations solutions then served as the starting points for systematic

screening.

The screening process required the development of crystallization matrices. These matrices corresponded to the concentration of the components in the crystallization solutions and were created using the IBM-PC based spread sheet Lotus. \*\*I and implemented with the modified Accullex pipetting system.

The strategy in designing the matrices was to vary one crystallization condition (such as salt concentration) while holding the other conditions such as pH, and precipitant concentration constant. At the start of screening, the concentration range of the varied condition was large but the concentration vas uscessively refined until all wells in the micro-tier tray produced the same crystallization result. These results were scored as follows: crystals, birefringment precipitate, groundar precipitate, oil droplets and amorphous roundary concentration of that parameter was increased until a precipitant formed. After each tray was produced, it was left undisturbed for at least two days and then inspected for crystal growth. After this initial screening, the trays were then inspected on a weekly basis.

From this screening process, two independent solutions with the same pH and precipitant but differing in salts (MgC, LISCa), were identified which produced small (0.1 x 0.05 x 0.05 mm) crystals. Based on these results, a new series of concentration matrices were produced which varied MgCl with respect to LISCa white keeping the other crystalization parameters constant. This series of experiments resulted in identification of a solution which produced diffraction quality crystals (c approximately 0.5 mm) in about three weeks. To find this crystalization growth solution (100 mM less pH 5., 800 mM MgCls, 220 mM 20 LISC4 and 8% PEG 8k) approximately 8,000 conditions had been screened which consumed about 300 mg of crystalia.

The size of the crystals depended on the number of crystals forming per drop. Trylically 3 to 5 crystals would be formed with average size of (1.0 x 0.7 x 0.7 mm). Two morphologies which had an identical space group (P2,2;2;) and unit cell dimensions a =90.2, b=110.2, c=49.5 were obtained depending on whether so or not seeding (see below) was implemented. Without seeding, the r-hu-G-CSF crystals had one long flat surface and rounded adoes.

When seeding was employed, crystals with sharp faces were observed in the drop within 4 to 8 hours (0.05 by 0.05 mm). Within 24 hours, crystals had grown to (0.7 by 0.7 by 0.7 mm) and continued to grow beyond 2 mm depending on the number of crystals forming in the drop.

### d. Seeding and determination of nucleation initiation sites.

The presently provided method for seeding crystals establishes the number of nucleation initiation units in each individual well used fiver, after the optimum conditions for growing crystals had been determined).

The method here is advantageous in that the number of "seeds" affects the quality of the crystals, and this in turn affects the degree of resolution. The present seeding, here also provides advantages in that with seeding. G-CSF crystal grows in a period of about 3 days, whereas without seeding, the growth takes approximately three weeks.

In one series of production growth (see methods), showers of small but well defined crystals were produced oversight (<001 x 0.01 mm). Crystalization conditions were followed as described above except that a pipetite ip employed in previously had been reused. Presumably, the crystal showering effect was caused by small nucleation units which had formed in the used lip and which provided sites of nucleation for the crystals. Addition of a small amount (0.5 ul) of the drops containing the crystal showers to a new drop under standard production growth conditions resulted in a shower of crystals overnight. This method was used to produce several trays of drops containing crystal showers which we termed "seed stock".

The number of nucleation initiation units (NIU) contained within the "seed stock" drops was estimated to attempt to improve the reproducibility and quality of the n-th-GCSF crystats. To determine the number of NIU in the "seed stock", an aliquot of the drop was serially diluted along a 96 well microtiter plate. The microtiter plate was prepared by adding 50 ut of a solution containing equal volumes of n-th-GCSF (33 mg/ml) and the crystal growth solution (described above) in each well. An aliquot (3 ut) of one of the "seed stock" drops was transferred to the first well of the microtiter plate. The solution in the well was mixed and 3 ut was then transferred to the next well along the row of the microtiter plate. Each row of the microtiter plate was similarly prepared and the tray was sealed with plastic tape. Overnight, small crystals formed in state toolstom of the wells of the microtiter plate has similarly prepared and the tray was sealed with plastic tape. Overnight, small crystals formed in distinct on the original "seed stock." To produce large single crystals, the "seed stock" drop was appropriately diluted into fresh CGS and then an aliquot of this solution containing the NIU was transferred to a drop.

Once crystalization conditions had been optimized, crystals were grown in a production method in which 3 ml each of CGS and r-hu-G-CSF (33 mg/ml) were mixed to create 5 trays (each having 24 wells). This method included the production of the refined crystalization solution in liter quantities, mixing this solution with protein and placing the protein/crystalization solution in either henging drop or sitting drop s trays. This process typically yielded 100 to 300 quality crystals (POS mm) in about 5 days.

### e. Experimental Methods

### Materials

Crystallographic information was obtained starting with r-hu-met-G-GF with the amino acid sequence as provided in FIGURE 1 with a specific activity of 1.0 ± 0.6 x 10 °U mg (as measured by cell mitogenesis assay in a 10 mM acetate buffer at pH 4.0 (in Water for Injection) at a concentration of approximately 3 mg/ml solution was concentrated with an Amicon concentrator at 75 psi using a YM10 fitter. The solution 5 was trivicially concentrated 10 fold at 4° C and stored for several months.

### Initial Screening

Crystals suitable for X-ray analysis were obtained by vapor-diffusion equilibrium using hanging drops. For preliminary screening, 7 ull of the protein soulton at 33 mg/ml (as prepared above) was mixed with an equal volume of the well solution, placed on siliconized glass plates and suspended over the well solution utilizing Linbro tissue culture plates (Flow Laboratories, McLaam, VA). All of the pipeting was performed with the Accultex pipetter, however, trays were removed from the automated pipetter after the well solutions had been created and thoroughly mixed for at least 10 minutes with a table top shaker. The Linbro trays were set to the present of the pipetter which added the well and protein solutions to the siliconized cover sips. The cover slips were then inverted and sealed over 1 ml of the well solutions with silicon grease.

The components of the automated crystallization system are as follows. A PC-DOS computer system was used to design a matrix of crystallization solutions based on the concentration of their components. These matrices were produced with either MRF of the Lotus spread sheet (described above). The final 30 product of these programs is a data file. This file contains the information required by the SUX program to pipette the appropriate volume of the stock solutions to obtain the concentrations described in the matrices. The SUX program information was passed through a serial I/O port and used to dictate to the Accuflex pipetting system the position of the valve relative to the stock solutions, the amount of solution to be retrieved, and then pipetted into the wells of the microtiter plates and the X-Y position of each well (the 35 column/row of each well). Addition information was transmitted to the pipetter which included the Z position (height) of the syringe during filling as well as the position of a drain where the system pauses to purge the syringe between fillings of different solutions. The 24 well microtiter plate (either Linbro or Cryschem) and cover slip holder was placed on a plate which was moved in the X-Y plane. Movement of the plate allowed the pipetter to position the syringe to pipette into the wells. It also positioned the coverslips and vials and 40 extract solutions from these sources. Prior the pipetting, the Linbro microtiter plates had a thin film of grease applied around the edges of the wells. After the crystallization solutions were prepared in the wells and before they were transferred to the cover slips, the microtiter plate was removed from the pipetting system, and solutions were allowed to mix on a table too shaker for ten minutes. After mixing, the well solution was either transferred to the cover slips (in the case of the hanging drop protocol) or transferred to 45 the middle post in the well (in the case of the sitting drop protocol). Protein was extracted from a vial and added to the coverslip drop containing the well solution (or to the post). Plastic tape was applied to the top of the Cryschem plate to seal the wells.

### Production Growth

Once conditions for crystallization had been optimized, crystal growth was performed utilizing a production" method. The crystallization solution which contained 100 mM has pH 58, 380 mM hgCt2, 220 mM LiSO4, and 8% PEG 8K was made in 1 liter quantities. Utilizing an Eppindorf syringe pipetter, 1 mi algulots of this solution were pipetted into each of the wells of the Lindrop plate. A solution containing 50% of 5th is solution and 50% GCSF (33 mgml) was mixed and pipetted onto the siliconized cover silps. Typical volumes of these drops were between 50 and 100 ul and because of the large size of these drops, great care was taken in lipping the coversilize and suspending the drops over the well.

### Data Collection

The structure has been refined with X-PLOR (Bruniger, X-PLOR version 3.0, A system for crystallography and NMR, Yale University, New Haven CT) against 2.2Å data collected on an R-AXIS (Molecular S Structure, Corp. Houston, TX) imaging plate detector.

### f. Observations

As an effective recombinant human therapeutic, r-hu-G-CSF has been produced in large quantities and or gram levels have been made available for structural analysis. The crystallization methods provided herein are likely to find other applications as other proteins of interest become available. This method can be applied to any crystallographic project which has large quantities of protein (approximately 2-20 mg). As one skilled in the art will recognize, the present materials and methods may be modified and equivalent materials and methods may be available for crystallization of other proteins.

### B. Computer Program For Visualizing The Three Dimensional Structure of G-CSF

Although diagrams, such as those in the Figures herein, are useful for visualizing the three dimensional structure of G-GSF, a computer program which allows to stereoscopic viewing of the molecule is contemplated as preferred. This stereoscopic viewing, or "virtual reality" as those in the art sometimes refer to it, allows one to visualize the structure in its three dimensional form from every angle in a wide range of resolution, from macromolecular structure down to the atomic level. The computer programs cortemplated herein also allow one to change perspective of the viewing angle of the molecule, for example by rotating the molecule. The contemplated programs also respond to changes so that one may, for example, delete, as add, or substitute one or more images of atoms, including entire amino acid residues, or add chemical moleties to existing or substituted groups, and visualize the change in structure.

Other computer based systems may be used: the elements being: (a) a means for entering information, such as orthogonal coordinates or other numerically assigned coordinates of the three dimensional structure of G-CSF; (b) a means for expressing such coordinates, such as visual means so that one may view the 50 three dimensional structure with the composition of the G-CSF molecule, such as the amino acid composition; (c) optionally, means for entering information which alters the composition of the G-CSF molecule expressed, so that the image of such three dimensional structure distings the altered composition.

The coordinates for the preferred computer program used are presented in FIGURE 5. The preferred computer program is singlet III, version 4, available from Biosym in San Diego, CA. For the raw crystallographic structure, the observed intensities of the diffraction data ("F-obs") and the orthogonal coordinates are also deposited in the Protein Data Bank, Chemistry Department, Brookhaven National Laboratory, Upton, New York 119723, USA and these are herein incorporated by reference.

Once the coordinates are entered into the Insight II program, one can easily display the three of dimensional G-CSF molecule representation on a computer screen. The preferred computer system for display is Silicon Graphics 3Vo VOX (San Diego, CA). For stereoscopic viewing, one may wear eyewear (Crystal Eyes, Silicon Graphics) which allows one to visualize the G-CSF molecule in three dimensions stereoscopically, so one may turn the molecule and envision molecular design.

Thus, the present invention provides a method of designing or preparing a G-CSF analog with the aid of a computer comprising:

(a) providing said computer with the means for displaying the three dimensional structure of a G-CSF molecule, melecule including displaying the composition of moieties of said G-CSF molecule, preferably displaying the three dimensional location of each amino acid, and more preferably displaying the three dimensional location of each amino acid, and more preferably displaying the three dimensional location of each amino acid, and more preferably displaying the three dimensional location of each amino acid.

- (b) viewing said display;
  - (c) selecting a site on said display for alteration in the composition of said molecule or the location of a moiety; and
  - (d) preparing a G-CSF analog with such alteration.

The alteration may be selected based on the desired structural characteristics of the end-product G-CSF analog, and considerations for such design are described in more detail below. Such considerations include the location and compositions of hydrophobic amino add residues, particularly residues internal to the helical structures of a G-CSF molecule which residues, when altered, after the overall structure of the internal core of the molecule and may prevent receptor binding; the location and compositions of external

loop structures, alteration of which may not affect the overall structure of the G-CSF molecule.

FIGURES 2-4 illustrate the overall three dimensional conformation in different ways. The topological diagram, the ribbon diagram, and the barrel diagram all illustrate aspects of the conformation of G-CSF.

FIGURE 2 illustrates a comparison between G-CSF and other molecules. There is a similarity of a schietcure, although these growth factors differ in the local conformations of their loops and bundle geometrics. The up-up-down-down topology with two long crossover connections is conserved, however, amon all six of these molecules, desirile the dissimilarity in amino acid sequence.

FIGURE 3 illustrates in more detail the secondary structure of recombinant human G-CSF. This ribbon diagram illustrates the handedness of the helices and their positions relative to each other.

FIGURE 4 illustrates in a different way the conformation of recombinant human G-CSF. This "barrel" diagram illustrates the overall architecture of recombinant human G-CSF.

### C. Preparation of Analogs Using M13 Mutagenesis

7s This example relates to the preparation of G-GSF analogs using site directed mutagenesis techniques involving the single stranded bacteriophage MI3, according to methods published in PCT Application No. WO 85/0817 (Souza et al., published February 28, 1985, herein incorporated by reference). This method essentially involves using a single-stranded nucleic acid template of the non-mutagenized sequence, and binding to it a smaller oligonucleotide containing the desired change in the sequence. Pytholization 20 conditions allow for non-identical sequences to hybridize and the remaining sequence is filled in to be identical to the original template. What results is a double stranded molecule, with no of the two strands containing the desired change. This mutagenized single strand is separated, and used liself as a template for its complementary strand. This creates a double stranded molecule with the desired change.

The original G-CSF nucleic acid sequence used is presented in FIGURE 1, and the oligonucleotides 25 containing the mutagenized nucleic acid(s) are presented in Table 2. Abbreviations used herein for amino acid residues and nucleotides are conventional, see Stryer, Biochemistry, 3d Ed., W.H. Freeman and Company, NY, NY, 1988, inside back cover.

The original G-CSF nucleic acid sequence was first placed into vector M13mp21. The DNA from single stranded phage M13mp21 containing the original G-CSF sequence was then isolated, and resuspended in water. For each reaction, 200 ng of this DNA was mixed with a 1.5 pmole of phosphorylated oligonucleotide (Table 2) and suspended in 0.1M Tris, 0.01M MgCls, 0.05M DTT, 0.1mM ATP, pH 8.0. The DNAs were annealed by heating to 65° C and slowly cooling to room temperature.

Once cooled, 0.5mM of each ATP, dATP, dCTP, dGTP, TTP, 1 unit of T4 DNA ligase and 1 unit of Klenow fragment of E. coli polymerase 1 were added to the 1 unit of annealed DNA in 0.1M Tris, 0.025M 39 NaCl, 0.01M MgCls, 0.01M DTT, pH 7.5.

The now double stranded, closed circular DNA was used to transfect E, coll without further purification. Plaques were screened by lifting the plaques with nitrocellulose filters, and then hybridizing the filters with single stranded DNA end-labeled with P<sup>32</sup> for 1 hour at 55-60 °C. After hybridization, the filters were washed at 0-3 °C below the melt temperature of the oligo (2 °C to AT, 4 °C for °G-G) which selectively left 49 autoratiography signals corresponding to plaques with phage containing the mutated sequence. Positive clones were confirmed by sequencino.

Set forth below are the oligonucleoides used for each G-CSF analog prepared via the M13 mulagenesis method. The normerclature indicates the residue and the position of the original amino acid (e.g., Lysine at position 17), and the residue and position of the substituted amino acid (e.g., arginine 17). A substitution involving more than one residue is indicated via superscript notation, with commas between the noted positions or a semicolon indicating different residues. Deletions with no substitutions are so noted. The oligonucleoides exerce manufactured synthetically, although the method of preparation is not critical, any nucleic acid synthesis method and/or equipment may be used. The length of the oligo is also indicated. As indicated so above, these oligos were allowed to contact the single stranded phage vector, and then single nucleoiddes were added to complete the G-CSF analog nucleic acid sequence.

### Table 2

G-CSF ANALOGS	SEOUENCES (5'->, 3')	Length (nucleotide)	Seq. ID
Lys17->Arg17	CTT TCT GCT GCG TTG TCT GGA ACA	24	Э
Lys <sup>24</sup> ->Arg <sup>24</sup>	ACA GGT TCG TCG TAT CCA GGG TG	23	4
Lys <sup>35</sup> ->Arg <sup>35</sup>	CAC TGC AAG AAC GTC TGT GCG CT	23	s
Lys41->Arg41	CGC TAC TTA CCG TCT GTG CCA TC	23	9
Lys <sup>17,24,35</sup> -> Arg <sup>17,24,35</sup>	CTT TCT GCT GCG TTG TCT GGA ACA ACA GGT TCG TCG TAT CCA GGG TG CAC TGC AAG GAC GTCT GCG CT	23 24	L 80 6
Lys <sup>17</sup> ,24,41-> Arg <sup>17</sup> ,24,41	CTT TCT GCT GCG TTG TCT GGA ACA ACA GGT TCG TAT CCA GGG TG CGC TAC TTA CCG TCT GTC CCA TC	24 23 23	10
Lys17, 35, 41-> Arg17, 35, 41	TCT GCT GCG TTG TCT GGA	23	13
Lys24,35,41-> Arg24,35,41	CGC TAC TTA CCG TCT GTG CCA TC ACA GGT TCG TCG TAT CCA GGG TG CAC TGC AAG AAC GTC TCT GCG CT CCC TAC TTA CCG TCT CTC CCC TCC	នននេះ	15 16
	INC. 11A CCG 1CI GIG CCA	5.7	×

	Table 2 (con't)		
G-CSF_ANALOGS	SEQUENCES (5'->_3')	Length (nucleotide)	Seq. ID
Lys17,24,35,41-> Arg17,24,35,41	CTT TCT GCT GGG TTG TCT GGA ACA ACA GGT TGG TGG TGT GGG CT CAC TGC AAC AAC GCT CC CT GGC TAC TTA CGG CT GGC TAC TTA CGG TCT GG CG TC	24 23 23	19 20 21 22
Cys18->Ala18 Gln68->Glu68 Cys37,43-> Ser37,43	TCT GCT GAA AGC TCT GGA ACA GG CTT GTC CAT CTG AAG CTC TTC AG GAA AAA CTG TCC GCT ACT TAC AAA CTG TCC CAT CCG G	23 23 37	23 24 25
Gln <sup>26</sup> ->Ala <sup>26</sup> Gln <sup>174</sup> ->Ala <sup>174</sup>	TTC GTA ANA TCG CGG GTG ACG G TCA TCT GGC TGC GCC GTA ATA G	22	26 27
Arg <sup>170</sup> ->Ala <sup>170</sup>	CCG TGT TCT GGC TCA TCT GGC T	22	28
Arg167->Ala167	GAA GTA TCT TAC GCT GTT CTG CGT	24	29
Lys41->Ala41		22	3 8
His <sup>44</sup> ->Lys <sup>44</sup>	CAA ACT GTG CAA GCC GGA AGA G	22	32
Glu <sup>47</sup> ->Ala <sup>47</sup>	CAT CCG GAA GCA CTG GTA CTG C	22	33

# Table 2 (con't)

Seq. ID	34	35	36	37	38	39	40	41	42	43	4	45
Lengthinucleotidel	23	25	22	19	23	23	- 20	21	23	24	24	21
SEQUENCES (5'-> 3')	GGA ACA GGT TGC TAA AAT CCA GG	GAA CAG GTT CGT GCG ATC CAG GGT G	GAA ATG TCT GGC ACA GGT TCG T	TCC AGG GTG CCG GTG CTG C	AAG AGC TCG GTG AGG CAC CAG CT	CTC AAG GTG CTG AGC CGG CAT TC	GAG CTC GGT CTG GCA CCA GC	TCA AGG TGC TCT GCC GGC ATT	TCT GCC GCA AGC CTT TCT GCT GA	CTT TCT GCT GGC ATG TCT GGA ACA	CTA TTT GGC AAG CGA TGG AAG AGC	CAG ATG GAA GCG CTC GGT ATG
G-CSF ANALOGS	Arg <sup>23</sup> ->Ala <sup>23</sup>	Lys <sup>24</sup> ->Ala <sup>24</sup>	G1u20->A1a20	Asp <sup>28</sup> ->Ala <sup>28</sup>	Met 127->Glu127	Met138->Glu138	Met 127->Leu127	Met138->Leu138	Ser <sup>13</sup> ->Ala <sup>13</sup>	Lys <sup>17</sup> ->Ala <sup>17</sup>	Gln <sup>121</sup> ->Ala <sup>121</sup>	Glu124->Ala124

## the 2 (conft

25

G-CSF ANALOGS	SEQUENCES (5'-> 3')	Lengthinucleotidel	Seq. ID
Met 127,138-> Leu127,138	GAG CTC GGT CTG GCA CCA GC TCA AGG TGC TCT GCC GGC ATT	20 21	46
**Glu20->Ala20; Ser13->Gly13	GAA ATG TCT GGC ACA GGT TCG T	22	8
** This analog came about during clones were being sequenced to id Serl <sup>3</sup> ->Gly <sup>13</sup> analog was identified NNA rolumerase reartion misses	" This analog came about during the preparation of G-CSF analog Glu <sup>20</sup> ->Ala <sup>20</sup> . As several clones were being sequenced to identify the Glu <sup>20</sup> ->Ala <sup>20</sup> analog, the Glu <sup>20</sup> ->Ala <sup>20</sup> analog, the Glu <sup>20</sup> ->Ala <sup>20</sup> analog, the Glu <sup>20</sup> ->Ala <sup>20</sup> analog was identified. This double mutant was the result of an <u>in vitro</u> Klent has notwares reaction mission.	G-CSF analog Glu <sup>20</sup> ->Ala <sup>20</sup> . La <sup>20</sup> analog, the Glu <sup>20</sup> ->Ala ant was the result of an <u>An</u>	As severa 20; vitro Kleno

### 55 D. Preparation of G-CSF Analogs Using DNA Amplification

This example relates to methods for producing G-CSF analogs using a DNA amplification technique. Essentially, DNA encoding each analog was amplified in two separate pieces, combined, and then the total

sequence itself amplified. Depending upon where the desired change in the original G-CSF DNA was to be made, internal primers were used to incorporate the change, and generate the two separate amplified pieces. For example, for amplification of the 5° and of the desired analog DNA, as 5° tanking primer (complementary to a sequence of the plasmid upstream from the G-CSF original DNA) was used at one end of the region to be amplified, and an internal primer, capable of hybridizing to the original DNA but incorporating the desired change, was used for priming the other end. The resulting amplified region stretched from the 5° flanking primer through the internal primer. The same was done for the 3° terminus, using a 3° flanking primer (complementary to a sequence of the plasmid downstream from the G-CSF original DNA) and an internal primer complementary to the region of the internal endiation. Once the two "halves" (which may or may not be equal in size, depending on the location of the internal primer) were amplified, the two "halves" were allowed to connect. Once connected, the 5° flanking primer and the 3° flanking primer are were used to amplify the entire sequence containing the desired change.

If more than one change is desired, the above process may be modified to incorporate the change into the internal primer, or the process may be repeated using a different internal primer, alternatively, the gene 16 amplification process may be used with other methods for creating changes in nucleic acid sequence, such as the phage based mulagenesis technique as described above. Examples of process for preparing analogs with more than one change are described below.

To create the G-CSF analogs described below, the template DNA used was the sequence as in FIGURE 1 plus certain flatnking regions (from a plasmid containing the G-SFF coding region). These so flatnking regions were used as the 5° and 3° flanking primers and are set forth below. The amplification reactions were performed in 40 ut volumes containing 10 mM Tris-HO, 1.5 mM MQCs, 50 mM KCl, 0.1 mg/ml gelatin, pH 8.3 at 20° C. The 40 ut reactions also contained 0.1mM of each dNTP, 10 pmoise of each primer, and 1 ng of template DNA. Each amplification was repeated for 15° cycles. Each cycle consisted of 0.5 minutes at 94° C, 0.5 minutes at 50° C, and 0.75 minutes at 72° C. Flanking primers were 20° a nucleotides in length and internal primers were 20° to 25° nucleotides in length, This resulted in multiple copies of double stranded DNA encoding either the front portion or the back portion of the desired G-CSF analog.

For combining the two "halves," one fortieth of each of the two reactions was combined in a third DNA amplification reaction. The two portions were allowed to anneal at the internal primer location, as their ends so bearing the mutation were complementary, and following a cycle of polymerization, give rise to a full length DNA sequence. Once so annealed, the whole analog was amplified using the 5' and 3' flanking primers. This amplification process was repeated for 15 cycles as described above.

The completed, amplified analog DNA sequence was cleaved with Xbal and Xhol restriction endonuclease to produce cohesive ends for insertion into a vector. The cleaved DNA was placed into a
splasmid vector, and that vector was used to transform <u>E. coil.</u> Transformants were challenged with
kanamycin at 50 ug/ml and incubated at 30 °C. Production of <u>C-CFS</u> analog protein was confirmed by
polyacrylamide gel electrophoresis of a whole cell lysate. The presence of the desired mutation was
confirmed by DNA sequence analysis of plasmid purified trem the production isolate. Cultures were then
grown, and cells were harvested, and the <u>C-CFS</u> analogs were purified as set forth below.

Set forth below in Table 3 are the specific primers used for eachanalog made using gene amplification.

Table 3

Analog Seq. ID	Internal Primer(5'->3')	
His**->Ala**	5'primer-TTCCGGAGCGCACAGTTTG 3'primer-CAAACTGTGGGCTCCGGAAGAGC	49 50
Thr117->Ala117	5'primer-ATGCCAAATTGCAGTAGCAAAG 3'primer-CTTTGCTACTGCAATTTGGCAACA	51 52
Asp110-> Ala110	5'primer-ATCAGCTACTGCTAGCTGCAGA 3'primer-TCTGCAGCTAGCAGTAGCTGACT	53 54
Gin <sup>21</sup> ->Ala <sup>21</sup>	5'primer-TTACGAACCGCTTCCAGACATT 3'primer-AATGTCTGGAAGCGGTTCGTAAAAT	55 56
Asp113->Ala113	5'primer-GTAGCAAATGCAGCTACATCTA 3'primer-TAGATGTAGCTGCATTTGCTACTAC	57 58
His <sup>53</sup> ->Ala <sup>53</sup>	5'primer-CCAAGAGAAGCACCCAGCAG 3'primer-CTGCTGGGTGCTTCTCTTGGGA	59 60
For each analog,	the following 5' flanking primer was used:	-
	5'-CACTGGCGGTGATAATGAGC	61
For each analog,	the following 3' flanking primer was used:	
	3'-GGTCATTACGGACCGGATC	62

### 1. Construction of Double Mutation

5

20

25

To make G-CSF analog Gin<sup>12,21</sup>->Giu<sup>12,21</sup>, two separate DNA amplifications were conducted to create the two DNA mutations. The template DNA used was the sequence as in FIGURE 1 plus certain flanking regions (from a plasmid containing the G-CSF coding region). The precise sequences are listed below. Each of the two DNA amplification reactions were carried out using a Perkin Elmer/Cetus DNA Thermal Cycler. The 40 ut reaction mix consisted of 1X PCR Buffer (Cetus), 0.2 mM each of the 4 dXTPs (Cetus), 35 50 pmoles of each primer oligonucleotide, 2 ng of G-CSF template DNA (on a plasmid vector), and 1 unit of Tag polymerase (Cetus). The amplification process was carried out for 30 cycles. Each cycle consisted of 1minute at 94 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C.

- DNA amplification "A" used the oligonucleotides: 5' CCACTGGCGGTGATACTGAGC 3' (Seq. ID 63) and
- 40 5' AGCAGAAAGCTTTCCGGCAGAGAAGAAGCAGGA 3' (Seq. ID 64)

  - DNA amplification "B" used the oligonucleotides: 5' GCCGCAAAGCTTTCTGCTGAAATGTCTG-GAAGAGGTTCGTAAAATCCAGGGTGA 3' (Sen. ID 65) and
  - 5' CTGGAATGCAGAAGCAAATGCCGGCATAGCACCTTCAGTCGGTTGCAGAGCTGGTGCCA 3' (Sec. ID 66)
  - From the 109 base pair double stranded DNA product obtained after DNA amplification "A", a 64 base pair Xbal to Hindlil DNA fragment was cut and isolated that contained the DNA mutation GIn12.>Glu12. From the 509 base pair double stranded DNA product obtained after DNA amplification "B", a 197 base pair Hindlil to Bsml DNA fragment was cut and isolated that contained the DNA mutation Gln21->Glu21

The "A" and "B" fragments were ligated together with a 4.8 kilo-base pair Xbal to Bsml DNA plasmid so vector fragment. The ligation mix consisted of equal molar DNA restriction fragments, ligation buffer (25 mM Tris-HCl pH 7.8, 10 mM MgCl<sub>2</sub>, 2 mM DTT, 0.5 mM rATP, and 100 ug/ml BSA) and T4 DNA ligase and was incubated overnight at 14 °C. The ligated DNA was then transformed into E. coli FM5 cells by electroporation using a Bio Rad Gene Pulsar apparatus (BioRad, Richmond, CA). A clone was isolated and the plasmid construct verified to contain the two mutations by DNA sequencing. This 'intermediate' vector also 55 contained a deletion of a 193 base pair Bsml to Bsml DNA fragment. The final plasmid vector was constructed by ligation and transformation (as described above) of DNA fragments obtained by cutting and isolating a 2 kilo-base pair Sstl to BamHI DNA fragment from the intermediate vector, a 2.8 kbp Sstl to EcoRI DNA fragment from the plasmid vector, and a 360 bp BamHI to EcoRI DNA fragment from the

plasmid vector. The final construct was verified by DNA sequencing the G-CSF gene. Cultures were grown, and the cells were harvested, and the G-CSF analogs were purified as set forth below.

As indicated above, any combination of mutagenesis techniques may be used to generate a G-CSF analog nucleic acid (and expression product) having one or more than one alteration. The two examples above, using M13-based mutagenesis and gene amplification-based mutagenesis, are illustrative.

### E. Expression of G-CSF Analog DNA

The G-CSF analog DNAs were then placed into a plasmid vector and used to transform <u>E. coli</u> strain 10. FMS (ATCC9311). The present G-CSF analog DNAs contained on plasmids and in bacterial host cells are available from the American Type Culture Collection, Rockville, MD, and the accession designations are indicated below.

One liter cultures were grown in broth containing 10g tryptone, 5g yeast extract and 5g NaCl) at 30°C until reaching a density at A<sup>50</sup>0 of 0.5, at which point they were rapidly heated to 42°C. The flasks were allowed to continue shaking at 10r three hours.

Other prokaryotic or eukaryotic host cells may also be used, such as other bacterial cells, strains or species, mammalian cells in culture (COS, CHO or other types) insect cells or multicellular organs or organisms, or plant cells or multicellular organs or organisms, and a skilled practitioner will recognize the appropriate host. The present C-SFF analogs and related compositions may also be prepared synthetically, so as, for example, by solid phase peptide synthesis methds, or other chemical manufacturing techniques. Other crining and excressions systems will be apparent to those skilled in the art.

### F. Purification of G-CSF Analog Protein

55

Cells were harvested by centrifugation (10,000 x G, 20 minutes, 4 °C). The pellet (usually 5 grams) was resuspended in 30 ml of 1mM DTT and passed three times through a French press cell at 10,000 psi. The broken cell suspension was centrifuged at 10,000g for 30 minutes, the supernatant removed, and the pellet resuspended in 30-40 ml water. This was recentrifuged at 10,000 x G for 30 minutes, and this pellet was dissolved in 25 ml of 2% Sarkosyl and 50mM Tris at pH 8. Copper sulfate was added to a concentration of 30 40uM, and the mixture was allowed to stir for at least 15 hours at 15-25 °C. The mixture was then centrifuged at 20,000 x G for 30 minutes. The resultant solubilized protein mixture was diluted four-fold with 13.3 mM Tris, pH 7.7, the Sarkosyl was removed, and the supernatant was then applied to a DEAEcellulose (Whatman DE-52) column equilibrated in 20mM Tris, pH 7.7. After loading and washing the column with the same buffer, the analogs were eluted with 20mM Tris /NaCl (between 35mM to 100mM 35 depending on the analog, as indicated below), pH 7.7. For most of the analogs, the eluent from the DEAE column was adjusted to a pH of 5.4, with 50% acetic acid and diluted as necessary (to obtain the proper conductivity) with 5mM sodium acetate pH 5.4. The solution was then loaded onto a CM-sepharose column equilibrated in 20 mM sodium acetate, pH 5.4. The column was then washed with 20mM NaAc, pH 5.4 until the absorbance at 280 nm was approximately zero. The G-CSF analog was then eluted with sodium 40 acetate/NaCl in concentrations as described below in Table 4. The DEAE column eluents for those analogs not applied to the CM-sepharose column were dialyzed directly into 10mM NaAc, ph 4.0 buffer. The purified G-CSF analogs were then suitably isolated for in vitro analysis. The salt concentrations used for eluting the analogs varied, as noted above. Below, the salt concentrations for the DEAE cellulose column and for the CM-sepharose column are listed:

Table 4
Salt Concentrations

Analog	DEAE Cellulose	CM-Sepharose
Lys17->Arg17	35mM	37.5mM
Lys24->Arg24	35mM	37.5mM
Lys35->Arg35	35mM	37.5mM
Lys41->Arg41	35mM	37.5mM
Lys17,24,35-	35mM	37.5mM
>Arg17,24,35		
Lys17,35,41_	35mM	37.5mM
>Arg17,35,41		

25

### Table 4 Con't

5	Analog	DEAE Cellulose	CM-Sepharose
	Lys24,35,41_	35mM	37.5mM
	>Arg24,35,41		
10	Lys17,24,35,41	35mM	37.5mM
	->Arg17,24,35,41		
	Lys17,24,41_	35mM	37.5mM
	>Arg17,24,41		
15	Gln68->Glu68	60mM	37,5mM
	Cys37,43->Ser37,43	40 mM	37.5mM
	Gln26->Ala26	40mM	40 mM
20	Gln174->Ala174	40 mM	40 mM
	Arg170->Ala170	40 mM	4 0 mM
	Arg167->Ala167	40 mM	4 OmM
25	Deletion 167*	N/A	N/A
	Lys41->Ala41	160mM	40 mM
	His44->Lys44	40 mM	60mM
	Glu <sup>47</sup> ->Ala <sup>47</sup>	4 0 mM	4 0 mM
30	Arg23->Ala23	4 0 mM	40mM
	Lys24->Ala24	120mM	40mM
	$Glu^{20}->Ala^{20}$	4 0 mM	60mM
35	$Asp^{28}->Ala^{28}$	4 0 mM	80mM
	$Met^{127}->Glu^{127}$	80mM	4 0 mM
	$Met^{138}->Glu^{138}$	80mM	40mM
	Met127->Leu127	40 mM	40mM
40	Met 138->Leu138	4 0 mM	4 0 mM
	Cys18->Ala18	4 0 mM	37.5mM
	Gln12,21->Glu12,21	60mM	37.5mM
45	Gln12,21,68-	60mM	37.5mM
	>Glu12,21,68		
	Glu <sup>20</sup> ->Ala <sup>20</sup> ;		
50	Ser <sup>13</sup>		
	->Gly <sup>13</sup>	40 mM	80mM

Table 4 Con't

5	Analog	DEAE Cellulose	CM-Sepharose
	Met127,138_	40mM	4 0 mM
	>Leu127,138		
10 .	Ser13->Ala13	40mM	4 0 mM
•	Lys <sup>17</sup> ->Ala <sup>17</sup>	80mM	40mM
	$Gln^{121}->Ala^{121}$	40mM	60mM
15	Gln <sup>21</sup> ->Ala <sup>21</sup>	50mM	Gradient 0 -150mM
75	His44->Ala44**	40mM	N/A
	His53->Ala53**	5 0 mM	N/A
	Asp110->Ala110**	4 0 mM	N/A
20	Asp113->Ala113**	40mM	N/A
	Thr117->Ala117**	50mM	N/A
	Asp <sup>28</sup> ->Ala <sup>28</sup> ;	50mM	N/A
25	Asp110		
	Ala110**		
	Glu124->Ala124**	40mM	40mM

- \* For Deletion 167, the data are unavailable. \*\* For these analogs, the DEAE cellulose column alone was use for purification.
- The above purification methods are illustrative, and a skilled practitioner will recognize that other means are available for obtaining the present G-CSF analogs.

### G. Biological Assays

- Agardlass of which methods were used to create the present G-CSF analogs, the analogs were subject to assays for biological activity. Trillated thymidine saxsys were conducted to ascortain the degree of cell idivision. Other biological assays, however, may be used to ascortain the desired activity, Biological assays such as assaying for the ability to induce terminal differentiation in mouse WEH-SB OF to I buckernic cell line, also provides indication of G-CSF activity. See Nicola, et al., Blood 54; 614-27 (1979). Other in vitro assays may be used to ascertain biological activity and broise, and, and were Biochem. S8: 457-7 (1989). In general, the test for biological activity should provide analysis for the desired result, such as increase or decrease in biological activity (as compared to non-altered G-CSF), different biological activity (as compared to non-altered G-CSF), neceptor affinity analysis, or serum half-life analysis. The list is incomplete, and those skilled in the art will reconsize other assays useful for totaling for the desired and result.
- The 3H-thymidine assay was parformed using standard methods. Bone marrow was obtained from sacrificed female Baib C mice. Bone marrow cells were briefly suspended, centrifuged, and resuspended in a growth medium. A 160 ul aliquot containing approximately 10,000 cells was placed into each well of a 86 well micro-tier plate. Samples of the purified G-GSF analogies prepared above) were added to each well, and incubated for 68 hours. Tritiated thymidine was added to the wells and allowed to incubate for 5 sadditional hours. After the 5 hour incubation time, the cells were harvested, filtered, and thoroughly rinsed. The filters were added to a valic containing scitnillation fluid. The bota emissions were counted (LKB Betaplate scintillation counter). Standards and analogs were analyzed in triplicate, and samples which the substantially above or below the standard curve were re-assayed with the proper distinto. The results

reported here are the average of the triplicate analog data relative to the unaltered recombinant human G-CSF standard results.

### H. HPLC Analysis

High pressure liquid chromatography was performed on purified samples of analog. Although peak position on a reverse phase HPLC column is not a definitive indication of structural similarly between two proteins, analogs which have similar retention times may have the same type of hydrophobic interactions with the HPLC column as the non-altered molecule. This is one indication of an overall similar structure.

38 Asriples of the analog and the non-altered recombinant human 6-CSF were analyzed on a reverse phase (0.4s x 25 cm) Vydac 214TPS4 column (Separations Group, inc. Hesperia, CA). The purified analog G-CSF samples were prepared in 20 mM acetate and 40 mM NaCl solution buffered at pH 5.2 to a final concentration of 0.1 mg/ml to 5 mg/ml, depending on how the analog performed in the column. Navigar amounts (depending on the concentration) were loaded onto the HPLC column, which had been equilibrated to with an aqueous solution containing 1% isopropanol, 52.8% acetonifrie, and .39% trifluoro acetate (TFA). The samples were subjected to a gradient of 0.88%/mlnute acetonifrie, and .30% trifluoro acetate (TFA).

### I. Results

Presented below are the results of the above biological assays and HPLC analysis. Biological activity is the average of triplicate data and reported as a percentage of the control standard (non-altered G-CSF). Relative the LC peak position is the position of the analog G-CSF relative to the control standard (non-altered G-CSF) peak. The "" or ""-" symbols indicate whether the analog HPLC peak was in advance of or followed the control standard peak (in minutes). Not all of the variants had been analyzed for relative HPLC peak, and only those so analyzed are included below. Also presented are the American Type Culture Collection designations for E\_coll host cells containing the nucleic acids coding for the present analogs, as prepared above.

### Table 5

					& Normal
			Relative		G-CSF
Seq. ID	Seq. ID Variant	Analog	HPLC Peak	ATCC No.	Activity
19	1	Lys17->Arg17	N/A	69184	N/A
89	2	Lys24->Arg24	N/A	69185	N/A
69	е	Lys35->Arg35	N/A	69186	N/A
0,	4	Lys41->Arg41	N/A	69187	N/A
11	S	Lys17,24,35->Arg17,24,35	N/A	69169	N/A
72	9	Lys17, 35, 41->Arg17, 35, 41	N/A	69192	N/A
73	7	Lys24, 35, 41->Arg24, 35, 41	N/A	69191	N/A
74	60	Lys17, 24, 35, 41	N/A	69193	N/A
		->Arg17, 24, 35, 41			
75	6	Lys17, 24, 41->Arg17, 24, 41	N/A	69190	N/A
9/	10	Gln68->Glu68	N/A	69196	N/A
LL	11	Cys37,43->Ser37,43	N/A	69197	N/A
7.8	12	G1n <sup>2</sup> 6->A1a <sup>2</sup> 6	96.+	69201	518
19	13	Gln174->Ala174	+.14	69202	1008
80	14	Arg170->Ala170	+.78	69203	100%

## Table 5 Con

Normal 8

Seq. ID         Variant         Analog         HPLC Feak         ATCC NO.         ACTIVITY           81         15         Argle7-Alalef         +.54         69204         110h           82         17         Lys4L-Alalef         +.54         69204         110h           83         16         His44-Alalef         +.25         69206         814           84         18         His44-Alalef         +.15         69206         814           85         19         Glud*-Alad        153         69212         70h           86         20         Acg23-Alad         +.14         69205         03           86         21         Lys4A-Alade         +.195         69213         04           89         22         Glu20-Alade         +.195         69210         04           89         23         Asp28-Alade        30         69210         04           90         24         Met 137-Sclu127         N/A         69220         N/A           91         25         Met 138-Alade         N/A         6929         N/A           92         26         Met 138-Alade         N/A         69199         N/A				Relative		G-CSF
15   Arg167->Ala167   +.54   69204     16   Deletion   167  99   69207     17   Lys41->Ala41   +.25   69208     18   Hig44->Lyg44   -1.53   69212     19   Clu47->Ala47   +.14   69208     20   Arg32->Ala23  03   69205     21   Lys24->Ala24   +.14   69205     22   Clu20->Ala20  03   69201     23   Asp28->Ala28  00   69211     24   MeL127->Clu127   N/A   69223     25   MeL134->Clu127   N/A   69223     26   Cyg48->Ala18   N/A   69199     27   MeL138->Leul77   N/A   69199     28   Cyg48->Ala20   Cyg48->Ala20     30   Clu12.21.66   Cyg49     31   Clu20->Ala20; Ser13   +1.74   69209     31   Clu20->Ala20; Ser13   +1.74   69209     32   Cyg48->Ala20; Ser13   +1.74   69209     33   Clu20->Ala20; Ser13   +1.74   69209     34   Clu20->Ala20; Ser13   +1.74   69209     35   Cyg48->Ala20; Ser13   +1.74   69209     36   Cyg49   Cyg49   Cyg49   Cyg49     37   Cyg49   Cyg49   Cyg49     38   Cyg49   Cyg49   Cyg49     39   Cyg49   Cyg49   Cyg49     30   Cyg49   Cyg49   Cyg49     30   Cyg49   Cyg49   Cyg49     31   Cyu20->Ala20; Ser13   +1.74   69209     32   Cyg49   Cyg49   Cyg49     33   Cyg49   Cyg49   Cyg49     34   Cyg49   Cyg49     35   Cyg49   Cyg49     36   Cyg49   Cyg49     37   Cyg49   Cyg49     38   Cyg49   Cyg49     39   Cyg49   Cyg49     30   Cyg49   Cyg49	Seq. ID	Variant	Analog	HPLC Peak		Activity
Deletion 16799 69207  Lys41->Ala41 +.25 69208  His44-Lyg44153 69208  His424-Lyg44153 69212  Arg23-AAla2303 69212  Lys24->Ala24 +1.95 69213  Glu30->Ala2003 69210  Asp28->Ala20007 69211  Asp28->Ala20007 69211  Met 138->Leu127 N/A 69223  Met 138->Leu127 N/A 69199  Glu127->Leu127 N/A 69199  Glu127->Leu127 N/A 69199  Glu20->Ala20 Ser13 +1.74 69195	81	15	Arg167->Ala167	+.54	69204	1108
Lys41->Ala41  His44-bys44  -1.53  GP208  His44-bys44  -1.53  GP202  Arg23->Ala23  -1.35  GP205  Arg24->Ala23  -1.35  GP205  Lys24->Ala23  -1.35  GP205  Lys24->Ala23  -1.35  GP205  Lys24->Ala24  +1.95  GP211  Asp28->Ala29  Het 138->Leu127  Het 138->Leu138  Het 138->Leu138  Het 138->Leu138  Het 138->Leu138  Het 138->Leu127  Hor GP205  GP207  Het 138->Leu138  Het	82	16	Deletion 167	99	69207	N/A
H1844->Lyg44 -1.53 69212  G1d7->Ala47 +14 69205  Lyg5d->Ala23 -0.3 69206  Lyg5d->Ala24 +1.95 69213  G1u20->Ala20 -0.07 69211  Asp8a->Ala28 -0.07 69211  Met 127->Clu127 N/A 69222  Met 138->Leu138 N/A 69199  Gys18->Ala28 N/A 69199  Gys18->Ala28 N/A 69199  Gln12.21.66->Clu12.21 N/A 69199  Gln12.21.66->Clu12.21 N/A 69199  Gln12.21.66->Clu12.21 N/A 69199  Gln2.21.66->Clu12.21 N/A 69199	83	11	Lys41->Ala41	+.25	69208	818
CU47->Ala47  Arg23-AAa23  Lys42-AAa24  Lys42-AAa24  CU28-AAa20  CU38-B-AAa20  CU38-B-AAa28  CU38-B-AAa28  CY38-B-AAa28  MA 69223  Met.138->Leu127  MA 69222  Met.138->Leu127  MA 69199  Cys18->Ala8  Cln12.21.66-Sclu12,21  Cln12.21.66-Sclu12,21,68  Clu20-AAa20  Clu20-AAa20, Ser13  1.74  69205	84	18	His44->Lys44	-1.53	69212	70%
Arg <sup>23</sup> ->Ala <sup>23</sup> 03     69206       Lys <sup>24</sup> ->Ala <sup>24</sup> +1.95     69213       Gu <sup>20</sup> ->Ala <sup>20</sup> -0.07     69211       Asp <sup>28</sup> ->Ala <sup>28</sup> -3.0     69210       Het <sup>127</sup> ->Gu <sup>1127</sup> N/A     69223       Met <sup>138</sup> ->Leu <sup>127</sup> N/A     69223       Het <sup>138</sup> ->Leu <sup>127</sup> N/A     69199       Cys <sup>18</sup> ->Ala <sup>20</sup> N/A     69199       Cys <sup>18</sup> ->Ala <sup>21</sup> N/A     69186       Gln <sup>22</sup> , 2-yala <sup>21</sup> N/A     69186       Gln <sup>22</sup> , 2-yala <sup>21</sup> N/A     69194       Gln <sup>22</sup> , 2-yala <sup>20</sup> Ser <sup>13</sup> +1.74     69209	82	19	Glu47->Ala47	+.14	69205	*0
Lys <sup>24</sup> ->Ala <sup>24</sup> +1.95 69213 Glu <sup>20</sup> ->Ala <sup>20</sup> -0.07 69211 Asp <sup>28</sup> ->Ala <sup>20</sup> -0.07 69211 Asp <sup>28</sup> ->Ala <sup>20</sup> -0.07 69210 Met <sup>27</sup> ->Leu <sup>1</sup> <sup>27</sup> N/A 69222 Met <sup>138</sup> ->Leu <sup>1</sup> <sup>27</sup> N/A 69199 Gyll <sup>27</sup> ->Leu <sup>1</sup> <sup>27</sup> N/A 69199 Gyll <sup>27</sup> ->Lou <sup>1</sup> <sup>27</sup> N/A 69199 Glu <sup>27</sup> ->Ala <sup>27</sup> ->21,68 N/A 69195 Glu <sup>20</sup> ->Ala <sup>20</sup> , Ser <sup>13</sup> +1.74 69209	98	20	Arg <sup>23</sup> ->Ala <sup>23</sup>	03	69206	318
Glu <sup>20</sup> ->Ala <sup>2</sup> 0 -0.07 69211 Asp <sup>28</sup> ->Ala <sup>2</sup> 830 69210 Het <sup>120</sup> ->Glu <sup>20</sup> - Het <sup>138</sup> ->Leu <sup>138</sup> N/A 69222 Het <sup>138</sup> ->Leu <sup>138</sup> N/A 69199 Gys <sup>18</sup> ->Ala <sup>18</sup> N/A 69199 Gys <sup>18</sup> ->Ala <sup>18</sup> N/A 69199 Glu <sup>20</sup> ->Ala <sup>2</sup> 1 N/A 69199 Glu <sup>20</sup> ->Ala <sup>2</sup> 1 N/A 69199 Glu <sup>20</sup> ->Ala <sup>2</sup> 1 N/A 69199 Glu <sup>20</sup> ->Ala <sup>2</sup> 0, Ser <sup>13</sup> 1.74 69209	18	21	Lys <sup>24</sup> ->Ala <sup>24</sup>	+1.95	69213	80
Asp28->Ala28        30         69210           Met127->Glu127         N/A         69223           Met138->Glu138         N/A         69222           Met138->Leu127         N/A         69196           Met138->Leu138         N/A         69196           Cys18->Ala18         N/A         69196           GIn12.21-Gl-Scu12,21         N/A         69194           GIn2.21-Gl-Scu12,21,68         N/A         69194           GIn2.2-Ala20, Ser13         +1.74         69209	88	22	Glu <sup>20</sup> ->Ala <sup>20</sup>	-0.07	69211	*0
Met 127->G1u127     N/A     69223       Met 138->G1u138     N/A     69222       Met 138->Leu127     N/A     69198       Met 138->Leu138     N/A     69199       Cys18-An1a18     N/A     69199       G1n12, 21.>G112, 21     N/A     69186       G1n2, 21.>G2->G1u2, 21, 68     N/A     69195       G1u20->A1a20;     Ser 13     +1.74     69209	89	23	Asp <sup>28</sup> ->Ala <sup>28</sup>	30	69210	1478
Met 138->G1u138         N/A         69222           Met 138->Leu127         N/A         69198           Met 138->Leu138         N/A         69199           Gys18-Antal8         N/A         69188           Gln2,21-G1u12,21         N/A         69184           Gln2,21-G6-SG1u12,21         N/A         69194           Glu20->Ana20, Ser13         +1.74         69209	6	24	Met 127->Glu127	N/A	69223	N/A
Met.127->Leu127         N/A         69198           Met.138->Leu138         N/A         69199           Cys18->Azial9         N/A         69188           GL12,21->Lu12,21         N/A         69194           Gln12,21->GL02,21,68         N/A         69195           GLu20->Azia20, Ser13         +1.74         6209	16	25	Met 138->Glu138	N/A	69222	N/A
Met. <sup>138</sup> ->Leul <sup>38</sup> Cys <sup>18</sup> ->Ala <sup>18</sup> Gla <sup>2</sup> (2)->Cla <sup>2</sup> (2)-2 N/A 69194  Gla <sup>2</sup> (2)-2 Sul <sup>2</sup> (2) N/A 69194  Gla <sup>2</sup> (2)-2 Sul <sup>2</sup> (2) 68 N/A 69195  Gla <sup>2</sup> (2)-Ala <sup>2</sup> (2), Ser <sup>13</sup> +1.74 69209	95	56	Met <sup>127</sup> ->Leu <sup>127</sup>	N/A	69198	N/A
Cys <sup>18</sup> ->Ala <sup>18</sup> N/A 69188 Gln <sup>12</sup> , <sup>21</sup> ->Glu <sup>12</sup> , <sup>21</sup> N/A 69194 Gln <sup>12</sup> , <sup>21</sup> , <sup>68</sup> ->Glu <sup>20</sup> ->Ala <sup>20</sup> ; Ser <sup>13</sup> +1.74 69209	93	27	Met138->Leu138	N/A	69199	N/A
Gln <sup>12</sup> ,21->Glu <sup>12</sup> ,21 N/A 69194 Gln <sup>12</sup> ,21,68->Glu <sup>12</sup> ,21,68 N/A 69195 Glu <sup>20</sup> ->Ala <sup>20</sup> ; Ser <sup>13</sup> +1.74 69209	94	28	Cys <sup>18</sup> ->Ala <sup>18</sup>	N/A	69188	N/A
Gln <sup>1</sup> 2,21,68->Glu <sup>1</sup> 2,21,68 N/A 69195 Glu <sup>2</sup> 0->Ala <sup>2</sup> 0, Ser <sup>1</sup> 3 +1.74 69209	92	53	Gln12, 21->Glu12, 21	N/A	69194	N/A
+1.74 69209	96	30	Gln12, 21, 68->Glu12, 21, 68	N/A	69195	N/A
	16	31	Glu <sup>20</sup> ->Ala <sup>20</sup> ; Ser <sup>13</sup>	+1.74	69209	80

#
g
Ч
न
а

					% Normal
			Relative		G-CSF
Seq. ID Variant Analog	Variant	Analog	HPLC Peak	ATCC No.	Activity
		->G1y <sup>13</sup>			
96	32	Met127,138->Leu127,138	+1.43	69200	886
66	33	Ser <sup>13</sup> ->Ala <sup>13</sup>	0	69221	110%
100	34	Lys <sup>17</sup> ->Ala <sup>17</sup>	+.50	69226	70%
101	35	Gln121->Ala121	+2.7	69225	100%
102	36	Gln <sup>21</sup> ->Ala <sup>21</sup>	+0.63	69217	9.68
103	37	His44->Ala44	+1.52	69215	10.8%
104	38	His53->Ala53	+0.99	69219	8.3%
105	39	Asp110->Ala110	+1.97	69216	29%
106	40	Asp <sup>113</sup> ->Ala <sup>113</sup>	-0.34	69218	80
107	41	Thr117->Ala117	+0.4	69214	9.78
108	42	Asp <sup>28</sup> ->Ala <sup>28</sup> ; Asp <sup>110</sup>	+3.2	69220	20.6%
		A1a110			

Table 5 Con't

5

10.

15

25

30

G-CSF	Activity	75%	80	the oligo which	red identically to	
	HPLC Peak ATCC No. Activity	69224		rtent error 1	thus was prepa	
Relative	HPLC Peak	+0.16	+0.53	of an inadve	a II'), and t	illable.
	Analog	Glu124->Ala124	Phell4->Val 114, Tll7->All7** +0.53	**This analog was apparently a result of an inadvertent error in the oligo which	was used to prepare number 41, above (Thril'->Ala 11'), and thus was prepared identically to	"N/A" indicates data which are not available.
	Seq. ID Variant Analog	43	44	**This	to prepa	"N/A"
	Seq. ID	109	110		was used	circ proc

### 1. Identification of Structure-Function Relationships

The first step used to design the present analogs was to determine what moieties are necessary for structural integrity of the G-CSF molecule. This was done at the amino acid residue level, although the

atomic level is also available for analysis. Modification of the residues necessary for structural integrity results in change in the overall structure of the G-CSF molecule. This may or may not be desirable, depending on the analog one wishes to produce. The working examples here were designed to maintain the overall structural integrity of the G-CSF micespot call, for the purpose of maintain G-CSF receptor integrity of the G-CSF receptor (as used in this section below, the "G-CSF receptor" refers to the natural G-CSF receptor, found on hematopoietic cells). It was assumed, and confirmed by the studies presented here, that G-CSF receptor binding is a necessary step for at least one biological activity, as determined by the above biological assays.

As can be seen from the figures, G-CSF (here, recombinant human met-G-CSF) is an antigarated 4- alpha helical bundle with a leth-anded twist, and with overall dimensions of 45 Å x 30 Å x 24Å. The tour helices within the bundle are referred to as helices A, B, C and D, and their connecting loops are known as the AB, BC and CD (loops. The helix crossing angies range from -167.5 to -159.4 \* Helices A, B, and C are straight, whereas heir D contains two kinds of structural characteristics, at (dly 150 and Ser 160 (of the recombinant human met-G-CSF). Overall, the G-CSF molecules is a bundle of four helices, connected in series by external loops. This structural information was then correlated with known functional information. It was known that residues (including methionine at position 1) 47, 23, 24, 20, 21, 44, 53, 113, 110, 28 and 114 may be modified, and the effect on biological activity would be substantial.

The majority of single mutations which lowered biological activity were centened around two regions of G-CSF that are separated by 30Å, and are located on different faces of the four helik bundle. One region so involves interactions between the A helix and the D helix. This is further confirmed by the presence of salt bridges in the non-attent moleculae as follows:

Atom	Helix	Atom	Helix	Distance
Arg 170 N1	D	Tyr 166 OH	Α	3.3
Tyr 166 OH	D	Arg 23 N2	Α	3.3
Glu 163 OE1	D	Arg 23 N1	Α	2.8
Arg 23 N1	Α	Gln 26 OE1	Α	3.1
Gln 159 NE2	D	Gin 26 O	Α .	3.3

Distances reported here were for molecule A, as indicated in FIGURE 5 (wherein three G-CSF annolcules crystallized together and were designated as A, B, and C), As can be seen, there is a web of stall bridges between helix A and helix D, which act to stabilize the helix A structure, and therefore affect the overall structure of the G-CSF molecule.

30

The area centering around residues Glu 20, Arg 23 and Lys 24 are found on the hydrophilic face of the A helix (residues 20-37). Substitution of the residues with the non-charged alanine residue at positions 20 and 23 resulted in similar HPLC retention times, indicating similarity in structure. Alteration of these sites altered the biological activity (as indicated by the present assays). Substitution at Lys 24 altered biological activity. but did not result in a similar HPLC retention time as the other two alterations.

The second site at which alteration lowered biological activity involves the AB helix. Changing glutamine at position 47 to alanie (natalog no. 19, above) orduced biological activity (in the thymidine uptake assay) to zero. The AB helix is predominantly hydrophobic, except at the amino and carboxy termini; it contains one unro a 31° helix. There are two histadines at each termini (Hs 44 and His 56) and an additional glutamate at residue 46 which has the potential to form a sath bridge to His 44. The fourier transformed infra red spectrographic enalysis (FIRI) of the analog suggest this analog is structurally similar to the non-altered recombinant G-CSF molecule. Further testing showed that this analog would not crystallize under the same conditions as the non-altered recombinant molecule.

Alterations at the carboxy terminus (Gln 174, Arg 187 and Arg 170) had little effect on biological activity, in contrast, deletion of the last eight residues (167-178) lowered biological activity, These results may indicate that the deletion destabilizes the overall structure which prevents the mutant from proper binding to the G-CSF receptor (and thus initiating signal transduction).

Generally, for the G-CSF internal core — the internal four helix bundle lacking the external loops —the hydrophobic internal residues are essential for structural integrity. For example, in helix A, the internal hydrophobic residues are (with methionine being position 1) Phe 14, Cys 18, Val 22, Ile 25, Ile 32 and Leu 36. Generally, for the G-CSF internal core — the internal four helix bundle lacking the external loops —the hydrophobic internal residues are essential for structural integrity. For example, in helix A, the internal hydrophobic residues are (with methionine being position 1 as in FIGURE 1) Phe 14, Cys 18, Val 22, Ile 25, Ile 32 and Leu 35. The other hydrophobic residues are (with methionine being position 1 as in FIGURE 1) Phe 14, Cys 18, Val 22, Ile 25, Ile 32 and Leu 35. The other hydrophobic residues (again with the met at position 1) are: helix B, Alar 72,

Leu 76, Leu 79, Leu 83, Tyr 86, Leu 90 Leu 93; helix C, Leu 104, Leu 107, Val 111, Ala 114, lle 118, Met 122; and helix D, Val 154, Val 158, Phe 161, Val 164, Val 168, Leu 172.

The above biological activity data, from the presently prepared G-CSF analogs, demonstrate that modification of the external loops interfere losal with G-CSF overall structure. Preferred loops for analog 5 prepration are the AB loop and the CD loop. The loops are relatively flexible structures as compared to the helices. The loops may contribute to the proteolysis of the molecule. G-CSF is relatively flast acting in vivo as the purpose the molecule servers is one prevents a response to a biological challenge, i.e., selectively stimulate neutrophils. The G-CSF turnover rate is also relatively fast. The flexibility of the loops may provide a "handle" for proteases to attach to the molecule to inactivate the molecule. Modification of the loops to prevent protease degradation, yet have (via retention of the overall structure of non-modified G-CSF) no loss in biological activity may be accomplished.

This phenomenon is probably not limited to the G-CSF molecule but may also be common to the other molecules with known similar overall structures, as presented in Figure 2. Altertation of the external loop of, for example hGH, Interferon 8, ft.2, GM-CSF and ft.4 may provide the least change to the overall structure. 5 The external loops on the GM-CSF molecule are not as flexible as those found on the G-CSF molecule, and this may indicate a longer serum life, consistent with the broader biological activity of GM-CSF. Thus, the external loops from the beta-sheet structure, which may make the loops more flexible (similar to those G-CSF) and therefore make the molecule more susceptible to protease degradation (and thus increase the turnover rate).

Alteration of these external loops may be effected by stabilizing the loops by connection to one or more of the internal helices. Connecting means are known to those in the art, such as the formation of a beta sheet, salt bridge, disulfide bonding or hydrophobic interactions, and other means are available. Also, deletion of one or more moieties, such as one or more amino acid residues or portions thereof, to prepare an abbreviated molecule and thus eliminate certain portions of the external loops may be effected.

28 Thus, by alteration of the external loops, preferably the AB loop (amino acids 58-72 of r-hu-met G-CSF) or the CD loop (amino acids 118 to 145 of 1-hu-met-G-CSF), and less preferably the amino terminus (amino acids 1-10), one may therefore modify the biological function without elimination of G-CSF G-CSF receptor binding. For example, one may: (1) increase half-life (or prepare an oral dosage form, for example) of the G-CSF molecule by, for example, decreasing the ability of proteases to act on the G-CSF molecule or adding so chemical modifications to the G-CSF molecule, such as one or more polyethylene glycol molecules or enteric coatings for oral formulation which would act to change some characteristic of the G-CSF molecule as described above, such as increasing serum or other half-life or decreasing antigenicity; (2) prepare a hybrid molecule, such as comber or with part or all of another protein such as another cytokine or another protein which effects signal transduction via entry through the cell through a G-CSF G-CSF receptor 5 transport mechanism; or (3) increase the biological activity as in, for example, the ability to selectively stimulate neutrophils (as compared to a non-modified G-CSF molecule). This list is not limited to the above exemplers.

Another aspect observed from the above data is that stabilizing surface interactions may affect biological activity. This is apparent from comparing analogs 2 and 40. Analog 22 contains a substitution of 40 the charged asparagine residue at position 28 for the neutrally-charged alanine residue in that position, and such substitution resulted in a 50% increase in the biological activity (as measured by the disclosed thymidine uptake assays). The asparagine residue at position 28 has a surface interaction with the asparagine residue at position 113; both residues being negatively charged, there is a certain amount of instability (due to the repelling of like charged moieties). When, however the asparagine at position 113 is of replaced with the neutrally-charged alanine, the biological activity drops to zero (in the present assay system). This indicates that the asparagine at position 113 is critical to biological activity, and elimination of the asparagine at position 114 possesses.

The domains required for G-CSF receptor binding were also determined based on the above analogs prepared and the G-CSF structure. The G-CSF receptor binding domain is located at residues (with 50 methionine being position 1) 11-57 (between the A and AB helix) and 100-118 (between the B and C helicos). One may also prepare abbreviated molecules capable of binding to a G-CSF receptor and initiate signal transduction for selectively stimulating neutrophils by changing the external loop structure and having the receptor binding domains remain intact.

Residues essential for biological activity and presumably G-CSF receptor binding or signal transduction have been identified. Two distinct sites are located on two different regions of the secondary structure. What is here called "Site A" is located on a helix which is constrained by salt bridge contacts between two other members of the helical bundle. The second site, "Site B" is located on a relatively more flexible helix, AB. The AB helix is potentially more sensitive to local pri-changes because of the type and position of the

residues at the carboxy and amino termini. The functional importance of this flexible helix may be important in a conformationally induced fit when binding to the G-CSF receptor. Additionally, the extended portion of the D helix is also indicated to be a G-CSF receptor binding domain, as ascertained by direct mutational and indirect comparative protein structure analysis. Deletion of the carboxy terminal end of rinu-meti-G-CSF reduces activity as it does for high, see, Cunningham and Wells, Science 244: 1081-1084 (1989). Cytokines which have similar structures, such as IL-6 and GM-CSF with predicted similar topology also center their biological activity along the carboxy end of the D helix, see Baza, Immunology Today 11: 350-354 (1980).

A comparison of the structures and the positions of G-CSF receptor binding determinants between G-SF and field suggests both molecules have similar means of signal transduction. Two separate G-CSF receptor binding sites have been identified for fiGH be Vos et al., Science 255: 306-32 (1991). One of these binding sites (called "Site I") is formed by residues on the exposed faces of IndI's helix 1, the connection region between helix 1 and 2, and helix 4. The second binding site (called "Site II") is formed by surface residues of the fixer 1 and belix.

The G-CSF receptor binding determinates identified for G-CSF are located in the same relative positions as those identified for field. The G-CSF receptor binding site located in the connecting region between helix A and B on the AB helix (Site A) is similar in position to that reported for a small piece of helix (residues 38-47) of hGH. A single point mutation in the AB helix of G-CSF significantly reduces biological activity (as accertained in the present assays), indicating the role in a G-CSF receptor-ligand interface. Binding of the G-CSF receptor may destabilize the 3° helical nature of this region and induce a conformation change improving the binding energy of the ligand/G-CSF receptor complex.

In the hGH receptor comptex, the first helix of the bundle donates residues to both of the binding sites required to dimerize the hGH receptor Mutational analysis of the corresponding helix of G-CSF (helix A) has identified three residues which are required for biological activity. Of these three residues, Giu 20 and Arg 24 lie on one face of the helical bundle towards helix C, whereas the side chain of Arg 23 (in two of the three molecules in the asymmetric unit) points to the face of the bundle towards helix D. The position of side chains of these biologically important residues indicates that similar to hGH, G-CSF may have a second G-CSF receptor binding site along the interface between helix A and helix C. In contrast with the hGH molecule, the amino terminus of G-CSF has a limited biological role as deletion of the first 11 residues has little effect on the biological activity.

30 As indicated above (see FIGURE 2, for example), G-CSF has a topological similarity with other cytokines. A correlation of the structure with previous biochemical studies, mutational analysis and direct comparison of specific residues of the hGH receptor complex indicates that G-CSF has two receptor binding sites. Site A lies along the interface of the A and D helices and includes residues in the small shells. Site B also includes residues in the small bits but lies along the interface between helices A and C. The 5c conservation of structure and relative positions of biologically important residues between G-CSF and hGH is one indication of a common method of signal transduction in that the receptor is bound in two places. It is therefore found that G-CSF ranalogs possessing altered G-CSF receptor binding domains may be prepared by alteration at either of the G-CSF receptor binding sites (residues 2-6-7 and 1-64-175).

Knowledge of the three dimensional structure and correlation of the composition of G-CSF protein makes possible a systematic, rational method for preparing G-CSF analogs. The above working examples have demonstrated that the limitations of the size and polarity of the side chains within the core of the structure dictate how much chance the molecule can tolerate before the overall structure is chanced.

### SEQUENCE LISTING

5	(1) GENERAL INFORMATION:	
	(i) APPLICANT: Amgen Inc.	
	(ii) TITLE OF INVENTION: G-CSF ANALOG COMPOSITIONS AND METHODS	
10	(iii) NUMBER OF SEQUENCES: 110	
15	(iv) CORRESPONDENCE ADDRESS:  (A) ADDRESSES Angen Inc. (B) STREET: Amgen Center, 1840 DeHavilland Drive (C) CITY: Thousand Oaks (D) STATE: California (E) COUNTRY: United States of America (F) ZIP: 91320-1789	
20	(v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Ploppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS	
	(2) INFORMATION FOR SEQ ID NO:1:	
25	(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 565 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
30	(ii) MOLECULE TYPE: DNA (genomic)	
	(ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 30554	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:	
	TCTAGAAAAA ACCAAGGAGG TAATAAATA ATG ACT CCA TTA GGT CCT GCT TCT Met Thr Pro Leu Gly Pro Ala Ser 1	53
40	TCT CTG CCG CAA AGC TTT CTG CTG AAA TGT CTG GAA CAG GTT CGT AAA Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys $^{10}$	101
45	ATC CAG GOT GAC GOT GCT GCA CTG CAA GAA AAA CTG TGC GCT ACT TAC 11e Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr 30 10 10 10 10 10 10 10 10 10 10 10 10 10	149
50		

	AAA Lys	CTG Leu	TGC	CAT	CCG Pro 45	GAA Glu	GAG Glu	CTG Leu	GTA Val	CTG Leu 50	CTG Leu	GGT Gly	CAT	TCT	Leu 55	GGG Gly	19
5	Ile	Pro	TGG Trp	GCT Ala 60	CCG	CTG Leu	TCT Ser	TCT Ser	TGT Cys 65	CCA Pro	TCT Ser	CAA Gln	GCT	CTT Leu 70	Gln	CTG Leu	24
10 .																GGT Gly	29
•.	CTT Leu	CTG Leu 90	CAA Gln	GCT Ala	CTG Leu	GAA Glu	GGT Gly 95	ATC Ile	TCT Ser	CCG Pro	GAA Glu	CTG Leu 100	GGT Gly	CCG Pro	ACT	CTG	34
15	GAC Asp 105	Thr	CTG Leu	CAG Gln	CTA Leu	GAT Asp 110	GTA Val	GCT Ala	GAC Asp	TTT Phe	GCT Ala 115	ACT Thr	ACT Thr	ATT Ile	TGG Trp	CAA Gln 120	389
20	CAG Gln	ATG Met	GAA Glu	GAG Glu	CTC Leu 125	GGT Gly	ATG Met	GCA Ala	CCA Pro	GCT Ala 130	CTG Leu	CAA Gln	CCG Pro	ACT Thr	CAA Gln 135	GGT Gly	437
	GCT Ala	ATG Met	CCG Pro	GCA Ala 140	TTC Phe	GCT Ala	TCT Ser	GCA Ala	TTC Phe 145	CAG Gln	CGT Arg	CGT Arg	GCA Ala	GGA Gly 150	GGT Gly	GTA Val	485
25	CTG Leu	GTT Val	GCT Ala 155	TCT Ser	CAT His	CTG Leu	CAA Gln	TCT Ser 160	TTC Phe	CTG Leu	GAA Glu	GTA Val	TCT Ser 165	TAC Tyr	CGT Arg	GTT Val	533
30	CTG Leu	CGT Arg 170	CAT His	CTG Leu	GCT Ala	CAG Gln	CCG Pro 175	TAAT	'AGAZ	TT C							565
	(2)	INFO	RMAT	CION	FOR	SEQ	ID N	0:2:									
35			(i)	(	A) L B) T	ENGT	RACT H: 1 ami OGY:	75 a no a	mino		ds						
		(	ii)	MOLE	CULE	TYP	E: p	rote	in								
40							CRIP			-							
	Met 1	Thr	Pro	Leu	Gly 5	Pro	Ala	Ser	Ser	Leu 10	Pro	Gln	Ser	Phe	Leu 15	Leu	
	Lys	Cys	Leu	G1u 20	Gln	Val	Arg	Lys	11e 25	Gln	Gly .	Asp	Gly	Ala 30	Ala	Leu	
45	Gln	Glu	Lys 35	Leu	Cys	Ala	Thr	Tyr :	Lys	Leu	Cys :	His	Pro 45	Glu	Glu	Leu	

	Val	Leu 50	Leu	Gly	His	Ser	Leu 55	Gly	Ile	Pro	Trp	Ala 60		Leu	Ser	Ser	
5	Cys 65	Pro	Ser	Gln	Ala	Leu 70	Gln	Leu	Ala	Gly	Cys 75	Leu	Ser	Gln	Leu	His 80	
-	Ser	Gly	Leu	Phe	Leu 85	Tyr	Gln	Gly	Leu	Leu 90	Gln	Ala	Leu	Glu	Gly 95	Ile	
10	Ser	Pro	Glu	Leu 100	Gly	Pro	Thr	Leu	Asp 105	Thr	Leu	Gln	Leu	Asp 110	Val	Ala	
	Asp	Phe	Ala 115	Thr	Thr	Ile	Trp	Gln 120	Gln	Met	Glu	Glu	Leu 125	Gly	Met	Ala	
	Pro	Ala 130	Leu	Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140	Phe	Ala	Ser	Ala	
15	Phe 145	Gln	Arg	Arg	Ala	Gly 150	Gly	va1	Leu	Val	Ala 155	Ser	His	Leu	Gln	Ser 160	
	Phe	Leu	Glu	Val	Ser 165	Tyr	Arg	Val	Leu	Arg 170	His	Leu	Ala	Gln	Pro 175		
20	(2)	INFO	RMAT	ON	FOR	SEQ	ID 1	10:3:									
25		(i)	0	A) I B) I C) S	ENGT YPE: TRAN	H: 2 nuc DEDN	leid ESS:	se p aci	airs d	i							
						PE:											
30	CTT					SCRI G AA		N: S	EQ 1	D NO	:3:						24
	(2)	INFO	RMAT	ION	FOR	SEQ	ID N	0:4:									
35		(i)	(	A) L B) T C) S	ENGT YPE : TRAN	ARAC H: 2 nuc DEDN OGY:	3 ba leic ESS:	se p aci sin	airs d								
40		(ii)	MOL	ECUL	E TY	PE:	DNA										
						SCRI		N: S	EQ I	D NO	:4:						
	ACAG	GITC	G1 C	GIAT	CCAG	G GT	G										23
45																	

	(2) INFORMATION FOR SEQ ID NO:5:	
5	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleia acad (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
10	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:	
	CACTGCAAGA ACGTCTGTGC GCT	2
15	(2) INFORMATION FOR SEQ ID NO:6:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:	
25	CGCTACTTAC CGTCTGTGCC ATC	2
	(2) INFORMATION FOR SEQ ID NO:7:	
30	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:	
	CTTTCTGCTG CGTTGTCTGG AACA	24
40	(2) INFORMATION FOR SEQ ID NO:8:	
45	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
50		

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:	
	ACAGGTTCGT CGTATCCAGG GTG	23
5	(2) INFORMATION FOR SEQ ID NO:9:	
10	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 23 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
-	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:	
15	CACTGCAAGA ACGTCTGTGC GCT	23
	(2) INFORMATION FOR SEQ ID NO:10:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
25	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:	
	CTTTCTGCTG CGTTGTCTGG AACA	24
30	(2) INFORMATION FOR SEQ ID NO:11:	
35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:	
40	ACAGGTTCGT CGTATCCAGG GTG	23
	(2) INFORMATION FOR SEQ ID NO:12:	
45	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single	
50		

	(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:	
5	CGCTACTTAC CGTCTGTCCC ATC	23
	(2) INFORMATION FOR SEQ ID NO:13:	
10	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 24 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
15	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	
	CTTTCTGCTG CGTTGTCTGG AACA	24
20	(2) INFORMATION FOR SEQ ID NO:14:	
25	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:	
30	CACTGCAAGA ACGTCTGTGC GCT	23
	(2) INFORMATION FOR SEQ ID NO:15:	
35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:	
	CGCTACTTAC CGTCTGTGCC ATC	23

	(2) INFORMATION FOR SEQ ID NO:16:	
5	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANCEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
10.	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:	
•.	ACAGGTTCGT CGTATCCAGG GTG	23
	(2) INFORMATION FOR SEQ ID NO:17:	
15	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 23 base pairs  (B) TYPE: nucleic acid  (C) STRANDENNESS: single  (D) TOPOLOGY: linear  (ii) MOLECULE TYPE: INA	
20	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:	
	CACTGCAAGA ACGTCTGTGC GCT	23
25	(2) INFORMATION FOR SEQ ID NO:18:	
30	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(x1) SEQUENCE DESCRIPTION: SEQ ID NO:18:	
35	CGCTACTTAC CGTCTGTGCC ATC	23
	(2) INFORMATION FOR SEQ ID NO:19:	
40	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRAUMENNESS; single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
45		

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:	
	CTTTCTGCTG CGTTGTCTGG AACA	24
5	(2) INFORMATION FOR SEQ ID NO:20:	
10	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 23 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:	
15	ACAGGTTCGT CGTATCCAGG GTG	23
	(2) INFORMATION FOR SEQ ID NO:21:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDENMSS: single (D) TOPOLOGY: linear	
25	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:	
	CACTGCAAGA ACGTCTGTGC GCT	23
30	(2) INFORMATION FOR SEQ ID NO:22:	
35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:	
40	CGCTACTTAC CGTCTGTGCC ATC	23
	(2) INFORMATION FOR SEQ ID NO:23:	
45	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single	
50		

	(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
5	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:	
	TCTGCTGAAA GCTCTGGAAC AGG	2
	(2) INFORMATION FOR SEQ ID NO:24:	
10,	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
15	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:	
	CTTGTCCATC TGAAGCTCTT CAG	23
20	(2) ANTONNATION FOR ORD AN AG	
	(2) INFORMATION FOR SEQ ID NO:25:	
25	(i) SEQUENCE CHARACTERISTICS:  (A) LEMGTH: 37 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:	
30	GAAAAACTGT CCGCTACTTA CAAACTGTCC CATCCGG	37
	(2) INFORMATION FOR SEQ ID NO:26:	
35	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDENESS: single  (D) TOPOLOGY: linear	
40	(ii) MOLECULE TYPE: DNA	
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:	
	TTCGTAAAAT CGCGGGTGAC GG	22
45		

	(2) INFORMATION FOR SEQ ID NO:27:	
5	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (3) TYPS: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:	
•.	TCATCTGGCT GCGCCGTAAT AG	22
	(2) INFORMATION FOR SEQ ID NO:28:	
15	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TFPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
20	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:	
	CCGTGTTCTG GCTCATCTGG CT	22
25	(2) INFORMATION FOR SEQ ID NO:29:	
30	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 24 base pairs  (B) TfPs: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:	
35	GAAGTATCTT ACGCTGTTCT GCGT	24
	(2) INFORMATION FOR SEQ ID NO:30:	
40	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH -25 base pairs (B) TYPS: nucleic acid (C) STRANDENNESS: single (D) TOPOLOGY: linear	
45	(ii) MOLECULE TYPE: DNA	

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:	
	GAAGTATCTT ACTAAGTTCT GCGTC	25
5	(2) INFORMATION FOR SEQ ID NO:31:	
10.	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDMESS: single (D) TOPOLOGY: linear	
•	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:	
15	CGCTACTTAC GCACTGTGCC AT	22
	(2) INFORMATION FOR SEQ ID NO:32:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPLOGY: linear	
25	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:	
	CAAACTGTGC AAGCCGGAAG AG	22
30	(2) INFORMATION FOR SEQ ID NO:33:	
35	(i) SEQUENCE CHARACTERISTICS:  (A) LENOTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDENMESS: single  (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:	
40	CATCCGGAAG CACTGGTACT GC	22
	(2) INFORMATION FOR SEQ ID NO:34:	
45	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single	
50		

	(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
5	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:	
	GGAACAGGTT GCTAAAATCC AGG	2
	(2) INFORMATION FOR SEQ ID NO:35:	
•.	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPS: nucleic acid (C) STRANDEDNESS: single (D) TOPLOGY: linear	
15	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:	
	GAACAGGTTC GTGCGATCCA GGGTG	25
20	(2) INFORMATION FOR SEQ ID NO:36;	
25	(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: mucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:	
30	GAAATGTCTG GCACAGGTTC GT	22
	(2) INFORMATION FOR SEQ ID NO:37:	
35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: mucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:	
	TCCAGGGTGC CGGTGCTGC	19
	•	
45		

	(2) INFORMATION FOR SEQ ID NO:38:	
5	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:	
•	AAGAGCTCGG TGAGGCACCA GCT	23
15	(2) INFORMATION FOR SEQ ID NO:39:	
	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 23 base pairs (B) TTPS: nucleic acid (C) STRANDENNESS: single (D) TOPOLOGY: linear	
20	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:	
	CTCAAGGTGC TGAGCCGGCA TTC	23
25	(2) INFORMATION FOR SEQ ID NO:40:	
30	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDENNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:	
-	GAGCTCGGTC TGGCACCAGC	20
	(2) INFORMATION FOR SEQ ID NO:41:	
40	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
45	(ii) MOLECULE TYPE: DNA	
50		

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:	
	TCAAGGTGCT CTGCCGGCAT T	21
	i di	21
5	(2) INFORMATION FOR SEQ ID NO:42:	
10 .	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (3) TYPS: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
•.	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:	
15	TCTGCCGCAA GCCTTTCTGC TGA	23
	(2) INFORMATION FOR SEQ ID NO:43:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
25	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:	
	CTITCTGCTG GCATGTCTGG AACA	24
30	(2) INFORMATION FOR SEQ ID NO:44:	
35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:	
40	CTATTTOGCA AGCGATGGAA GAGC	24
	(2) INFORMATION FOR SEQ ID NO:45:	
45	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 Dase pairs (B) TFPs: nucleic acid (C) STRANDEDNESS: single	
50		

(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:	
CAGATGGAAG CGCTCGGTAT G	2
(2) INFORMATION FOR SEQ ID NO:46:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:	
GAGCTCGGTC TGGCACCAGC	20
(2) INFORMATION FOR SEQ ID NO:47:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 21 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:	
TCAAGGTGCT CTGCCGGCAT T	21
(2) INFORMATION FOR SEQ ID NO:48:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:	
GAAATGTCTG GCACAGGTTC GT	22
	(ii) MOLECULE TYPE: DNA  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:  CAGATGGAAG CGCTCGGTAT G  (2) INFORMATION FOR SEQ ID NO:46:  (1) SEQUENCE CHARACTERISTICS: (3) INFORMATION FOR SEQ ID NO:46: (6) STRANDEDMESS: single (7) FORDINGON: linear  (8) TYPE: nucleic acid (8) MOLECULE TYPE: DNA (8) SEQUENCE DESCRIPTION: SEQ ID NO:46: GAGCTCGGTC TGGCACCAGC  (2) INFORMATION FOR SEQ ID NO:47: (1) SEQUENCE CHARACTERISTICS: (A) LENNTH: 21 base pairs (B) TYPE: nucleic acid (C) TOPOLOGY: linear  (ii) MOLECULE TYPE: DNA (8) SEQUENCE DESCRIPTION: SEQ ID NO:47: TCAAGGTGCT CTGCCGGCAT T  (2) INFORMATION FOR SEQ ID NO:48: (1) SEQUENCE CHARACTERISTICS: (A) LENNTH: 22 base pairs (I) STRANDEDMESS acid (I) STRANDEDMESS acid (I) STRANDEDMESS acid (II) MOLECULE TYPE: DNA (XI) SEQUENCE DESCRIPTION: SEQ ID NO:48:

	(2) INFORMATION FOR SEQ ID NO:49:	
5	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (b) TYPS: nucleic acid (c) STRANDEDNESS: single (d) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
10 .	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:	
٠	TTCCGGAGCG CACAGTTTG	19
	(2) INFORMATION FOR SEQ ID NO:50:	
15	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRADEDNESS: single (D) TOPOLOGY: linear	
20	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:	
	CGAGAAGGCC TCGGGTGTCA AAC	23
25	(2) INFORMATION FOR SEQ ID NO:51:	
30	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TTPE: nucleic acid (C) STRAMDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:	
35	ATGCCAAATT GCAGTAGCAA AG	22
	(2) INFORMATION FOR SEQ ID NO:52:	
40	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 base pairs (B) TYPS: nucleic acid (C) STRANDEDMESS: single (D) TOPOLOSY: linear	
45	(ii) MOLECULE TYPE: DNA	
50		

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:	
	ACAACGGTTT AACGTCATCG TTTC	:
5		
	(2) INFORMATION FOR SEQ ID NO:53:	
10	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:	
15	ATCAGCTACT GCTAGCTGCA GA	
	ALCAGETACT GETAGETGEA GA	22
	(2) INFORMATION FOR SEQ ID NO:54:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
25	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:	
	TCAGTCGATG ACGATCGACG TCT	23
30		
•••	(2) INFORMATION FOR SEQ ID NO:55:	
35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:	
40	TTACGAACCG CTTCCAGACA TT	22
	(2) INFORMATION FOR SEQ ID NO:56:	
45	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TFPS: nucleic acid (C) STRANDEDNESS: single	
50		

	(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
5	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:	
	TANAATGCTT GGCGAAGGTC TGTAA	25
	(2) INFORMATION FOR SEQ ID NO:57:	
10	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
15	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:	
	GTAGCAAATG CAGCTACATC TA	22
20	(2) INFORMATION FOR SEQ ID NO:58:	
25	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TIPS: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:	
30	CATCATCGTT TACGTCGATG TAGAT	25
	(2) INFORMATION FOR SEQ ID NO:59:	
35	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 20 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:	
	CCAAGAGAAG CACCCAGCAG	20
45		
*3		
50		

	(2) INFORMATION FOR SEQ ID NO:60:	
5	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TIPS: nucleic acid (C) STRANDENISS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:	
•	AGGGTTCTCT TCGTGGGTCG TC	22
	(2) INFORMATION FOR SEQ ID NO:61:	
15	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TTPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
20	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:	
	CACTGGCGGT GATAATGAGC	20
25	(2) INFORMATION FOR SEQ ID NO:62:	
30	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:	
33	CTAGGCCAGG CATTACTGG	19
	(2) INFORMATION FOR SEQ ID NO:63:	
40	(i) SEQUENCE CHARACTERISTICS: (A) LEMGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRAMERDNESS: single (D) TOPOLOGY: linear	
45	(ii) MOLECULE TYPE: DNA	
50		

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:	
	CCACTGGCGG TGATACTGAG C	21
5	CONCIDENCE INTERCEDING C	
•	(2) INFORMATION FOR SEQ ID NO:64:	
10 .	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3) base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:	
15	AGCAGAAAGC TTTCCGGCAG AGAAGAAGCA GGA	33
	(2) INFORMATION FOR SEQ ID NO:65:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TIPS: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
25	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:	
	GCCGCAAAGC TTTCTGCTGA AATGTCTGGA AGAGGTTCGT AAAATCCAGG GTGA	54
30	(2) INFORMATION FOR SEQ ID NO:66:	
35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:	
40	CTGGAATGCA GAAGCAAATG CCGGCATAGC ACCTTCAGTC GGTTGCAGAG CTGGTGCCA	59
	(2) INFORMATION FOR SEQ ID NO:67:	
45	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear	
50		

### (ii) MOLECULE TYPE: protein

(xi)	SEQUENCE	DESCRIPTION .	SEO	TD	NO - 67 -

•	Met 1	Thr	Pro	Leu	Gly 5	Pro	Ala	Ser	Ser	Leu 10	Pro	Gln	Ser	Phe	Leu 15	Le
10.	Arg	Cys	Leu	Glu 20	Gln	Val	Arg	Lys	11e 25	Gln	Gly	Asp	Gly	Ala 30	Ala	Le
•	Gln	Glu	Lys 35	Leu	Cys	Ala	Thr	Tyr 40	Lys	Leu	Cys	His	Pro 45	Glu	Glu	Let
15	Val	Leu 50	Leu	Gly	His	Ser	Leu 55	Gly	Ile	Pro	Trp	Ala 60	Pro	Leu	Ser	Sei
	Cys 65	Pro	Ser	Gln	Ala	Leu 70	Gln	Leu	Ala	Gly	Сув 75	Leu	Ser	Gln	Leu	His 80
20	Ser	Gly	Leu	Phe	Leu 85	Tyr	Gln	Gly	Leu	Leu 90	Gln	Ala	Leu	Glu	Gly 95	Ile
	Ser	Pro	Glu	Leu 100	Gly	Pro	Thr	Leu	Asp 105	Thr	Leu	Gln	Leu	Asp 110	Val	Ala
25	Asp	Phe	Ala 115	Thr	Thr	Ile	Trp	Gln 120	Gln	Met	Glu	Glu	Leu 125	Gly	Met	Ala
	Pro	Ala 130	Leu	Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140	Phe	Ala	Ser	Ala
30	Phe 145	Gln	Arg	Arg	Ala	Gly 150	Gly	Val	Leu	Val	Ala 155	Ser	His	Leu	Gln	Ser 160
	Phe	Leu	Glu	Val	Ser	Tyr	Arg	Val	Leu	Arg	His	Leu	Ala	Gln	Pro	

(2) INFORMATION FOR SEQ ID NO:68:

# (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
  (B) TYPE: amino acid
  (D) TOPOLOGY: linear

# (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 10 15 Lys Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 55

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 87

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 87

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 113

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 150

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 170

(2) INFORMATION FOR SEQ ID NO:69:

10

15

25

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 15
- Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu
  20 25 30

  Gln Glu Arg Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu
  35 40
- Val Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
  50 55 60
  - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80
- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 10. Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175 (2) INFORMATION FOR SEQ ID NO:70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70: Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 10 15 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160

	Phe Le	u GI	vaı	165		Arg	vai	Leu	170		Leu	Ala	GIn	175	
5	(2) IN	FORMA	TION	FOR	SEC	ID	NO : 7	1:							
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids														
10		(ii)	MOL		TOPO	: am LOGY PE:	: 1i	near							
		(xi)	SEQ	UENC	E DE	SCRI	PTIO	N: S	EQ I	D NO	:71:				
15	Met Th	r Pro	Leu	Gly 5	Pro	Ala	Ser	Ser	Leu 10	Pro	Gln	Ser	Phe	Leu 15	Leu
	Arg Cy	Leu	Glu 20	Gln	Val	Arg	Arg	11e 25	Gln	Gly	Asp	Gly	Ala 30	Ala	Leu
20	Gln Gl	Arg 35	Leu	Cys	Ala	Thr	Tyr 40	Lys	Leu	Cys	His	Pro 45	Glu	Glu	Leu
	Val Let 50	Leu	Gly	His	Ser	Leu 55	Gly	Ile	Pro	Trp	Ala 60	Pro	Leu	Ser	Ser
25	Cys Pro	Ser	Gln	Ala	Leu 70	Gln	Leu	Ala	Gly	Cys 75	Leu	Ser	Gln	Leu	His 80
	Ser Gly	' Leu	Phe	Leu 85	Tyr	Gln	Gly	Leu	Leu 90	Gln	Ala	Leu	Glu	Gly 95	Ile
30	Ser Pro	Glu	Leu 100	Gly	Pro	Thr	Leu	Asp 105	Thr	Leu	Gln	Leu	Asp 110	Val	Ala
	Asp Phe	115	Thr	Thr	Ile	Trp	Gln 120	Gln	Met	Glu	Glu	Leu 125	Gly	Met	Ala
35	Pro Ala	Leu	Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140	Phe	Ala	Ser	Ala
40	Phe Glr 145	Arg	Arg	Ala	Gly 150	Gjy	Val	Leu	Val	Ala 155	Ser	His	Leu	Gln	Ser 160
	Phe Leu	Glu	Val	Ser 165	Tyr	Arg	Val	Leu	Arg 170	His	Leu	Ala	Gln	Pro 175	
45	(2) INF	ORMAT	rion	FOR	SEQ	ID N	IO:72	:							
		(i)	- 1	JENCE (A) I (B) I	ENGT	H: 1 ami	.75 a	mino		ds.					
50															

58

(ii) MOLECULE TYPE: protein

\* (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

(2) INFORMATION FOR SEQ ID NO:73:

40

- (i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
  15

  Lys Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu
  20
  25

  Gln Glu Arg Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu
  40
  40

Val Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 10 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175

(2) INFORMATION FOR SEQ ID NO:74:

### (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Arg Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Arg Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala

55

20

25

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175 (2) INFORMATION FOR SEQ ID NO:75: 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 10 15 Arg Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175

	(2)	INFORMATION	FOR	SEO	ID	NO:76
--	-----	-------------	-----	-----	----	-------

- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Glu Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 170

(2) INFORMATION FOR SEO ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

55

35

40

45

50

(2) INFORMATION FOR SEQ ID NO:78:

35

- (i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 175 amino acids
  - (A) LENGTH: 175 amino acids
    (B) TYPE: amino acid
    (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 50 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (2) INFORMATION FOR SEQ ID NO:79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60

10

20

25

50

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 105 Thr Leu Gln Leu Asp Val Ala 105 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 125

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 80 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 90

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Ala Pro 170

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 175 amino acids
(B) TYPE: amino acid
(D) TOFOLOGY: linear

(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 10

Lys Cys Leu Glu Glu Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

15

20

25

55

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Ala His Leu Ala Gln Pro

50 165 170 175

(2)	INFORMATION	FOR	CEO	TD	NO. 01.
(2)	INFORMATION	FUR	SEQ	ıυ	NO:81:

- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:
- 10
  - Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
- Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu
- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu
  - Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
    - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95
    - Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala
  - Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala
  - Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala
    - Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145
    - Phe Leu Glu Val Ser Tyr Ala Val Leu Arg His Leu Ala Gln Pro 165 170 175

### (2) INFORMATION FOR SEQ ID NO:82:

30

35

40

50

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 174 amino acids (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

- (2) INFORMATION FOR SEQ ID NO:83:
  - (i) SEQUENCE CHARACTERISTICS:

    (A) LENGTH: 175 amino acids

    (B) TYPE: amino acid

    (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu

  15

  Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu
  20

  Gln Glu Lys Leu Cys Ala Thr Tyr Ala Leu Cys His Pro Glu Glu Leu
  45

  Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
  50

  60

  Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
  15

  Met Thr Pro Leu Gly Flor Flor Trp Ala Pro Leu Ser Ser
  50

  Met Thr Pro Leu Gly Flor Flor Trp Ala Pro Leu Ser Ser
  50

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 110

Asp Phe Ala Thr Thr Ile Trp Gin Gln Met Glu Glu Leu Gly Met Ala 115

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 136

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 175

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 175 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
1 1 5
Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu
20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Lys Pro Glu Glu Leu

15 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
50 50 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125

55

25

	Pro	Ala 130		Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140		Ala	Ser	Ala
	Phe 145	Gln	Arg	Arg	Ala	Gly 150	Gly	Val	Leu	Val	Ala 155	Ser	His	Leu	Gln	Se 16
	Phe	Leu	Glu	Val	Ser 165		Arg	Val	Leu	Arg 170		Leu	Ala	Gln	Pro 175	
0	(2)	INF	orma	TION	FOR	SEQ	ID :	NO : 8	5 :							
5			(i)	SEQ	(A) (B)	LENG TYPE	ARAC TH: : am LOGY	175 . ino .	amin acid		iđs					
			(ii)	MOL	ECUL	Е ТҮ	PE: ]	prot	ein							
0			(xi)	SEQ	UENC	E DE	SCRI	PTIO	N: SI	BQ I	OM C	: 85 :				
-	Met 1	Thr	Pro	Leu	Gly 5	Pro	Ala	Ser	Ser	Leu 10	Pro	Gln	Ser	Phe	Leu 15	Leu
5	Lys	Cys	Leu	Glu 20	Gln	Val	Arg	Lys	Ile 25	Gln	Gly	Asp	Gly	Ala 30	Ala	Let
	Gln	Glu	Lys 35	Leu	Cys	Ala	Thr	Tyr 40	Lys	Leu	Cys	His	Pro 45	G1u	Ala	Leu
0	Val	Leu 50	Leu	Gly	His	Ser	Leu 55	Gly	Ile	Pro	Trp	Ala 60	Pro	Leu	Ser	Ser
	Cys 65	Pro	Ser	Gln	Ala	Leu 70	Gln	Leu	Ala	Gly	Cys 75	Leu	Ser	Gln	Leu	His 80
5	Ser	Gly	Leu	Phe	Leu 85	Tyr	Gln	Gly	Leu	Leu 90	Gln	Ala	Leu	Glu	Gly 95	Ile
	Ser	Pro	Glu	Leu 100	Gly	Pro	Thr	Leu	Asp 105	Thr	Leu	Gln	Leu	Asp 110	Val	Ala
0	Asp	Phe	Ala 115	Thr	Thr	Ile	Trp	Gln 120	Gln	Met	Glu	Glu	Leu 125	Gly	Met	Ala
	Pro	Ala 130	Leu	Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140	Phe	Ala	Ser	Ala
5	Phe 145	Gln	Arg	Arg	Ala	Gly 150	Gly	Val	Leu	Val	Ala 155	Ser	His	Leu	Gln	Ser 160
		_			_											

121	INFORMATION	FOR	CEO	TD	NO.OC.

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 175 amino acids
    - (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEO ID NO:86:
  - Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
- Lys Cys Leu Glu Gln Val Ala Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30
  - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45
- 0 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 60
  - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80
- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95
  - Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110
  - Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125
    - Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140
    - Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160
    - Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 170

# (2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

55

Met 1	Thr	Pro	Leu	Gly 5	Pro	Ala	Ser	Ser	Leu 10	Pro	Gln	Ser	Phe	Leu 15	Leu
Lys	Cys	Leu	Glu 20	Gln	Val	Arg	Ala	Ile 25	Gln	Gly	Asp	Gly	Ala 30	Ala	Leu
Gln	Glu	Lys 35	Leu	Cys	Ala	Thr	Tyr 40	Lys	Leu	Суѕ	His	Pro 45	Glu	Glu	Leu
Val	Leu 50	Leu	Gly	His	Ser	Leu 55	Gly	Ile	Pro	Trp	Ala 60	Pro	Leu	Ser	Ser
Cys 65	Pro	Ser	Gln	Ala	Leu 70	Gln	Leu	Ala	Gly	Cys 75	Leu	Ser	Gln	Leu	His 80
Ser	Gly	Leu	Phe	Leu 85	Tyr	Gln	Gly	Leu	Leu 90	Gln	Ala	Leu	Glu	Gly 95	Ile
Ser	Pro	Glu	Leu 100	Gly	Pro	Thr	Leu	Asp 105	Thr	Leu	Gln	Leu	Asp 110	Val	Ala
Asp	Phe	Ala 115	Thr	Thr	Ile	Trp	Gln 120	Gln	Met	Glu	Glu	Leu 125	Gly	Met	Ala
Pro	Ala 130	Leu	Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140	Phe	Ala	Ser	Ala
Phe 145	Gln	Arg	Arg	Ala	Gly 150	Gly	Val	Leu	Val	Ala 155	Ser	His	Leu	Gln	Ser 160
Phe	Leu	Glu	Val	Ser 165	Tyr	Arg	Val	Leu	Arg 170	His	Leu	Ala	Gln	Pro 175	

(2) INFORMATION FOR SEQ ID NO:88:

# (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:
  - Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 10 15
- Lys Cys Leu Ala Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  $20 \hspace{1cm} 25 \hspace{1cm} 30$ Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45

35

(2) INFORMATION FOR SEQ ID NO:89:

10

25

30

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 175 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Ala Gly Ala Ala Leu
25
Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 45
45
Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
50
Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His
65
Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125

Pro	Ala 130	Leu	Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140	Phe	Ala	Ser	Al
Phe 145	Gln	Arg	Arg	Ala	Gly 150	Gly	Val	Leu	Val	Ala 155		His	Leu	Gln	Se:
Phe	Leu	Glu	Val	Ser 165	Tyr	Arg	Val	Leu	Arg 170		Leu	Ala	Gln	Pro 175	
(2)	INF	ORMA	TION	FOR	SEQ	ID I	NO:9	0:							
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TTPE: amino acid (D) TOPOLOGY: linear															
<pre>(ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:</pre>															
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:  Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu															
Met 1	Thr	Pro	Leu	Gly 5	Pro	Ala	Ser	Ser	Leu 10	Pro	Gln	Ser	Phe	Leu 15	Leu
Lys	Cys	Leu	Glu 20	Gln	Val	Arg	Lys	Ile 25	Gln	Gly	Asp	Gly	Ala 30	Ala	Let
Gln	Glu	Lys 35	Leu	Cys	Ala	Thr	Tyr 40	Lys	Leu	Cys	His	Pro 45	Glu	Glu	Leu
Val	Leu 50	Leu	Gly	His	Ser	Leu 55	Gly	Ile	Pro	Trp	A1a 60	Pro	Leu	Ser	Ser
Cys 65	Pro	Ser	Gln	Ala	Leu 70	Gln	Leu	Ala	Gly	Cys 75	Leu	Ser	Gln	Leu	His 80
Ser	Gly	Leu	Phe	Leu 85	Tyr	Gln	Gly	Leu	Leu 90	Gln	Ala	Leu	Glu	Gly 95	Ile
Ser	Pro	Glu	Leu 100	Gly	Pro	Thr	Leu	Asp 105	Thr	Leu	Gln	Leu	Asp 110	Val	Ala
Asp	Phe	Ala 115	Thr	Thr	Ile	Trp	Gln 120	Gln	Met	Glu	Glu	Leu 125	Gly	Glu	Ala
Pro	Ala 130	Leu	Gln	Pro	Thr	Gln 135	Gly	Ala	Met	Pro	Ala 140	Phe	Ala	Ser	Ala

7

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 170

45

1	21	INFORMATION	EV B	CPA	TD	NO.01.

10

25

45

50

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
- Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30
- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45
- 20 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
  - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His
  - Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95
    - Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala
  - Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125
  - Pro Ala Leu Gln Pro Thr Gln Gly Ala Glu Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160
  - Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175
    - (2) INFORMATION FOR SEQ ID NO:92:
      - (i) SEQUENCE CHARACTERISTICS:
        - (A) LENGTH: 175 amino acids(B) TYPE: amino acid
        - (D) TOPOLOGY: linear
      - (ii) MOLECULE TYPE: protein
      - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe L u Leu 15

Lys Cys Leu Glu Gin Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 25

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 55

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 75

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 90

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100

Asp Phe Ala Thr Thr Ile Trp Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 115

Phe Gln Arg Arg Ala Gly Gly Val Leu Varg His Leu Ala Gln Pro 175

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 175

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 175

(2) INFORMATION FOR SEC ID NO:93:

10

15

30

35

50

- (i) SEQUENCE CHARACTERISTICS:

  (A) LENGTH: 175 amino acids
  (B) TYPE: amino acid
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 115

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 120

Pro Ala Leu Gln Pro Thr Gln Gly Ala Leu Pro Ala Phe Ala Ser Ala 130

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 140

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:
(A) LEMOTH: 175 amino acids
(B) TYPE: amino acids
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

20

25

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

  Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 15

  Lys Ala Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25

  Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 15 40

  Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 55 55

  Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 75

  Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85

  Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100

  Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala

		130	200	01			135	GLY	Ala	Het	FIO	140		ALG	Sei	Ale
5	Phe 145	Gln	Arg	Arg	Ala	Gly 150	Gly	Val	Leu	Val	Ala 155		His	Leu	Gln	Ser 160
	Phe	Leu	Glu	Val	Ser 165	Tyr	Arg	Val	Leu	Arg 170		Leu	Ala	Gln	Pro 175	
10	(2)	Total Sag 15 No.55.														
	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 175 amino acids  (B) TYPE: amino acid															
15	(B) TYPE: amino acid (D) TOPOLOGY: linear															
(ii) MOLECULE TYPE: protein																
20		(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:  Het Thr Pro Leu'Gly Pro Ala Ser Ser Leu Pro Glu Ser Phe Leu Leu														
***	Met 1	Thr	Pro	Leu	Gly 5	Pro	Ala	Ser	Ser	Leu 10	Pro	Glu	Ser	Phe	Leu 15	Leu
25	Lys	Cys	Leu	Glu 20	Glu	Val	Arg	Lys	Ile 25	Gln	Gly	Asp	Gly	Ala 30	Ala	Leu
	Gln	Glu	Lys 35	Leu	Cys	Ala	Thr	Tyr 40	Lys	Leu	Cys	His	Pro 45	Glu	Glu	Leu
30	Val	Leu 50	Leu	Gly	His	Ser	Leu 55	Gly	Ile	Pro	Trp	Ala 60	Pro	Leu	Ser	Ser
	Cys 65	Pro	Ser	Gln	Ala	Leu 70	Gln	Leu	Ala	Gly	Cys 75	Leu	Ser	Gln	Leu	His 80
35	Ser	Gly	Leu	Phe	Leu 85	Tyr	Gln	Gly	Leu	Leu 90	Gln	Ala	Leu	Glu	Gly 95	Ile

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 <sup>5</sup> Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 155 160

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 105

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 120

125

126

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175

50

- (2) INFORMATION FOR SEQ ID NO:96:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 175 amino acids
      - (B) TYPE: amino acid
        (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:
  - . Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Glu Ser Phe Leu Leu
- Lys Cys Leu Glu Glu Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu
  20 25 30
- 20 25 30
- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45
- Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50

  Cys Pro Ser Glu Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 57
- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95
- Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala
- Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125
- Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140
  - Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160
- Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 170
  - (2) INFORMATION FOR SEQ ID NO:97:
    - (i) SEQUENCE CHARACTERISTICS:
      - (A) LENGTH: 175 amino acids
      - (B) TYPE: amino acid
      - (D) TOPOLOGY: linear
    - (ii) MOLECULE TYPE: protein
    - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

55

45

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Gly Phe Leu Leu 15

Lys Cys Leu Ala Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 25

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 85

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 175

- (2) INFORMATION FOR SEO ID NO:98:
  - (i) SEQUENCE CHARACTERISTICS:

    (A) LENGTH: 175 amino acids
    (B) TYPE: amino acid
    (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 15

Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Leu Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Leu Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro

- (2) INFORMATION FOR SEQ ID NO:99:
  - (i) SEQUENCE CHARACTERISTICS:

(ii) MOLECULE TYPE: protein

- (A) LENGTH: 175 amino acids (B) TYPE: amino acid
- (D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ala Phe Leu Leu 1 5 10 15
- Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30
- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45
- Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60
- Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His
- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile
- Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110

- Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala
  115

  Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala
  130

  Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser
  145

  Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro
  165

  Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro
  165
  175
- (2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:

  (A) LENGTH: 175 amino acids

  (B) TYPE: amino acid
- (D) TOPOLOGY: linear
  (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

  Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 15

  Ala Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20

  Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 40

  Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50

  Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65

  Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 90

  Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100

  Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 130

  Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130

  Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145

  Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 175

(2) INFORMATION FOR SEQ ID NO:101:

10

15

20

25

30

35

40

45

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 175 amino acids
    - (B) TYPE: amino acid (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
- Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30
  - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45
  - Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60
  - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80
  - Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95
  - Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala
- Asp Phe Ala Thr Thr Ile Trp Gln Ala Met Glu Glu Leu Gly Met Ala
  - Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala
- Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175
  - (2) INFORMATION FOR SEQ ID NO:102:
    - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid
      - (D) TOPOLOGY: linear
    - (ii) MOLECULE TYPE: protein
    - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Ala Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175

(2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS: (D) TOPOLOGY: linear
  - (A) LENGTH: 175 amino acids (B) TYPE: amino acid
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Ala Pro Glu Glu Leu
- Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 120 125 10 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 140 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175

(2) INFORMATION FOR SEQ ID NO:104:

(ii) MOLECULE TYPE: protein

- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear

15

25

50

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  $20 \hspace{1cm} 25 \hspace{1cm} 30$ Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Gly Ala Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (2) INFORMATION FOR SEQ ID NO:105: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid 15 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105: Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 10 15 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 175 176 177

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Ala Val Ala 105

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 135

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145

150

150

150

150

(2) INFORMATION FOR SEQ ID NO:106:

5

10

35

40

45

50

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEO ID NO:106:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
- Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30
  - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45
- Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 20
  - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 75 80
- Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95
  - Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala
- Ala Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140
  - Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 150 155 160
- Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175
  - (2) INFORMATION FOR SEQ ID NO:107:
    - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids
      - (B) TYPE: amino acid (D) TOPOLOGY: linear
    - (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 10 15 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 10 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Ala Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala 130  $$135\$ Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser 145 \$150\$Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro

- (2) INFORMATION FOR SEQ ID NO:108:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 175 amino acids (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Ala Gly Ala Ala Leu
  - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45
- Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 50

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:
- Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu
  15
  Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu
  20
  25
  30
- Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu
  35 40

  Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
  50 60
- Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 65 70 80 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Cln Ala Leu Glu Gly Ile 85 90
- Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  $_{50}$   $\,$  100  $\,$  105  $\,$  110

55

15

25

- Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Ala Leu Gly Met Ala 115 115 115 120 1 12
- Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala 100 105 106 Leu Gly Met Ala Asp Val Ala Thr Ala Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala 115 126
- Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala
  130

  Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser
  145

  150

  Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 85 90 95

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 165 170 175

# 55 Claims

A method for preparing a G-CSF analog comprising the steps of:

 (a) viewing information conveying the three dimensional structure of a G-CSF molecule;

- (b) selecting from said viewed information at least one site on said G-CSF molecule for alteration;
   (c) preparing a G-CSF molecule having such alteration; and
- (d) optionally, testing such G-CSF molecule for a desired characteristic.
- 5 2. A computer based method for preparing a G-CSF analog comprising the steps of:
  - (a) providing computer expression of the three dimensional structure of a G-CSF molecule;
  - (b) selecting from said computer expression at least one site on said G-CSF molecule for alteration;
  - (c) preparing a G-CSF molecule having such alteration; and,
- (d) optionally, testing such G-CSF molecule for a desired characteristic.
- 3. A method for preparing a G-CSF analog with the aid of a computer comprising:
  - (a) providing said computer with the means for displaying the three dimensional structure of a G-CSF molecule including displaying the composition of molecies of said G-CSF molecule, preterably displaying the three dimensional location of each amino acid, and more preferably displaying the
- three dimensional location of each atom of a G-CSF molecule; (b) viewing said display:
  - (c) selecting a site on said display for alteration in the composition of said molecule or the location of a moiety; and
  - (d) preparing a G-CSF analog with such alteration.
- A computer-based method for preparing a G-CSF analog comprising the steps of:
  - (a) viewing the three dimensional structure of a G-CSF molecule via a computer, said computer having been previously programmed (i) to express the coordinates of a G-CSF molecule in three dimensional space, and (ii) to allow for entry of information for alteration of said G-CSF expression and viewing thereof;
  - (b) selecting a site on said visual image of said G-CSF molecule for alteration;
    - (c) entering information for said alteration on said computer;
    - (d) viewing a three dimensional structure of said altered G-CSF molecule via said computer;
    - (e) optionally repeating steps (a)-(e) above:
- (f) preparing a G-CSF analog with said alteration; and
- (g) optionally testing said G-CSF analog for a desired characteristic.
- In a computer-based apparatus for displaying the three dimensional structure of a molecule, the improvement comprising means for correlating said three dimensional structure of a G-CSF molecule
- 35 with the composition of said G-CSF molecule.
  - A method for crystallization of a protein comprising the steps of:
     (a) combining, optionally by automated means, aqueous aliquots of said protein with either (i)
- aliquots of a salt solution, each aliquot having a different concentration of salt; or (ii) aliquots of a precipitant solution, each aliquot having a different concentration of precipitant.
  - (b) selecting at least one of said combined aliquots, said selection based on the formation of precrystalline forms, or, if no precrystalline forms are so produced, increasing the protein starting concentration of said acueous allowouts of protein and repeating step (a):
  - (c) after said salt or said precipitant concentration is selected, repeating step (a) with said previously unselected solution in the presence of said selected concentration; and,
  - (d) repeating step (b) and step (a) until a crystal of desired quality is obtained.
  - 7. A method of claim 6 wherein each combination pursuant to step (a) is performed in a range of pH.
- 50 8. A method of claim 6 wherein said combining of step (a) is done in the presence of a nucleation initiation unit.
  - A G-CSF analog having an amino acid sequence different from that of Figure 1 in that:
     (a) the N-terminal methionine is optional; and
  - (b) one or more of amino acids 58-72 (i) is substituted with one or more different amino acids or (ii) deleted; or (iii) chemically modified.

- A G-CSF analog of claim 9 wherein said analog is more resistant to proteolysis than a G-CSF molecule of Figure 1.
- 11. A G-CSF analog of claim 10 wherein at least one of said amino acids is chemically modified by the addition of a polyethylene glycol molecule.
  - 12. A G-CSF analog having an amino acid sequence different from that of Figure 1 in that:
  - (a) the N-terminal methionine is optional; and(b) one or more of amino acids 119-125 (i) is substituted with one or more different amino acids or
- (ii) deleted; or (iii) chemically modified.
   13. A G-CSF analog of claim 12 wherein said analog is more resistant to proteolysis than a G-CSF
- molecule of Figure 1.
- 15 14. A G-CSF analog of claim 12 wherein at least one of said amino acids is chemically modified by the addition of a polyethylene glycol molecule.
  - A G-CSF molecule having the AB loop stabilized by connecting such loop to one or more of helices A, B, C, or D.
- A G-CSF molecule having the CD loop stabilized by connecting such loop to one or more of helices A,
   B C or D.
- A G-CSF analog, optionally in a pharmaceutically effective carrier, optionally in a pharmaceutically
  effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>17</sup>.> Arg<sup>17</sup> and
  the N-terminal methorine is optional.
  - 18. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>25</sup>->Arg<sup>25</sup> and the N-terminal methionine is optional.
- A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>4</sup>1->Arg<sup>4</sup>1 and the N-terminal methionine is potional.
- A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>17,24,35</sup>-> Arg<sup>17,24,35</sup> and the N-terminal methionine is optional.
- A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>17,36,41</sup> and the N-terminal methionine is optional.
- 40 22. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>24,35,41</sup>->Arg<sup>24,35,41</sup> and the N-terminal methionine is optional.
  - 23. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>17,24,35,41</sup> ->Arg<sup>17,24,35,41</sup> and the N-terminal methionine is optional.
  - 24. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>17,24,41</sup>->Arg<sup>17,24,41</sup> and the N-terminal methionine is optional.
- A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Gln<sup>68</sup>->Gln<sup>68</sup> and the N-terminal methionine is optional.
  - 26. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Cys<sup>37,43</sup>-> Ser<sup>37,43</sup> and the N-terminal methionine is optional.
- 55 27. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that GIn<sup>26</sup>.>Ala<sup>26</sup> and the N-terminal methionine is optional.

- 28. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Gln<sup>174</sup>-> Ala<sup>174</sup> and the N-terminal methionine is optional.
- 29. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Arg<sup>170</sup>->Ala<sup>170</sup> and the N-terminal methionine is optional.
- 30. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Arg1<sup>67</sup> -> Ala1<sup>67</sup> and the N-terminal methionine is optional.
- 10 31. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that there is a deletion at position 167 and the N-terminal methionine is cotional.
- A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>1</sup>->Ala<sup>1</sup> and the N-terminal methionine is optional.
  - 33. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Hist<sup>4</sup>->Lys<sup>4</sup> and the N-terminal methionine is optional.
- 34. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Glu<sup>47</sup>->-Ala<sup>47</sup> and the N-terminal methionine is optional.
  - 35. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure t in that Arg<sup>23</sup>->Ala<sup>23</sup> and the N-terminal methionine is optional.
  - 36. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys<sup>24</sup> -> Ala<sup>24</sup> and the N-terminal methionine is optional.
- 37. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Glu<sup>20</sup>-> Ala<sup>20</sup> and the N-terminal methionine is optional.
- 38. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Asp<sup>26</sup>-> Ala<sup>26</sup> and the N-terminal methionine is optional.
- 35 39. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Met<sup>127</sup> -> Glu<sup>127</sup> and the N-terminal methionine is optional.
  - 40. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from tha of Figure 1 in that Met<sup>138</sup> -> Glu<sup>138</sup> and the N-terminal methionine is optional.
  - 41. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Met<sup>127</sup>.>Leu<sup>127</sup> and the N-terminal methionine is optional.
- 42. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Met<sup>138</sup>-> Leu<sup>138</sup> and the N-terminal methionine is optional.
  - 43. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Cys<sup>18</sup>.>Ala<sup>18</sup> and the N-terminal methionine is optional.
- 44. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Gin<sup>12.21</sup>->Glu<sup>12.21</sup> and the N-terminal methionine is optional.
  - 45. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Gln<sup>12,21,86</sup>.> Glu<sup>12,21,86</sup> and the N-terminal methionine is optional.
  - 46. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Glu<sup>20</sup>->Ala<sup>20</sup>; Ser<sup>13</sup>->Gliv<sup>13</sup> and the N-terminal methionine is cotional.

- 47. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Met<sup>127,138,></sup>-> Leu<sup>127,138</sup> and the N-terminal methionine is optional.
- 48. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Ser<sup>13</sup>-> Ala<sup>13</sup> and the N-terminal methionine is optional.
- 49. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Lys¹²-> Ala¹² and the N-terminal methionine is optional.
- 10. 50. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that GIn<sup>121</sup>-> Ala<sup>121</sup> and the N-terminal methionine is optional.
  - 51. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Gln<sup>21</sup>-> Ala<sup>21</sup> and the N-terminal methionine is optional.
  - 52. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that His<sup>44</sup>->Ala<sup>44</sup> and the N-terminal methionine is optional.
- 53. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein said amino acid sequenc differs from that of Figure 1 in that His<sup>53</sup>-> Ala<sup>53</sup> and the N-terminal methionine is optional.
  - 54. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Asp110->Ala110 and the N-terminal methionine is optional.
- 25 55. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Asp<sup>113</sup>-> Ala<sup>113</sup> and the N-terminal methionine is optional.
  - 56. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Thr<sup>117</sup>->Ala<sup>117</sup> and the N-terminal methionine is optional.
  - 57. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Asp<sup>28</sup>->Ala<sup>28</sup>: Asp<sup>110</sup> ->Ala<sup>110</sup> and the N-terminal methicnine is optional.
- 35 58. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Glu<sup>124</sup> -> Ala<sup>124</sup> and the N-terminal methionine is optional.
- 59. A G-CSF analog, optionally in a pharmaceutically effective carrier, wherein the amino acid sequence differs from that of Figure 1 in that Phe<sup>114</sup>->Val<sup>114</sup>, Thr<sup>117</sup>->A<sup>117</sup> and the N-terminal methionine is optional.
  - The G-CSF analog DNA-containing plasmids and bacterial host cells transformed therewith available from the American Type Culture Collection under the accession numbers ATCC 69184, 69195, 69196, 69107, 59188, 69199, 69190, 69191, 69192, 69193, 69194, 69195, 69196, 69197, 69199, 69200, 69201, 69202, 69203, 69204, 69205, 69206, 69207, 69208, 69209, 69210, 69211, 69212, 69213, 69214, 69215, 69216, 69217, 69218, 69219, 69220, 69221, 692224, 69224, 69224, 69224, 69224, 69214

50

Met Thr Pto Ley Gly Pto Ala
TCTABARANACCAAGGAGGTAATAATA ATG ACT CCA TTA GGT CCT CTT

"Ser Ser Lew Pto Gln Ser Pte Lew Lew Lys Cys Lew Glw Gln
TCT TCT CTG CCG CAA AGC TTT CTG CTG AAA TGT CTG GAA CAG

Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Lew Gln Glu Lys Lew
GTT CGT AAA ATC CAG GGT GAC GGT GCT GCA CTG CAA GAA AAA CTG

Cys Ala Thr Tyr Lys Lew Cys His Pto Glw Glw Lew Val Lew Lew
TGC GCT ACT TAC AAA CTG TGC CAT CCG GAA GAG CTG GTA CTG CTG

Gly His Ser Lew Gly Ile Pto Ttp Ala Pto Lew Ser Ser Cys Pto
GGT CAT TCT CTT GGG ATC CCG TGG GCT CCG CTG TCT TCT TGT CCA

Ser Gln Ala Lew Gln Lew Ala Gly Cys Lew Ser Gln Lew His Ser
TCT CAA GCT CTT CAG CTG GCT GCT TCT CTA CTG CAT TCT

Gly Lew Pte Lew Tyr Gln Gly Lew Lew Gln Ala Lew Glw Gly Ile
GGT CTT CTC CTG TAT CAG GCT GCT CTT CTG CAA GCT CTG GAA GCT

Ser Pto Glw Lew Gly Pto Ttr Lew Asp Tth Lew Gln Lew Asp Val
TCT CCG GAA CTG GGT CCG ACT CTG GAC ACT CTG CAG CTA GAT

Ala Asp Pte Ala Thr Thr Ile Ttp Gln Gln Met Glw Glw Lew Glw
GCT GAC TTT GCT ACT ACT ACT TTG GCA CAG ATG CAG AGG CTG GGT

Met Ala Pto Ala Lew Gln Pto Ttr Gln Gly Ala Met Pto Ala Pte
ATG GCA CCA GCT CTG CAA CCG ACT CAA GGT GTA TCC

His Lew Gln Ser Pte Gln Arg Arg Ala Gly Gly Val Lew Val Ala Ser
CCT TCT CAA TCT CTG CAA CCG ACT CTA GGT GTT CTG


His Lew Gln Ser Pte Lew Glw Val Ser Tyr Arg Val Lew Arg His
CAT CTG CAA TCT TTC CTG GAA GTT CTG CAT

Lew Ala Gln Pto CA

Met Ala Gln Pto CA

Met Cad GCT CTA TAC AATTC

FIGURE 1






FIGURE 3




FIGURE 4

```
२२२<sup>२२२२</sup>१२२<sup>२२२२२</sup>२२४<sub>२</sub>२२२<sup>२</sup>२२२<sub>१</sub>२२२२२२२२
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 
 <sup>ददरद</sup>ददरद<sup>ददरदरदर</sup>ददरदद<sup>दददददद</sup>दद<sub>दद</sub>दद्दद<sup>द</sup>ददद्ददद
    Many states that to the state of the state o
```

+CAIRL: 5

₹	7	7	7	7	7	7	7	7	₹	₹	7	7	7	₹	< :	₹3	:	;	3	3	~	3	₹	₹	₹:	7	7	7	₹	7	7	7	3	~	7	7	₹	7	7	₹	7	<	₹;	;		ξ.	ċ
00.51,19	00'0 00'1	00'0 00'1	00'0 90'1	99.17.00	00.05.00	20.21.64	0070	On 11.53	20.15	100 70:44	001700	00 70,03	27.77	42.339 61.839 0.301 1.CO 26.13	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	20,00		00 10 77	20.24.26	1.00 /5.87	1.00 27.68	1.00 0.00	200	00 71.68	40.067 59.550 0.720 1.00 77.02		2.037 1.00 25.55	0: 27.80	00 29.95	29, 45	0: 0:0	C. 10. 10.	00 11 27	1.00, 41.95	1.03 32,00	DO 25.R1	17:92 00	66.25.00	00. 1.00	63.85.00	97.7.10					27 100	
3.333	₹ 7	2.539	3.216		1.96.1	0.0	0.629 1.0	0.15	- 707	1.439	9:1-1		0.352	1000					1.684	3 -4-465	1 -5.890	5 -6.042	19 -6.552	= :	0770		7.037	2.890	3.526	2915	- - -	200		1.995	7.7	2.960	3.655	1691	38	0.886		90				Š	
32 59.975	51.637 (40.498	539 60.65	317 59.30	55 59.893	88 60.068	969'09 6	505.09	67 61.841	15 62.694	97 63.834	25 63.230	88 63.28	908 108	9 61.839	13 50.783	41 747 59 713 -1 447	41 729 58 539 -7 341	59.04	163 57.99	550 56.85	732 58.35	.421 59.26	.743 57.6	07 59 239	200	20.022	86 58.191	36 59.352	89 59.251	83 60.460	42.547 60.454 2.	66. 62. 789	37 62 502	539 63.07	44.063 61.811	H 62.264	65'79 10	39.882 62.270	50 61.950	79 62 69	9	867.79	9000	33703 60	201 28 107	( C 84)	
3		<del>.</del>	š	ş	Ŧ	\$	•	Ť	\$3.0	Ī.	•		7	7		; =	=	7	42	7	4	∓ 2	₹ 2	= 3	į		1	40.9	39.8	<u>+</u>	2	•		Ŧ	ž	39.6	39.	36	9				27.040				
2									2	~ :	4 ;	¥;	2:	۲ <sup>۲</sup>	,,	. 3	3	Z	3	3	3	ž	ş	z:	4; 2>		;;	Y 27	×	2 2	~ :		7	ď	sb 7	*	2 2	7.	2	٠,	2 :	6	2		4 A	9	;
152 NZ L	1711 651	77	155 1123	290	57.0	28 N	29	5	5	162 CG2	3	9	2	200		2	170 CR G	20 00 171	172 CD G	173 OE1 G	174 NE2 G	75 1121 0	176 11122	200			200	182 C GL	1830 GL	184 N AS	SA 18 18	55	IN CO AS	4 100 681	130 OD5 A	191 C ASI	SV 0 761	193 N GE	= 5	5	2	3	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2			200	,
ATOM	V .	2	Y	VICE	MOLY	Y	1	1	5	V I	2	V	TO V		1	MOLV	MOLV	MOTA	ATOM	MOLY	MOTA	ATOM	Y	V C			Į.	ATOM	MOLY	ATOM	A 10 M	9	ATOM	MOLY	ATOM	ATOM	ATOM	MOTA	2	Y					7	NO.	
₹:		7	7	₹ ;	7	7 :	₹:	₹:		₹:	7	7	;	; ;		7	₹	7	7	7	7	₹	₹.	7:	; ;		; <b>=</b>	₹	7	₹	₹;	; =	7	₹	₹	₹	₹	₹.	₹:	₹ :	₹:		? 7	:	; =	2 =	
1.00 35.25	7.5		20.78	2	23.5	00.33.30	20.32			25.37	1	7.0		8	8	00 28 51	00 28 65	25.85	00 000	24.94	.00 24.09	100 19.97	78.57	25.65 26.65	22.5	8	45.667 56.593 -1.892 1.00 20.67	.00 20.45	100	200	8.5	87.78	1.00 29.5	43.562 55.377 -5.303 1.00 0.00	1.00 0.00	1.00 24.22	000	000	90.00	10.07	977		24.25	2	9	10 46 19	
4 -1.167	0.00		2	2	9	9									7.7.7	-2.288	-1.563	-3.521	4.013	1917	-5.526 1	6.036	9	2 2	32	305	3 -1.892	1.635	- 304	9.769	60		9009	77 -5.303	30 -6.789	1 6.891	13 -7.709	02 -6.793	0200	700		8	8 8		9		
52.053 55.33	200						9	38.00		9		000	200	9	0.00	24 59.765	27 60.242	82 59.319	48 58.980	182 59.30	08 58.614	154 58.37	757	26.24	27.75	2	65 56.59	94 SS.13	25	30 54 44	2	33 53	567 54.66	.562 55.3	.956 54.7	345 52.60	780 52.7	936 51.8	2 436 57.783	27.75	28.013	2	20.00	99	3	85.05	
20 52 02					200										:=		48.0	486	7 49.4	4	4	ş		•			5	3 46.1	2:	÷			23	2	<b>∓</b> ≈	<b>₹</b>											
S 62.0	3 5				3 2			5		3	3	5 6		F21 CIN	E CON	300	N 0	N VAL	1 VAL	۲ ۸۲ د	G VAL	2	7	3			CA ARG	CB ARG	CG ARG	20	NE ARG	7 VBC	NIII ARG	III ARG	HIIZ ARG	MII2 ARG	IIIZI ARG	11122 ARG	9 9	) YE	5	63	3 2	1	3 5	ž	
MUTA 101 MUTA																		_	_	_	_	_	_	7	_	_	_	-						_	_	_	_				-					130	

DOUBLE S

```
z<sub>2</sub>22<sup>2,2</sup>222<sub>2</sub>722222<sub>2</sub>72222<sub>2</sub><sup>72<sup>7</sup>2<sup>7</sup>27<sub>22</sub>727<sup>7</sup>2<sup>7</sup>272<sub>7</sub>2722</sup>
 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 
  z=555060cz=50068z=550cz=556666z=25666655
```

```
13.11 (2.23) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.24) (2.
  11.25 6.244 10.55 10.55 11.55 10.55 11.55 10.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55 11.55
```

101

**JCURES** 

```
2<sub>55</sub>727<sup>7</sup>7777222<sub>5</sub>77772222277777222<sub>5</sub>7777222277777777
```

102

KEE

```
### CASE | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 | 1997 
     4-1,54-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4-1,154-6

4
   $100 close-rine in to the control of the control of
 28282828282828
```

KITIKE S

```
gqq223<sub>gqqq</sub>qqqq232334qqq23qqq<sub>q</sub>qqq<sup>2</sup>qqqq<sup>2</sup>qqqq<sup>2</sup>qqq<sub>q</sub>qqq
=55555000z=55500z=55500z=55500z=55500z=55500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=5500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500z=500
   5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

5555

   4.00 The 12 to 12
```

```
4.00 (273) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (410) 11.75 (
   11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00
```

105

≅

```
13.45 (A.1.) 1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 (1.00 
    4.00 The page 100 pag
```

FIGURE 5

```
99.58
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
99.59
```

TOURE 5

```
10.00 month of the control of the co
00z=5800z=5898888800z=5800z=588800z=5800z=588888
```

2 300.7

n=5=2;	222555	-22222222		<sup>2</sup> 2 <sup>2</sup> 2222 <sub>2</sub> 22 <sub>2</sub> 2222 <sub>2</sub>
****		~ · · · · · · · · · · · · · · · · · · ·		*** *********
22,185	73278	1,000 0,000 1,000	2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
85555	51555	595955556		900000000000000000000000000000000000000
5.269 8.219 6.071 5.326 5.826	3.859 -2.477 6.027 1. 6.844	3 + 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	28 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	25.25.25.25.25.25.25.25.25.25.25.25.25.2
523253 4444	222222	-222-235 -222-235 -325-235	200287274463	45-4-45-55-35-35-45
65.476 65.059 65.069 65.901 65.479	33422	5.2.38883282	62.54 62.79 63.79 63.79	65.25 66.87 66.4 66.4 66.4 66.4 66.4 66.4 66.4 66.
37.291 37.950 37.801 37.213 39.216	25.25 25 25 25 25 25 25 25 25 25 25 25 25 2	2.594 7.796 7.796 7.936 7.936 7.936	25.56.56.56.56.56.56.56.56.56.56.56.56.56	110 110 110 110 110 110 110 110 110 110
22.25.47			444444444444	4.110 6.247 4.247
25.28.28.28.28.28.28.28.28.28.28.28.28.28.	252222	58888888888	5::::::::::::::::::::::::::::::::::::::	5555555557737366
555333 55553	999999	666666666	######################################	CON PRE 16
00z=55	886.cz=	2225 <u>85555</u>	z=588200z=5	586655000x=588660
		2828666666	20	22222222222222222222222222222222222222
22222	2000000		***********	ATOM A TOM A
*****	*****	********	********	*****
mn_558				
			2 ~~	
	`??? <sub>?</sub> ??	. m.a	; <sub>2</sub> 555 <sup>5</sup> 55555	\$\$\$\$\$\$\$ <sup>\$</sup> \$\$\$\$\$\$\$
35.66 31.87 0.00 29.61 27.63	29.24.74 29.26 A3.29 29.26 A3.20 26.77 A3.20 28.22 A3.20	30.67 34.66 34.66 56.08 76.78	27.8 5.65.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7	22.17 43 43 43 43 43 43 43 43 43 43 43 43 43
1.00 35.66 1.00 31.87 1.00 0.00 1.00 29.61 1.00 27.63	1.00 24.74 / 1.00 29.91 / 43 / 1.00 29.91 / 43 / 1.00 29.26 / 43 / 1.00 26.77 / 4.00 28.20 / 4.00 28.27 / 4.0	1.00 30.67 A3 1.00 26.48 A 1.00 26.48 A 1.00 26.48 A 1.00 26.78 A 1.00 26.78 A 1.00 26.12 A 1.00 26.23 A 1.00	1.00 27.82 A3 1.00 26.80 A3 1.00 26.80 A3 1.00 26.91 A3 1.00 24.74 A3 1.00 26.94 A3 1.	100 31.7 A 3 100 31.7 A 3 100 31.7 A 3 100 31.3 A 3 100 31.5 A 3 100 31.5 A 3 100 31.7 A 3 10
349 1.00 35.66 (451 1.00 31.87 (7.00 31.87 (7.00 31.87 (7.00 31.87 (7.00 37.87 (7.00 37.97	1.279 1.001 24.74 / 1.279 1.001 24.74 / 1.252 1.00 19.91 / 1.231 1.00 19.26 / 1.252 1.00 19.27 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.00 18.22 / 1.256 1.	316 1.00 30.67 AS 5.090 1.00 26.48 A 5.496 1.00 26.48 A 3 111 1.00 26.48 A 3 111 1.00 26.78 A 3 446 1.00 26.78 A 3 5.69 1.00 26.73 A 3 5.60 1.00 2	1.945 1.00 77.87 A3 375 1.00 77.82 A3 375 1.00 28.00 A3 375 1.00 28.77 A3 375 1.00 28.77 A3 375 1.00 28.77 A3 375 1.00 28.77 A3 375 1.00 28.75 A3 375 1.00 2	354 100 31.17 A.3 A.3 A.4
01 -0.349 1.00 33.66 / 18 0.451 1.00 31.87 / 18 0.451 1.00 31.87 / 18 0.40 0.275 1.00 29.61 / 18 0.275 1.00 27.63 / 18 0.275 1.00 27	286 1.279 1.00 24,74 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	99 - 5.316 LIO 30.67 A3 (181 - 5.096 LIO 20.48 A (181 - 5.096 LIO 20.46 A (181 - 5.096 LIO 20.46 A (181 - 5.096 LIO 20.60	18 2-594 100 72 17 17 17 17 17 17 17 17 17 17 17 17 17	5 4-354 100 31.17 A) 5 4-354 100 31.17 A) 5 5-351 100 33.5 A) 5 5-351 100 33.6 A) 5 5-351 100 31.9 A) 6 5-351 100 31.8 A)
68.501 -0.349 1.00 35.66 68.418 0.451 1.00 31.87 68.306 1.00 1.00 0.00 0.00 68.306 1.45 -0.125 1.00 25.61 66.015 1.00 27.63 1.65 -0.125 1.00 27.63 1.65 -0.125 1.00 27.63 1.65 -0.125 1.00 27.63 1.65 -0.125 1.00 27.63 1.65 -0.125 1.00 27.63 1.65 -0.125 1.00 27.63 1.	Coc. 100 24.74 A 66.329 4 1.762 1.00 24.74 A 66.329 4 1.762 1.00 29.01 A 66.329 2.361 1.00 29.26 A 66.329 2.361 1.00 29.26 A 66.607 2.356 1.00 20.00 A 3 66.607 2.356 1.00 20.00 A 3 66.607 2.356 1.00 26.77 A 66.607 2.356 1.00 26.72 A	69.211 - 5.090 1.00 3.047 Ai 3.090 1.00 3.044 A	71.128 - 5.98 100.17.87 A	4406 4444 100 117 A 4
664 68.501 -0.349 1.00.35.66 / 486 68.418 0.451 1.00.31.87 / 4867 68.906 1.00.1.87 / 4867 68.906 1.00.1.87 1.00.25.61 / 4419 65.145 -0.125 1.00.25.63 / 4419 65.145 -0.125 1.00.25.63	350 (67.29 - 1.10 (47.4 ) 351 (67.29 - 1.52 ) 100 (9.9) 1 43 (67.29 - 1.32) 1 100 (1.75 ) 351 (64.22 - 1.33) 1 100 (1.75 ) 13 (1.75	3.50 69.21 LIO 30.67 Ai 3.50 69.21 - 5.50 10.0 30.6 Ai 3.50 66.21 - 5.50 10.0 4.6 Ai 3.50 66.21 - 4.11 1.00 56.0 Ai 3.50 66.10 - 2.16 1.00 57.0 Ai 3.50 69.57 - 2.16 1.00 57.0 Ai 3.50 69.57 - 3.16 1.00 50.0 Ai 3.50 69.57 - 3.16 1.00 50.0 Ai	331 07450 1002172 Air	90 4644 4511 1511 15 40 4644 4511 1511 15 40 4644 4511 1511 15 40 4644 4544 4511 15 40 4644 4544 4544 4544 4544 4544 4544
33.664 68.501 -0.349 1.00.35.66 31.486 68.418 0.451 1.00.31.87 30.867 68.906 1.00.00 1.00 30.387 67.340 -0.031 1.00.27.81 25.419 67.145 -0.115 1.00.27.74 38.883 66.035 -0.976 1.00.27.74	2300 66.229 - 1.79 1.00 24.94 31.31 67.294 - 1.762 1.00 29.91 31.30 66.239 - 2.393 1.00 31.75 31.216 68.452 - 2.361 1.00 29.36 30.81 69.219 - 1.860 1.00 0.00 31.359 68.607 - 3.755 1.00 26.77 30.811 69.858 - 4.160 1.00 28.27	78-94 68-95 - 5.316 to 03 nbr/ 78-94 18-95 - 5.316 to 03 nbr/ 78-37 17-35 - 5.456 to 03 4-6 310.02 66-62 - 4-111 to 02 60 310.02 66-62 - 4-111 to 02 60 310.02 66-62 - 4-111 to 02 60 310.02 68-02 - 4-111 to 02 60 313.02 68-23 - 4-141 to 02 60 313.02 68-23 - 4-141 to 03 62 313.02 68-23 - 4-241 to 03 62 313.02 68-23 - 4-241 to 03 62 313.02 68-23 - 4-241 to 03 62 313.02 68-23 - 4-242 to 03 63 313.02 68-23 50 313.02 68-23	35.29 1.72 2.545 1.00 2.73 35.31 6.7450 -1375 1.00 5.60 35.515 6.724 -1219 1.00 36.7 35.515 6.724 -139 1.00 34.0 35.515 6.724 -139 1.00 34.0 35.52 6.725 6.725 6.725 35.52 6.725 6.725 6.725 35.52 6.725 6.725 6.725 35.52 6.725 6.725 6.725 35.72 6.725 6.725 6.725 35.72 6.725 6.725 6.725 6.725	MON 400 4430 03117 MIN 6441 5444 00 0431 MIN 6441 5444 00 0431 MIN 6441 5441 00 0431 MIN 6441 5441 00 1441 MIN 6441 5441 00 1441 MIN 6441 5441 00 1441 MIN 6441 5441 00 0431 MIN 6441 5441 00 0431 MIN 6441 6441 00 0431 MIN 6441 00
151 31.644 66.501 -0.349 1.00 35.64 1152 31.446 66.448 0.451 1.00 31.87 1152 310.846 66.396 1.00 1.00 1.00 1152 310.878 67.340 -0.275 1.00 27.64 1152 28.448 67.145 -0.175 1.00 27.64 152 28.48 67.145 -0.075 1.00 27.64	152 31.351 67.29 41.762 100.29.91 152 31.351 67.29 41.762 100.29.91 152 31.352 66.252 -2.393 1.00.31.75 153 31.236 68.452 -2.395 1.00.29.76 153 31.359 68.6607 -3.355 1.00.26.77 153 30.881 69.858 4-160 1.00.26.77	133 2544 68424 - 5316 100 3067 133 2544 7545 5-546 100 5-64 133 3024 7352 5-456 100 5-64 134 3022 6642 - 4111 100 500 135 3492 66410 - 5212 100 557 154 3130 66525 - 5416 100 500 154 3130 66525 - 5416 100 500 154 3130 66525 - 5416 100 562 154 3130 66525 - 5416 100 562 154 3657 70,285 - 5251 100 5621 154 3657 70,285 - 5251 100 5621	14 153.1 151	
151 31.644 66.501 -0.349 1.00 35.64 1152 31.446 66.448 0.451 1.00 31.87 1152 310.846 66.396 1.00 1.00 1.00 1152 310.878 67.340 -0.275 1.00 27.64 1152 28.448 67.145 -0.175 1.00 27.64 152 28.48 67.145 -0.075 1.00 27.64	152 31.351 67.29 41.762 100.29.91 152 31.351 67.29 41.762 100.29.91 152 31.352 66.252 -2.393 1.00.31.75 153 31.236 68.452 -2.395 1.00.29.76 153 31.359 68.6607 -3.355 1.00.26.77 153 30.881 69.858 4-160 1.00.26.77	133 2544 68424 - 5316 100 3067 133 2544 7545 5-546 100 5-64 133 3024 7352 5-456 100 5-64 134 3022 6642 - 4111 100 500 135 3492 66410 - 5212 100 557 154 3130 66525 - 5416 100 500 154 3130 66525 - 5416 100 500 154 3130 66525 - 5416 100 562 154 3130 66525 - 5416 100 562 154 3657 70,285 - 5251 100 5621 154 3657 70,285 - 5251 100 5621	14 153.1 151	
O GLY 151 33,644 68,501 0,349 1,00 35,64 NAL 152 31,446 68,418 0,451 1,00 31,87 11 VAL 152 30,457 667,40 0,751 1,00 31,87 CC NAL 157 30,918 67,40 0,275 1,00 75,61 CC NAL 157 38,819 66,033 0,356 1,00 77,51 CC NAL 157 38,819 66,033 0,356 1,00 77,51	C. VAI. 132 11.351 67.294 -17.762 11.00 19.01 O. VAI. 132 11.351 67.294 -17.762 11.00 19.91 O. VAI. 132 11.350 66.273 -2.391 1.00 19.17 N. LED 153 10.285 66.422 -2.361 1.00 19.26 C. LED 153 10.285 66.07 19.286 1.00 19.00 C. LED 153 10.281 69.885 4.160 1.00 0.00 18.27	CG 111 13 134-10 446-4316 100 100 70 70 70 70 70 70 70 70 70 70 70 70 7	CC VVL 154 3533 0530 -3310 -330 07373 (VVL 154 5533) 0530 -3375 100 0540 0 VVL 154 5533) 0530 -3375 100 0540 0 VVL 155 5530 0530 -3375 100 0540 0 VVL 155 5530 0530 -3375 100 0540 0 VVL 155 5530 0530 0530 0530 0530 0530 0530	C 6 28 18 1.1.10 (4.10 4.44) (4.10 1.11) (
O GLY 151 33,644 68,501 0,349 1,00 35,64 NAL 152 31,446 68,418 0,451 1,00 31,87 11 VAL 152 30,457 667,40 0,751 1,00 31,87 CC NAL 157 30,918 67,40 0,275 1,00 75,61 CC NAL 157 38,819 66,033 0,356 1,00 77,51 CC NAL 157 38,819 66,033 0,356 1,00 77,51	C. VAI. 132 11.351 67.294 -17.762 11.00 19.01 O. VAI. 132 11.351 67.294 -17.762 11.00 19.91 O. VAI. 132 11.350 66.273 -2.391 1.00 19.17 N. LED 153 10.285 66.422 -2.361 1.00 19.26 C. LED 153 10.285 66.07 19.286 1.00 19.00 C. LED 153 10.281 69.885 4.160 1.00 0.00 18.27	CG 111 13 134-10 446-4316 100 100 70 70 70 70 70 70 70 70 70 70 70 70 7	CC VVL 154 3533 0530 -3310 -330 07373 (VVL 154 5533) 0530 -3375 100 0540 0 VVL 154 5533) 0530 -3375 100 0540 0 VVL 155 5530 0530 -3375 100 0540 0 VVL 155 5530 0530 -3375 100 0540 0 VVL 155 5530 0530 0530 0530 0530 0530 0530	
1121 O GLY 151 33,664 68,501 0,349 1.003,564 1122 W.W. 152 31,466 68,418 0.451 1.003,137 1122 W.W. 152 30,846 68,418 0.451 1.003,137 1122 W.W. 152 30,846 68,418 0.451 1.003,137 1.109,561 1.115 CR W.M. 157 39,949 6,140 0.475 1.109,754 1.115 CR W.M. 157 28,949 6,140 0.475 1.109,754 1.109	1136 C. W.I. 153 11.516 (57.54 - 1.78) 10.134.74 11.29 C. W.I. 153 11.516 (57.54 - 1.78) 10.159.1 11.20 W. LEU 153 11.216 (64.52 - 2.53) 1.00.11.5 11.31 M. LEU 153 11.216 (64.52 - 2.56) 1.00.12.5 11.31 M. LEU 153 10.181 (62.19 - 1.86) 1.00.00.06.71 11.31 C. LEU 153 10.181 (64.19 - 4.25) 1.00.00.6.71	HIS GOLD IS 359-04 Seles -5.116 LOD DAY 1115 GOLD IS 315-04-5.116 LOD DAY 1117 GOLD IS 310-04-311 5.000 1-00 1117 GOLD IS 310-04-310 5.000 1-00 1119 GOLD IS 310-04-04-110 1-00 1119 W. VI. 153 310-04-310 1-00 100 COLD IS 310-04-310 5.00 1-00 100 COLD IS 310 5.00 1-	Her GOVAL 144 15521 1512 1554 1507718 1545 1507718 150	C 6 28 18 1.1.10 (4.10 4.44) (4.10 1.11) (

110

GIRE

```
15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00 15.00
```

ΞΞ	Ξ≅	= ;	2	= =	=	<b>= =</b>	E	= =	Ē	Ξ	Ē	æ	Ę;	Ē	Ē	2 2	=	==	Ē	=	Ξ.	=	Ē	<b>=</b> :	=	=	= :	=	2	Ē	Ξ:	i	Ξ	Ę
1,00 0,00	1.00 36.70	1.00 41.68	00154.57	9 9	00'0 00'1	00 26.27	00 24.75	00100	00 18.0B	15.43	001150	87.75 00	67.17.00	000	1.00 79.12	00 32.76	1.00 57.8H	3	00 000	979	00 27.45	00 000	77.77.00.	00 27.65	00 27.09	00'0 00	07.87.00	100 24.88	1.00 23.57	1.00 25.52	17.200 1.00	1.00 26.74	00'0 00'1	00 14.95
10.948	0 11.706	12.127	10.933	90901	2 10.183	200	12.547	3 2 2	14.296	14.577	16.749	1 889	9	1.803	9 10.313	8 9.962	3 10.816		01 11.971	9007	1 8.325 1	9043	7 7.348 1	7.574	8.819	9.523	1 20%	10.77	11.977	1 9912	7	659	3	
42.791 31.235	1.372 27.660	45.829 27.544 12.127 1.00 41.68	750 26.49	6.057 27.43	7.998 25.79	.464 28.598 .970 27.810	892 28.835	556 28 147	146 28.622	7.874 27.87	787 28.967	594 28.437	978 27.492	194 30.41	7.450 29.96	7.366 31.43	6.429 33.61	100	34.823 33.5	714 29 29	775 28.88	1967 889	3.195 2B.42	.632 26.949	025 26-429	460 26.957	1618 23.03	1427 24.55	0.627 24.52	302 24.63	120 24.830	36.390 25.739	861 26 444	343 25.825
**	≋≋	≈:		ŠŽ	ž.	::	2	2	:2	2	22	2	≈≛	92	2	22	≈:	;;		3 5	2	::	2	2	: 2	2		: 2	~	≈;		:2	2	ŝe
478 II LYS	480 CB LYS	482 CD LYS	484 NZ LYS	486 1122 LT	487 1123 LY	489 O LYS	490 N IIE	492 CA ILE	493 CB ILE	494 CG2 III	30	497 C ILE	498 O HE	2005	501 CA GU	666 886 886 886 886 886 886 886 886 886	204 CD CD	200	507 HEZ1 GLN	27 J 200	\$10 O CIN	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	513 CA GLI	2140	SI6 N ASP	SIT II ASP	35	\$20 CG ASP	\$21 OD! AS	SY 700 775	323 C ASP	22 × 25	\$26 II GLY	23 C GY
MOTA	MOTA MOTA	MOTA	TQ.	V V	ATOM	Y OF	V.IOM	4	ATOM	MQ.	100	MOTA	Ž	V V	MOTA	MOTA	MOLY	MOLY	VIQ.	ATOM	ATOM	200	ATOM	W C	TO V	ATOM	TO C	ATOM	ATOM I	Y OM	V V	ATOM	MOLY	VION V
Ē.	2 E	<u>.</u> =	==	: E	<b>=</b> :	ē	<b>=</b> :	ē =	ā	= =		=	==	: E	=	<b>5 5</b>	18	=	=	=	=	ē	<u>=</u>			<b>=</b> ;		. =	<b>.</b>	<b>=</b>		E	E,	==
1.00 28.24	1.00 27.12 1.00 28.06	1.00 0.00	1.00 34.25	1.00 \$5.51	1.00 \$8.95	1.00 27.30	1.00 27.08	0000	1.00 26.28	200 26.78	1.00	1.00 35.98	1.00 39.31	1.00	1.00 26.21	1.00 30.69	000 000	90	1.00	2,007,007	1.00 23.72	000	1.00 27.19	97.62.001	10041.88	1.00 47.42	000 000	1.00 49.54	1.00 0.00	000	1.00 45.74	88	1.00 29.13	00 29.17
	12.889 39 13.795	74 14.448	98 13.469	94 12.907	133 12.021	3 13.354	12.437	15.268	40 15.176	77 16.691	67 18 442	162 18.808	136 19.347	514 19.11	14.789	36 14.269 52 14.984	15.426	14.793	14.027	13.066	3 12.632	9997	39 10.844	35 10.283	1.929	76 7.096	200	837 5.246	989 4.259 1.00	428 5.805		399 3.980	10.430	11.759
44.563 40.	45.373 35.2	45.957 35.974 14.448 1.00 0.00 1	47.376 34.1	49.545 32.	50.113 32.	45.134 33.1	44.662 32.5	45.229 33.6	44.074 31.	44.143 31.5	45.752 31.0	46.472 30.	45.110 31.	44.571 32	42.615 31.9	42.186 30.8	42.199 33.7	19914 344	38.706 34	40.174 32.7	39.475 32.0	42.099 33.6	41.309 32.5	42.794 33.5	42.880 33	41.972 32.6		42.575 33	42.522 33	43.156 34.428	41.178 32.161	41.154.32	41.624 31.4	47.413 30.7
912	2 2	22	25	22	23	€.	2:	==	≂:		==	₹	23	₹	=	==	2	::	:2	3-	~:	2 2	2	23	32	2	2:	22	2	2	23 23	32	23	≅≅
≥	-=														=	⋾⋜	<:	: :	>	> <	1	ξž	•	ac o	: 5	4	× 6	۶₹	•	~				
1427 CD2 IBU	1430 N GE	25 S	23 69 65	435 CD CEL	436 OEI GI	438 C GLU	139 0 000	33	442 CA GI	3	98	446 OE1 C	447 NE2	449 IIE22	\$0 C C	220	453		\$	3	V 0 65	2 = 2	49 CY	5	9	466 NE A	2	2 6 6 4	470 HIII	471 11112	Ž	24.5	475 C AR	22

```
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100
```

113

IGURE S

```
| 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 
   $555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.55
$555.5
```

IGURE S

Ξ

```
1199 - 1481 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 1510 - 15
```

TIRES

```
=500z=5586800z=5586800z=5586800z=5886868686868686
```

117

```
| 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 
         2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 
         20090
         | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 
      20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
20139
```

```
336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6 336.6
```

IGURE S

```
13.21
13.22
13.22
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
13.23
  002=30583002=3058383-6598500E=253-0558002=3050
    4400 11346 11346 11340 1000 0000 0000 11346 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 11340 1134
```

HGURE S

```
13.00 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 1.200 
     11.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10 (1.10
```

PICURE 5

22222	2222222222	======================================	2
.00 28.33 .00 (480 1.00 28.39 1.00 21.42 1.00 20.42	100 22.89 30 26.45 30 27.42 30 27.42 30 22.41 100 28.40 110 38.94 110 42.09 120 46.45	1,00 0.00 1,00 0.00	1.00 12.54 1.00 12.54
7 15.383 1 1 14.997 1 10 15.721 12 15.547 18 15.734 14 15.734	14 15.072 7 14.822 1, 7 14.822 1, 14.822 1, 15.318 1, 15.318 1, 15.318 1, 15.41 1, 1	13.524   13.	6 17317 16 16 16 16 16 16 16 16 16 16 16 16 16
9.630 28.63 9.624 27.76 11.211 26.9- 13.437 27.81 33.805 28.0	34.07 (8.714   15.072   13.072	34.034 28.1 1.512 32.62 2.427 33.42 2.427 33.42 2.420 32.66 5.595 37.06 5.595 34.00 5.6637 33.59 2.6637 33.59	1003 13749 (1650 1010) 1109 1104 1104 1104 1104 1104 1104 1104
******		22000000000	
250 CG LE 250 CG LE 250 CG LE 250 CG LE 250 CG LE 250 CG LE	2505 C H H G G G G G G G G G G G G G G G G G	1516 HE22 1517 C E25 1518 O E25 1	1
A A A A A A A A A A A A A A A A A A A	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	100 A	ATOM 2 AT
22223	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	22 22 22 22 22 22 22 22 22 22 22 22 22	8
1.00 28.59 1.00 28.59 1.00 28.96 1.00 29.29 1.00 29.29 1.00 31.02	1.00 27.52 1.00 60.00 1.00 26.18 1.00 27.87 1.00 25.49 1.00 27.17 1.00 27.10 1.00 27.20 1.00 26.00	1.00 2462 1.00 23.01 1.00 23.96 1.00 23.96 1.00 26.13 1.00 26.13 1.00 26.13 1.00 26.13	100 30.10 100 31.10 100 31.10 100 31.10 100 03.21 100 03.21 100 03.21 100 03.21 1100 03.
84 10.214 267 9.881 152 9.004 785 8.346 475 7.875 09 10.890 447 10.853	43 11.819 09 11.836 18 12.817 18 13.636 19 12.931 19 12.320 35 14.086 49 14.318	112 15.157 110 15.745 100 15.745 1467 16.802 33 14.332 33 14.738 30 13.089 45 12.744 48 12.235 91 10.869 91 10.869	H 11803 4 11655 4 11655 5 11655 6 11006 6 11006 6 11006 6 11007 6 1100
25.859 20.4 26.079 22. 24.845 22. 24.627 23. 25.021 21. 25.849 23.7	24-923 23.5 24-404 22.7 24-404 22.7 23-43 24.1 22.098 24.1 21.750 25. 25.742 24-9 25.838 26.0 26.531 23.0	27.712 24.7 28.236 22.2 29.568 23.27.76 22.28.812 24.8 29.639 24.8 29.639 24.5 28.579 23.7 30.034 24.5 30.034 24.5 30.034 24.5	11.11 1.14 1.14 1.15 1.15 1.15 1.15 1.15
32.23.23.23.3	22222222222	****	18
## <b>\$</b> \$\$\$\$\$\$	462444444444444444444444444444444444444	242322222222222222222222222222222222222	2478 2478 2478 2478 2482 2482 2483 2483 2483 2483 2483 248

122

```
| No. of a control of a control
       11.00 to 0.00 to 0.00
```

FIGURE S

```
0<sub>99</sub>99<sub>6</sub>999<sup>99</sup>9<sub>9</sub>999<sup>99</sup>99<sup>99</sup>999<sup>99</sup>998<sup>9</sup>999<sup>9</sup>
         22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
2272
22722
22722
22722
22722
22722
22722
22722
22722
22722
22722
2
         19.10 (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) (19.10) 
26.55.1
26.55.1
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.2
26.55.
```

5	ē	-	<b>.</b>	-	3 5	7 (			: 0	-	-		-	_ :		, ;		10	-	-	5	_:	5 5	; =	:5	5	5 (		-	0	Ξ:	- 5		=	-	_	= :			0	-			_
27.70	27.78	000	22.12	(3.8)	£ 5	1000		000	000	0000	17.10	10,04	20.83	000	2			1.25.GR	23.84	24.57	N7.570	(W) (W)		95 7 7 00	26.52.00	D0 25.44	27.55															200		9
1327 14	2,668 1,00 24,38	2.890 1.00	27.2	200			1	9.695	8 435	9.065	3.462 1.00	3.848 1.04	2.794 1.00	00 884	717	900	1	3,432 1.00	1.346 1.00	0071 91671	0.123 1.0		9681	-336	3.511	3348	7	1	0.488 1.0	0.1 946.1.0	0.499 1.00 26.49		283 1.00	1.106 1.00	2.575 1.00	2.918 1.00				5.716	2.063 1.00	88		
4 53.147	53.05	23.05	27.653		25.23	20775	9 52 777	19 52.559	28 51.814	19 53.306	51.547	3 51.425	13.190 50.542			4 46 786	9 47 904	5 47.165	49.549	690'61	97	3	1	ď	Ĭ	25		12.850 49.696	4 51.312	6 51.109	46.300 \$2.704		51.913	1 51.921	\$1.073	1111	20.05			52 50 804	16161	96.8.9	78.875	2
13.5	7.06	5			42.579	7	40.51	24	24 40.2	39.61	43.76	44.92	<u> </u>		7		\$ 22	5 40.88	44.824	45.959	9	•			94-77-92				9 46.40	9 47.48	46.30		48.46	49.59	48.10	2	49.03			47.6	49.626	20.81	78.87	41.30
2804 O ARG 42	\$ :		2 X	SAL S	SAT	E 1.75 42	12 LYS 42	1 LYS 4	22 LYS 4.	13 EX. 43	7 5x 1	2	2			C2    F 42	GINE 42	D ILE 42	II.E 425	1 II.E 425	3	3		N	D CIN	E GN		N	₹ NS	Ģ Ng	3	3	ž	CLY 42	₹ 45V	₹ SV	₹ 5 4 5 4 5	2		20	ASP 428	₹ 45	7	4
N 2804	22	200	200	M 2809	2810 M	M 2811	4 2187 H	H 2813 H	= = = ×	281S I	7816 C	2			787	7822 M	M 2823 C	M 2824 C	M 2825 C	7826 F	283		200	783. C	7830 C	233		7	M 2837 C	M 2838 O	Z 5139		28.2	2843 0	7 5844 N	= S+8.	2846 C			2820	7 285 C	9 282 0	Z 582 Z	337 11
ATOM	24	1	QLV	OLV	OLV	24	OLY	υV	2	9	910	O V	= =	•	QI.V	A'ro	410	ATO	φ	OLV	900	26	25	P	VIO.	2	-	9	υ	Ψ	2		200	OLY.	ATO	Q.V	Q (	2		9	Q. Y	ΦŢ	OLV	VIO.
5																																												
1.00 39.61	7 -2.553 1.00 40.02	00 32 33	1.00 31.60	1.00 31.92	1.00 0.00	1.00 31.79	1.00 34.29	1.00 38.66	1.00 45.20	9.5	8	38	2 2	90	00 29 34	1.00 30.88	1.00 33.58	1.00 37.89	200	1.00	9000	20.00	80 60	1.00 23.57	00 000	200	00.70	8	1.00 26.22	1.00 28.77	1.00 27.49	3	200	1.00 22.81	1.00 25.55	1.00 25.38	000	2007	36	88	1.00 30.3	3 1.00 0.0	2 1.00 0.0	1.00 23.60
13 -1.244	07 -2.553	1.047	3 0.549	3 2.273	8 2.648	3.092	52 4.344	40 5.185	99 66	19 7.367		2	2	4004	61 4.283	19 4.984	34 6.463	25 7.058	36 6.398	95 8.275	202	2	300	?	1.803	10 0.651	977	10.0465	4 0.514	8 0.508	52.5	2	200	66 -0.807	98 -2.172	87 -3.216	73 -2.989	8			582	\$37 -5.02	385 6.27	1.432
32.866 53.8	33.349 53.7	16.102 54.04	37.198 \$3.973	35.974 54.48	35.068 54.5	37.078 54.9	36.477 55.4	37.430 56.2	36.952 56.4	37.173 50.	2.7.0	20.00	7 6 6 7 6	36.583 52.5	38.366 51.4	37.545 50.3	37.308 50.6	36.320 49.6	35.357 49.1	36.427 49.0	35.695 48.	707.75	20.00	38.379 50.8-	37.448 51.13	39.077 50.4	38.163 50.6	17 057 49 6	0.353 51.25	41.458 50.70	40.275 52.599 0.	39.402 33.0	1 00 549	40.167 55.3	40.525 54.7	39.707 55.3	39.168 56.1	39.629 54.9	0.70		38.960 55	38.539 56	38.865 55	42.429 53.24
5 7	2	-6	2	2	2	2	2	2	2	2	2,	2.5	2 =	=	2	=	≅	₹	₹	₹	÷:	7;	: =	: ~	~	≃:	3	::	2	≈	2:	2	35	2	2	2	2	₽	2	3	2	2	£	₹
2753 CG LEII	S CD2 LEU	6 C LEU	10 IE	2 2 2	010 H 6	5	000	3	8				N	NIO H 6	5	200	NIS 95 2	3 CB CIN	4 061 63	S NE2 CLY		7	300	N VAL	1 VAL	. C	3	3	6 C VAL	17 O VAL	I N ARC	19 II ANG		CCAR	3 CD ARG	H NE ARG	S HE ARG	M CZ ARG	7 NIII AR		N VIII V	HIIZI AR	22 IIII 22 AM	3 C ARG
MOL NO.										•	•	•														~ .	~ .	• •	~	~	TOM 2788	~	٠.	•~	~	~	~	~	~	~ -	•	•	-	-

FIGURE S

### 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 \$58888888888888888888888888888 

8555555	<sup>0</sup> 5565 <sup>55</sup> 555 <sup>55</sup> 65 <sub>5</sub> 55	6886868688 <sup>8888</sup> 888888888888888	=
1.00 41.44 1.40 0.00 1.00 42.05 1.00 42.05 1.00 62.28 1.00 62.28 1.00 62.28	1.00 91.00 1.00 91.00 1.00 91.00 1.00 91.00 1.00 90.73 1.00 90.73 1.00 35.75 1.00 35.75 1.00 35.75 1.00 35.75 1.00 35.75 1.00 35.75 1.00 35.31 1.00 36.31 1.00 36.31	100 51.8 100 31.5 100 31.5 100 31.5 100 31.5 100 31.5 100 31.5 100 41.8 100 41.8 100 41.8 100 41.8 100 41.8 100 41.8 100 41.8 100 41.8 100 51.8 100 51.8 100 52.8 100	CR Str.9k
15.002 42.380-12.749 15.370 43.340-12.761 15.370 43.340-12.761 15.370 43.05 14.059 15.370 45.089-14.162 15.3818 45.081-14.183	4,0074,4197,100,100,000,000,000,000,000,000,000,00	432 - 4,11-0 591 - 5,297 45 - 10,105 46 - 10,105 47 - 10,105 46 - 10,105 46 - 10,105 47 - 10,105 48 - 10,105 49 - 10,105 40 -	78 -8.594
55.08 55.32 55.02 54.96 54.10 54.10	56.136 57.36 57.36 59.75 59.75 61.54 59.11 59.11 57.27 57.27 57.28	1960 1961 - 1960 1961 1961 1961 1961 1961 1961 1961	57.745 33.3
\$ \$ \$ \$ \$ \$ \$ \$ \$	335555555555555555	######################################	ş
008 N GIU 009 H GIU 011 G GIU 012 G GIU 013 CD GIU 014 OEI GIU	100 00 00 00 00 00 00 00 00 00 00 00 00	100 100 100 100 100 100 100 100 100 100	38 CC 1EU
		A 100 M M M M M M M M M M M M M M M M M M	
55555555		<sub>0</sub> _0 <sub>0</sub> _0 <sub>0</sub> _0 <sub>0</sub> 0 <sub>0</sub> 00000 <sub>0</sub> 0 <sub>0</sub> 0000000	5
1.00 34.47 1.00 33.18 1.00 0.00 1.00 30.44 1.00 33.76 1.00 33.76	1.00 53.37 1.00 57.64 1.00 0.00 1.00 0.00 0.0 28.86 0.0 28.85 1.00 28.82 1.00 28.82 1.00 28.82 1.00 28.82 1.00 28.82 1.00 28.83 1.00 28.83 1.00 28.83	1.00 9.118 1.00 0.00 1.00 31.43 1.00 31.43 1.00 31.43 1.00 31.43 1.00 31.63 1.00 41.74 1.00 41.74 1	1.00 45.69
68 - 568 123 - 4.267 23 - 4.267 23 - 5.263 29 - 6.364 29 - 5.407 29 - 5.407	28 4-984 52 5-240 52 5-240 52 5-173 52 5-173 53 6-173 54 5-673 54 5-663 54	6.00 6.56 4.26 100.01.01.01.01.01.01.01.01.01.01.01.01.	11 -11.569
65.088 44.7 65.598 43.8 64.627 45.8 64.345 46.6 64.395 45.5 65.983 45.7 66.729 47.4	56.267 49.7 503 49.0 56.267 49.7 56.268 49.2 56.2 48.5 50.2 56.4 49.2 50.2 49.2 50.2 49.2 49.2 49.2 49.2 49.2 49.2 49.2 49	0.0700 455, 10.00 455,	4.769 40.5
\$\$ <b>;</b> ;;;;;	<u></u> \$\$\$\$\$ <u>\$</u> \$\$\$\$\$\$\$\$\$\$\$\$\$	555555555555555555555555555555555	ş
F F F F F F F F F F F F F F F F F F F	35555555555555555555555555555555555555	C C C C C C C C C C C C C C C C C C C	£
		C C C C C C C C C C C C C C C C C C C	
			N N

HGURE 5

```
1849 1441 733 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 10043 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100433 100
<u>ዹ</u>ጟጟጟጟጟጟጟቜቜቜቜፚዿ<sub>ፚ</sub>ፚፚፚፚፚቜጟቜቜቜቜቜቜቜቜቜዿዿዿቜቜቜቜዼዼዼዼዿፚቜቔቔዿቔቔቝ፟ቝቝቝ
```

ICURE 5

```
| 1844 | 1848 | 1841 | 1848 | 1841 | 1848 | 1841 | 1848 | 1841 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 1848 | 
      11.50 (4.54.5) (1.54.6) (4.54.5) (1.54.6) (4.54.5) (1.54.6) (4.54.5) (1.54.6) (4.54.5) (1.54.6) (4.54.5) (1.54.6) (4.54.5) (4.54.5) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.6) (4.54.
```

2	Q	3	õ	ũ	2	3	3		: :	0	Ü	3	3	30	Ö	ũ	3	2	2	30	2	3	c	č	3	3	3	2	3	3 ;	, 3	õ	3	30	2	2:	3	30	: 2	2	7	2	:
100 25 64	1.00 27.64	1.00 30.83	1.00 30.43	1.00 32.62	CO 25.28		200	00 75 16	00 77 00	100 27.81	1.00 28.63	1.00 28,15	00 27.13	00 24 88	00 0 00	1.00 33.01	1.00 38.68	100 Hr 07	000 50.83	200	00'0 00'1	1.00 0.00	.00 43.58	50 34 65	20.15	200	00 31.67	.00 34.71	F0'9E 00'	200	00 34.86	00 31.36	00 28 27	100 24 74	51.96.00	00 36.70	100 38.33	900	177 97 00	9.419 1.00 53.71	72,000.00	200	
2.099	0.725	0.183	14	205				2	7957	1.474	2	2.8.39	657		\$ 799	7.314	8.027	6 6	27.	6.77	9.78	9.286	986.	.715	85		100	1989	678		770	747	7		77.	5	2	45	1	9.419	8.785		
34,990	15.570	34.755	35.506		200	2009	2079	87.868	6130	10.13	1019	~ 0		22.9	6.127	35.809	2	2	707	35	34.353	35.560	4.867	1.828	6	,	2.500	3.678	2.943		5.634	0669	2065	9	843.5	374	4	9	9	-	7.160	3	
47.911	47.708	46.761	9		4007		47.267	49.0172	48.274	47.823	4P.73	18.98	20.00		47.984	49.430	9	9.5	9	~	45.723	44.489	50.582	51.582	50.482		50.818	\$2.802 3	53.789 3	200	54.139	53.898 3	23.127	26.5	54.879 35	55.985 30	8	25.595	3	54.711 33.471 9.	54.195	9	
\$	2	2	9	ì	2	8	8	5	8	ş	\$	2,	28	5	6	<u>5</u>		i		Ş	ç	\$	6	=	22	: 6	: 6	~	~:	2:	: 2	2	æ ŝ	25		-	z.	1	: 3	3	Į.	Į,	
3314 CA IBJ 4	E 2	3		į	3	1 P	23	2	69	29 29		2	3	3	3	S	3 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	3	90	S	E21 GIV	EZZGIA	S	N 0	<b>{</b> :	į	NA ALA	ķ	<u>۲</u>	3	4	19 FEB	3	9	3	3	3	3		3	a cui		35
33	3				330	3321	335	333	3324	3328	3376		3379	3330	333	333	3		1	3337	3338	33391	3340	334	~		3345	3346	3347		3350	3351	332		3355	3356	3327	3328		3361	3362	3363	5
ATOM	0		Y A	MOLV	ATOM	ATOM	A'DM	MQI.Y	ATOM	V TOW	V		MQI.V	AJOH	ATOM	ATOM			T A	MOLV	ATOM	MOLV	MOTA	MOLV	V C	1	ATOM	ATOM	MOT.	2	Į į	ATOM	NO.	1	MOLV	MOLY	MOLY V	MOLV MOLV		YQ.	ATOM	¥2.	5
8	30	10	33	3	ð	ວ	8	<u>ت</u>	c	3	38	; 0	ö	ä	3	ວ;	35	;	; 0	;≎	3	C	õ	ວ;	Ö	30	:3	2	გ;	35	; 3	a	3	30	3	8	0	<b>~</b>	, 0	ö	ວ	0 (	3
.00 37.46	3	8	1.00 47.98	1.00 46.78	90.84 00	.00 33.92	.00 34.25	00 32 75	00 000	00 33.74	200		1.00 40.07	00 33.95	00 33.84	33.67			00 13 17	1.00 32.79	1.00 33.73	1.00 34.59	1.00 34.63	00 35.58	28.5	0 17 00	90 97 00	26.95 00.	000 000	23.55	00 37.50	1.00 40.54	100 40 45	8 9	0000	00 28.53	00 28.72	28.32	3	4.033 1.00 25.75	98'52 00	25.05	00 0,00
3.925	7	917	\$.395	7.119	6.720	Ξ	1.826	66:	2	2			8	376					0.825	-1.579	7.044	-1.445	2.818	295	7	269	.942	1.708	1.565		7.485	7.469	7.79	9	7 702	707	Š			2	715	=	=
15.300	32.884	34.44	31.858	33.427	5.119	2,602	5.289	2	27				34.90	5.585	98			200	375	39.405	19.290	39.153	39.033	966	98.80	9	2001	1,691	3.545		7.979	39.252	40.346	20.00	18.340	6.455	242	35	3	2	3.946	4.798 2	7000
37.975	38.219	38.528	38.421	38.731	38.677 3	40.245 3	1 1 6 2	0.376	19.577				43.125	42.740 3	1,766	6	3	2.0	30	-2	877	4.533	44.618	43.451		y	45.258 3	43.270 3	2315	3 5	308	43.966	7	9	45.736	44.791 3	45.774 3	520		46.660 34.264 40	47,660 3	46.653 3	45.738
4 6 4	į	484	48	ŧ	ž	z.	:	8	2	9	1	ŧ	ş	2	2		1	4	4	436	4	ş	486	9	:	4	2	2	2	ì	ì	è	÷	ì	•		91	2:	3	:	2	2	689
CS PIE	DI PIE	D2 PILE	EI PILE	E ME	E Z	Ë	ž	3	3	3		100	20	3	3	Ĕ	1	ě	Ě	E T	EI TYR	NY TYR	E T	Ě	Ž	į	Ĕ	3	3	3	3	300	E	3	3	3	3	5	3	5	Ę	3	3
3263 C	3 59 C	ÿ 992	1267 C	201	5 69 C	2				,	276	277 C	278 C	279 C	0 0 0				285	286 C	1287 C.	1288 C	289 C	2	0 1626		294	N 5671	# 96Z	5	5.5	300 C	ō	2 3	Š	30S C	900	202	200	10	310	N 715	
ATOM																	•																										

130

```
$400 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0
      $150.8 $1.00 to 0.41
$150.8 $1
```

IGURE S

```
939<sup>33</sup>393<sub>3</sub>333<sup>333</sup>93<sub>3939</sub>93<sub>3</sub>333<sup>333</sup>333<sup>3</sup>33<sup>3</sup>33<sup>3</sup>33<sup>3</sup>33
      18.157 4.257 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1.051.1 1
        11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
11118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
1118
      ## 400 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ## 410 ##
```

E

10.00 at 10. 8080088002=0500=55002=5000=50808055588006Egg=55000 18.33 18.34 18.35 25255555555 11.17 (2015) 1.17 \$559 \$17.0 \$ 

5	3	J;	3	3	ð	ت: :	2 :	3 3	J	J	9 :	73	ō	Ç	38	9 5	5	3	0	3	20	Ö	0	20	20	Ð	0	90	0	3 5	) 3	Ĵ	3	7	3	J	2 :	ī	=	Ξ
3	.00 38.88	24.77	7	1.00 34.85	042.45	16.95		00 000	00.0	79'0'	20.00	900	031.43	31.74	37.02	0.7.90	000	0 49.48	70 51.97	9 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	3 6 6	00 0.00	00 000	97.76	1	10.0	10.00	192	074.34	32.30	97.66	86.1-5 00	00	200	000	10 0.00	19.61	7.87	000	17.08
2	9 6	99	13	9	 	2 : 2 :				<u> </u>																														
797	~	- 3	7	32.232 -1.140 1.	2	÷.		7	7	0.0		90	~	≈: •		7	9.6	55	≈	25	32	3	٠. تو		ã	ď	9	6	9	===	2	2	2	÷ :		25	-	~	3	7
34.90	35.66		33.6	32.23	5	9 2	2	6 29.9			37.436	28.04																												
61.543	60.90	196	59.490	29.145	23.58		5	59.47	59.15	20.50	8	59.750	58.160	58.81		59.743	60.389	8	29.36		9	62.02	9	2	59.348	99.148	59.53	61.820	63.280	64.54	65.34	66.15			3					
ž	7	3	÷	ž	£ :	į	\$	\$	\$	\$ 3	3	\$	5	3	3	3	\$47	54	3	33	3	ž	3	;	2	548	33	3	Ī	33	3	ž	7	Š	3	ž	3	7 5	£	£3
	Ē	3	3	ŝ	3	5 2	200	30 =	2	3 3	V V	¥	ARG	Ž,	1	ARG	ARG	ARG	¥ :	<b>*</b>	Z ARG	Z ARC	2 A R	2	ARG	A RG	9	¥ S	ARG	9 4	8	1 ARG	I ARG	Ž		Ž.	ARG.	1	ş	¥
⊃ c	22	= 2	2	58	30	56	3	32 IIE	33		2 2	32	5	50	35	ž	43 HE	\$ C	Ž :	9 5	Z	<b>■</b> 6+	≣ 4 8:		z	=	ಶ ಶ	88	8	2 E	10	₹ ~	Ē	Į:		Ĩ		o z	=	5
E.	2	Z	Ξ:		12	: = : =	3	2	Z:	32 33	. A	7	Z:	: :	::	Ä	E 3	Z.	Σ:	12	Ä	Ä	~:		Ž	ž	Ž		ž	× ×		2	2	š.	,,	2	2	<u> </u>		37
Y.		410	2			2	2	2	2	<b> </b>	P	¥	ę	2	2	2	2	2	2	? {	9	ę	2		5	ę	55	Ę	Q1.Y	9 5	9	V.IO	2	2	Ę	9	Ę	2 4	2	Į.
5;	30	o	n i	35	35	3 23	2	mi	56	35	3	0	<b>:</b>	3 2	3::	n	8	m i	8	3:	n	n.	<b>_</b> 2	3.5	:0	m	m :		_	88	3 m	m	n	- E	3:	:0	8	32	30	77
7 1.00 71.52	99	90	8	8	95 00	90 58	.00 \$5	8	3	8	1.00	9	8	3 8	8	00 49	8	00	88	8	9	00 45.6	8	8	1.00	90.	86	8	00 00	88	00 37.0	.00 38.2	.00	8	8	6 0	67 00.1	88	9	00.31.0
183	670	1961	3	9	ž	ē	£.	25	3	ő	6.2	5	6	2	Ē	395	362	9	8	ž	ž	365	8	3	Š	5	23	9	8		ş	820	2	8	ŝ	8	\$ 5	3.7	8.92	087
0.503	29.294	7		27.200	717	9:036	200	99		2	12.939	12.747	3.20		364	807	- ?	967		3	204	408	665	3	=	23	62.087 32.613 1.	~	136	900	17.2	720	9	26.		742	3.788	1984	3	150
49.437 3	3	2	200	ž	59 24	32	8	۳. و		2	8	20	ē:		8	~	2	2	2 2	3 9	~	2	5	35	3.5	*	22	2 2	3	25	12	29.36	57 34		•	9	Ξ	22	::	S
																																							; 3	3
539	3	\$ 3	3	3	ş	ž	Ξ.	ξ.		Ī	3	3,	Ī.	į	Ī	ž	\$	₹:	ž	3	Ĩ	3	3	3	3	3	33	ž	ž	ž	3	Ŧ	245	ξ.	:	3	ž	žž	3	\$ 5
OC PRO	8	<b>\$</b> :	{ }	ş	ž	ş	Ē	Ě		ž	HE I	Z .	E	ž	£	ž	ş	<b>\$</b>	<b>:</b>	1	ş	ž	# S	ğ	ă	. SE	¥ 6	Ş	ş	<b>{</b> :	\$ \$	ş	Ē	į	Ē	ž	E	2 PHE	i i	ž
80	9	Z :	: Č	7	٥	06	Z :	= 5	55	8	S	9		֡֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֡֡	٥	0	z	= 0	38	30	0	z	= i	50	8	2	**	z	= '	<u>ئ</u> ۋ	,	0	z	= :	5	98	5	80	֓֞֜֜֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֜֜֓֓֓֓֓֡֓֜֓֡֓֜֓֓֓֡֓֜֝֓֡֓֡֡֡֡֓֡֓֡֓֡֡֡֡֡֡֡	0
3671																																								
ATOM NOTA	ATOM		P	ATOM	ATOM A	ATOM	ATOM.		1	P	ΨQV	P P		Į.	ATOM	ATOM	P	NO.		V V	MQ.	AJOM	Š		ğ	ΨQΨ	ě	P	ATOM	Ž,		ATOM	ATOM	V O	1		ð	Ď.		ATOM

8.379 8.300 0002=0002=0002=0008085=0080808=0002=00002=00085=0000 

```
11.15 (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.15) (1.
        13926
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
13927
      იეგივ<sub>ე</sub>იეგიი<sub>ეგიე</sub>იეგიიი<sub>ეგიეცი</sub>იი<sup>ე</sup>გი<sub>ეგი</sub>იი<sub>ეგიეც</sub>იიიიიიი<sub>ე</sub>ვე
| 1845 4.074 3.081 10.04.19
| 1835 4.074 3.081 10.074.19
| 1837 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.081 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.074 10.074.19
| 1838 4.074 3.07
```

FIGURES

```
| 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 
  39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95

39.95


39.95

39.95

39.95

39
```

```
ATOM 4400 PH 1100 657 98.058 86.259 56.11 100 0.00 W
ATOM 4400 PH 1100 658 46.750 PH 4750 -1121 100 0.00 W
ATOM 4401 PH 1100 658 46.750 PH 4750 -1121 100 0.00 W
ATOM 4402 PH 1100 658 95.86 46.751 -1438 1.00 0.00 W
ATOM 4402 PH 1100 663 95.90 66.287 1.100 0.00 W
ATOM 4402 PH 1100 663 95.90 66.287 1.100 0.00 W
ATOM 4402 PH 1100 663 95.90 66.287 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1750 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1.100 1.100 0.00 W
ATOM 4402 PH 1100 664 1.100 0.00 W
ATOM 4402 PH 1100 667 1.100 0.00 W
ATOM 4402 PH 1100 671 1.100 1.100 0.00 W
ATOM 4402 PH 1100 671 1.100 1.100 0.00 W
ATOM 4402 PH 1100 671 1.100 1.100 0.00 W
ATOM 4402 PH 1100 671 1.100 1.100 0.00 W
ATOM 4402 PH 1100 671 1.100 1.100 0.00 W
ATOM 4402 PH 1100 671 1.100 1.100 0.00 W
ATOM 4402 PH 1100 671 1.100 0.00 W
ATOM 4403 PH 1100 671 1.100 0.00 PM 1100 PH 11
```



# EUROPEAN SEARCH REPORT

Application Number EP 94 10 1207

DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document with indication, where appropriate, of relevant passages Relevant to claim CLASSIFICATION OF THE APPLICATION (INC.) Category P.X DISSERTATION ABSTRACTS INTERNATIONAL B. 1-8 C12N15/27 vol. 54, no. 3 , September 1993 page 1239 T. OSSLUND ET AL 'The structure of C07K3/00 C12P21/02 C07K13/00 granulocyte-colony stimulating factor'
\* abstract \* G06F15/60 P.X PROCEEDINGS OF THE NATIONAL ACADEMY OF 1-8 SCIENCES OF USA vol. 90 , June 1993 , WASHINGTON US pages 5167 - 5171 C.P. HILL ET AL 'The structure of Granulocyte-colony-stimulating factor and its relationship to other growth factors' \* the whole document \* CELL STRUCTURE AND FUNCTION 43 vol. 17, no. 1, February 1992
pages 61 - 65
MASAHARU ISHIKAWA ET AL 'The sustitution
of Cysteine 17 of recombinant human G-CSF TECHNICAL FIELDS SEARCHED (Int.CL.S) with Alanine greatly enhanced its stability' C12N \* the whole document \* C07K C12P WO-A-87 01132 (KIRIN-AMGEN, INC.) \* claims; examples 7-9 \* & US-A-4 810 643 (KIRIN AMGEN , INC.) 7 March 1989 WO-A-89 05824 (GENETICS INSTITUTE, INC.)
\* the whole document especially page 17 17-22 table 2 , page 21 lines 16-19 and page 22 lines 25-37 \* & US-A-4 904 584 (GENETICS INSTITUTE) D -/--The present search report has been drawn up for all claims Place of search Date of completion of the search THE HAGUE 11 May 1994 Le Cornec. N CATEGORY OF CITED DOCUMENTS T: theory or priodple underlying the invention
E: earlier patent document, but published on, after the filing date
D: document cited to the application
L: document cited for other reasons X: particularly relevant if taken alone Y: particularly relevant if combined with a document of the same category A: technological background O: non-written disclosure O: intermediate document A : member of the same patent family, corresponding



# EUROPEAN SEARCH REPORT

Application Number EP 94 10 1207

	DOCUMENTS CONS	IDERED TO BE RELEVAN	Т	
Category	Citation of document with of relevant p	indication, where appropriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CL5)
A,D		28 February 1989 , IS AL 'Mutagenesis of human stimulating factor'	9-60	
D,Y	EP-A-O 344 796 (CHU KAISHA) * the whole documen	JGAI SEIYAKU KABUSHIKI	1-8	
Y	ligation of peptide solution' * the whole docume	NL 'Engineering sustrates for efficient		TECHNICAL FIELDS SEARGED (sat.Cl.5)
Υ,0	PA US pages 1358 - 1362 J. PANDIT ET AL	c human recombinant Stimulating Factor'	1-8	
P,A	* examples 1,9,10,1 * appendix 1 * * claims *	- page 17, line 5 * 11,13 */	1-8	-
	The present search report has I	Date of completion of the search		Transaction 1
	THE HAGUE	11 May 1994	Le	Cornec, N
X : part Y : part doc	CATEGORY OF CITED DOCUME ticularly relevant if taken alone ticularly relevant if combined with an unsent of the same category anological background	NTS T: theory or princip E: earlier patent do after the filing d	le underlying the cument, but pub- ate in the application	invention dished on, or



# EUROPEAN SEARCH REPORT

EP 94 10 1207

	DOCUMENTS CONS					
Category	Citation of document with i		riste,	Relevant to claim	CLASSIFICATION APPLICATION	
P,X	JOURNAL OF CELLULAF no. 17B , 26 JANUAF page 78 J. E. LAYTON ET / with its receptor : biological activity * abstract E 225 *	Y-10 FEBRUARY  L 'Interaction Dissociation and Receptor	1993 of G-CSF of	27,32, 34-38, 51-53		
A	EP-A-0 456 200 (BOE	HRINGER MANNHI	IM GMBH)			
D,A	JOURNAL OF APPLIED vol. 20 , 1987 pages 366 - 373 M.J. COX ET AL 'E automated protein o	xperiments wil	:h			
T	POUR LA SCIENCE vol. 183 , January pages 76 - 82 A. OLSON ET AL 'V biologiques'		iles		TECHNICAL SEARCHED	FIELDS (Let.CL.5)
Y	PROTEIN ENGINEERING INC. pages 35 - 44 M. KARPLUS 'The pre mutant strutures' * the whole documen	diction and Ar		1-8		
<b>A</b>	WO-A-88 01775 (GENE 1988	X CORPORATION)	10 March	•		
	The present search report has b	-				
	Place of search		en of the search		Exemiser	
X : pur	THE HAGUE  CATEGORY OF CITED DOCUME  Industry relevant if taken alone	E	theory or principl earlier patent doc after the filing de	e underlying the ument, but publ	ished on, or	
400	ticularly relevant if combined with an ument of the same category mological background	L L	: document cited is : document cited fo	other reasons		
O : noe	nnological background i-written disclosure rmediate document	<u>~</u>	: member of the sa	me patent famil	y, corresponding	
er : unte						